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Abstract 
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. There is 
heterogeneity of the clinical features of ALS including site of onset and rate of progression. 
Previously, ALS was considered to be a disease of the motor system. However, there is evidence that 
ALS patients can have cognitive impairment. Some patients meet the diagnostic criteria for 
Frontotemporal dementia (FTD). It is now thought that FTD and ALS are related neurodegenerative 
disorders, which fall on the same disease spectrum. A reliable biomarker is needed to monitor the 
progression of the disease and assess the effects of potential therapies. Sequential Window 
Acquisition of all theoretical fragment-ion spectra analysis (SWATHTM) is a reliable and powerful 
proteomic approach to investigate the biomarker proteins in complex samples such as blood.  
 
Method: 
The aim of the first study is to evaluate the utility of neurofilament levels as blood or cerebrospinal 
fluid (CSF) biomarker in patients with ALS by using a systematic search of Pubmed, Embase and 
Scopus databases. Meta-analysis of the data was performed.  
 
The aim of the second study is to screen for cognitive and behavioural impairment in people with 
ALS and controls with neuromuscular disease and to correlate these with clinical features. 108 people 
with ALS and 60 controls were recruited and assessed with the Addenbrooke’s cognitive 
examination-III (ACE-III), the Frontal assessment battery (FAB), and the executive function 
component of the Edinburgh cognitive and behavioural ALS screen (ECAS). The Amyotrophic lateral 
sclerosis-Frontotemporal dementia questionnaire (ALS-FTD-Q) and the Motor Neuron Disease 
Behavioural instrument (MiND-B) were administered to the caregivers of people with ALS. 
Longitudinal studies of cognition were performed in 37 ALS patients. 
 
The aim of the third study is to search for plasma biomarkers in ALS patients compared to healthy 
controls by using SWATH™ quantification analysis and to compare proteomic analysis of ALS 
patients with and without cognitive impairment (CI). 42 patients with ALS and 18 healthy controls 
were recruited. Western blot analysis was used to confirm the results of analysis and in an independent 
set of samples. Ingenuity pathway analysis (IPA) was performed. 
 
Results 
The systematic review found that levels of NF heavy chain and light chains were significantly 
elevated in the CSF of ALS patients compared to healthy controls/controls without parenchymal 
central nervous system (CNS) involvement and ALS mimic disease patients. NF light chain level in 
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CSF was higher in ALS patients than in neurological patients with CNS involvement (SMD=1.352, 
P=0.001). NF light chain concentration in blood was higher in ALS patients than in healthy 
controls/controls without CNS involvement (SMD=1.448, P<0.0001). NF heavy chain levels in CSF 
were negatively correlated disease duration and ALSFRS-R (r=-0.447, P<0.0001; r=-0.279, 
P=0.011). NF light chain levels in CSF were negatively correlated with disease duration (r=-0.486, 
P<0.0001). 
 
In the patient cohort, the frequencies of cognitive impairment based on the ACE-III and FAB were 
30.0% and 14.0%, in ALS and 11.7% and 3.3% in controls, respectively. In ALS, the frequencies of 
behavioural impairment based on ALS-FTD-Q and MiND-B were 32.1% and 39.4 %, respectively. 
ALS participants with cognitive impairment measured with ACE-III had significantly shorter survival 
time than those without. ALS participants with behavioural impairment measured with ALS-FTD-Q 
had worse prognosis than those without. No significant difference was found between the first two 
serial cognitive tests based on ACE-III and FAB by using a generalized estimating equation. 
 
Between ALS and controls, there were significant differences in the expression of 30 proteins. Of 
these, plasma gelsolin concentration was 1.2 fold higher in controls than ALS patients (P=0.006). 
Between controls and ALS with CI, there was significant difference in expression of 32 proteins. The 
clusterin level was 1.2 fold downregulated in patients with CI compared with controls (P=0.03). The 
observed changes in levels of gelsolin, clusterin, CD5L and ficolin 3 were validated by using western 
blot. Pathway analysis showed that the LXR/RXR pathway, complement pathway and coagulation 
pathway are regulated in ALS. 
 
Conclusions 
The results of the first study shows that NF heavy and light chain levels have potential to be used as 
markers of neural degeneration in ALS, but are not specific for the disease, and are more likely to be 
used as measures of disease progression. The results of second study indicate that there is a greater 
frequency of cognitive impairment in people with ALS than in patients with other neuromuscular 
diseases. The cognitive and behavioural tests are potential biomarkers of the prognosis of ALS. The 
results of cognitive tests are stable over 6 months and possibly longer. The results of the third study 
illustrate that clusterin, gelsolin and ficolin 3 are novel potential biomarkers to differentiate the ALS 
patients from healthy controls. Abnormalities in the LXR/RXR pathway suggest that lipid 
metabolism is involved in ALS. There are widespread changes in immune function and coagulation 
in ALS.  
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Chapter 1.  Introduction and literature review 
1.1  What is Amyotrophic lateral sclerosis (ALS) 
ALS is a fatal neurodegenerative disorder, which involves relentless and progressive loss of 
both upper and lower motor neurons. The incidence of ALS is about 1–2 per 100,000 worldwide [1]. 
Almost 90% of the cases are sporadic and 5-10% of the cases are familial [1, 2]. In Europe and United 
states, the median age of onset is about 60 to 65 years [3]. Generally the median survival of patients 
from symptom onset is about 3–5 years [4]. The main cause of the death is respiratory failure caused 
by weakness of the diaphragm. However, there is heterogeneity of disease survival, and 
approximately 20% ALS patients have lifespan ranging from 5 to 10 years [5], and 10% of patients 
can survive for more than 10 years after onset [6].       
The clinical manifestations of ALS are various, including muscle weakness, atrophy and 
fasciculations due to the loss of lower motor neurons (LMN) and brisk deep tendon reflexes 
(hyperreflexia) and increased muscle tone (hypertonia) due to the loss of upper motor neurons 
(UMN). The revised El Escorial criteria are used to make a definite diagnosis of ALS patients [7]. 
These criteria are as follows: 
Table 1. El Escorial criteria for ALS 
 
Using these criteria, ALS can be divided into clinically definite ALS, clinically probable ALS, 
and clinically possible ALS based on the number of anatomic regions involved [7]. In 2008, 
electrophysiological criteria were developed, to supplement the revised EL Escorial criteria [8]. The 
diagnostic sensitivity was increased by using the Awaji criteria without simultaneously increasing the 
false positive percentage. 
Presence 
A1: evidence of lower motor neuron (LMN) degeneration by clinical, 
electrophysiological or neuropathological examination 
A2: evidence of upper motor neuron (UMN) degeneration by clinical examination and 
A3: progressive spread of symptoms of signs within a region or to other regions as 
determined by history or examination 
Absence 
B1: electrophysiological or pathological evidence of other disease processed that might 
explain the sings of LMN and/or UMN degeneration, and 
B2: neuroimaging evidence of other disease processed that might explain the observed 
clinical and electrophysiological signs. 
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Currently, Riluzole is the only medication that has shown benefit in ALS. Riluzole has the 
function of reducing glutamate excitotoxicity. However, it has moderate efficacy, as it extends the 
average life expectancy by about only 2–3 months [9]. Edavarone has also been found to be beneficial 
[10]. Noninvasive ventilation (NIV) is available when the disease involves their respiratory system and 
can prolong the survival of the patients [11]. In the last decades, some drugs shown encouraging results 
on the rodent ALS models, but have proved to be ineffective in clinical trials of ALS patients [12].         
 
1.2  What is Frontotemporal dementia (FTD) 
FTD is the fourth most common dementia, behind Alzheimer Disease (AD), vascular dementia 
(VaD) and dementia with Lewy body [13, 14]. FTD is also the second most common dementia in 
patients who are younger than 65 years [14]. Males and females are affected equally [15]. 20% of FTD 
patients have a family history [16]. FTD was once known as Pick disease and accounts for 
approximately 15%-20% of all neurodegenerative dementias [17, 18]. The incidence of FTD is about 
15 per 100,000 people [19]. The pathology of FTD involves both grey and white matter. The atrophy 
of frontotemporal lobe is circumscribed and asymmetrical based on post-mortem pathology [20]. The 
clinical manifestations of FTD are variable and include problems with speech, change of personality, 
loss of awareness of personal appearance and hygiene, bizarre or uninhibited socially inappropriate 
behaviours and severe naming and word comprehension deficits [21]. Magnetic resonance imaging 
(MRI) shows asymmetrical atrophy of frontal and temporal lobes [20]. In FTD, some studies have 
reported hypometabolism of frontal and temporal lobes by using fludeoxyglucose positron emission 
tomography（FDG-PET）technology [22]. Several studies have indicated that if the orbitofrontal 
cortex is involved, there is behavioural disinhibition [23] and that abnormalities of the medial frontal 
and anterior cingulate, and right insula or striatum lead to apathy and eating disorder, respectively [24, 
25]. 
FTD can be classified into 2 main subtypes: frontal variant frontotemporal dementia (fvFTD) 
and primary progressive aphasia (PPA). PPA can be further categorized into non-fluent progressive 
aphasia, semantic dementia and logopenic progressive aphasia [26]. The frontal variant of FTD 
accounts for 80% of the total FTD patients. Sometimes fvFTD is referred to as behavioural variant 
FTD (bvFTD). The two terms are interchangeable. With progression of disease, some patients will 
manifest global cognitive dysfunction and also motor abnormalities including ALS probably due to 
the anatomical vicinity of frontal lobe and motor cortex [21]. 
The Neary criteria are used to make a definite diagnosis of FTD. The Neary criteria include 
diagnostic features, supportive features and exclusion features [27]. A definite diagnosis must meet the 
five core features which are insidious onset and gradual progression, early decline in social 
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interpersonal conduct, early impairment in regulation of personal conduct, early emotional blunting 
and early loss of insight. In 2011, the International Behavioural Variant Frontotemporal Dementia 
criteria consortium established a new diagnostic criteria for bvFTD [28]. The diagnostic criteria for 
PPA were also updated and the logopenic variant of PPA was included into the new guidelines [26]. 
The treatment for FTD is limited. Physical therapy and the education for the carer in the home 
care plays an important role in the bvFTD patients [29]. Speech therapy is also beneficial to patients 
with non-fluent progressive aphasia [30].  
 
1.3  Heterogeneity in the clinical features of ALS 
There is evidence that the incidence of ALS is greater in males than in females [31], but the 
gender differences vary in different age groups and the male to female ratio decreases steadily with 
age [32]. Gender usually does not affect the prognosis of ALS [33]. Some other papers reported that the 
incidence of ALS to be lower among people of African, Asian, and Hispanic ethnicities than among 
white people [34]. The age of onset varies among ALS patients. The median age of onset ranges from 
60 to 65 years [35]. Some ALS patients have a relatively young age of onset, developing disease in 
their third or fourth decade. The age of onset plays a role in the prognosis of the ALS patients, with 
evidence that subjects with advanced age (>60 years) of onset have a worse prognosis than those with 
younger age of onset [33]. Patients who develop the ALS at a young age generally have male gender 
bias and protracted disease progression [36].  
The heterogeneity of ALS is not only shown in the incidence rate and age of onset but also in 
other clinical features such as site of onset. The site of onset can be classified into bulbar, upper limb 
and lower limb. The frequencies of these three sites of onset equally ranges from 25% to 35% [37]. 
One study reported that the incidence of respiratory onset was 2.7% [38]. From the site of onset, disease 
spreads to the other sites of motor neuron system with the progression of ALS. However, the site of 
onset is not the only source of variability in clinical features. Some studies classified patients 
according to a combination of site of onset and degree of upper or lower motor neuron weakness. 
These give 8 types (classic, bulbar, flail arm, flail leg, pyramidal, respiratory, pure lower motor 
neuron, pure upper motor neuron [39]). These groups have different incidence and prognosis. For 
instance, the flail arm form (one type of progressive muscle atrophy) is much more prevalent in male 
patients. Compared with classic ALS form, flail arm and flail leg have a better prognosis [40, 41]. As to 
the pure lower motor neuron and upper motor neuron ALS, these two atypical ALS subgroups can 
progress to fulfil the criteria for ALS within approximately 4 years [42]. One study showed that primary 
lateral sclerosis (pure upper motor neuron ALS) patients could also develop lower motor neurone 
signs of muscle atrophy after 3-4 years onset of the symptom [43]. In subjects with classical ALS, 
those with bulbar onset also have a heterogeneous survival time [44]. Another study showed that the 
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bulbar onset is a risk factor for reduced lifespan [45]. Advanced neuroimaging of the brain also 
indicated that there is difference in a structural and metabolic rate between bulbar onset and limb 
onset patients [46]. 
The different combinations of UMN and LMN clinical signs further complicate the description 
of the heterogeneity of ALS. As mentioned above, typical ALS which manifests muscle atrophy and 
pyramidal degeneration, accounts for about 85% of the total ALS patients [47]. However, some patients 
are characterized by predominant spino-bulbar spasticity accompanied by slight muscle atrophy, 
which is termed upper motor neuron-dominant (UMN-D) [48]. As mentioned above, progressive 
muscular atrophy (PMA) is another restricted phenotype with pure lower motor neuron involvement. 
However, some studies report that nearly half of the autopsies of patients with PMA showed UMN 
degeneration [49-51]. Some researchers reported that the reason for this is that the lower motor neuron 
signs could mask the UMN degeneration [52]. The relationship between PMA and PMA with slight 
UMN signs is still unclear. 
The rate of disease progression varies among patients. Some patients have rapid progression to 
ALS, others continue with a more protracted form of ALS with slow rate of progression. The ALS 
functional rating scale (ALSFRS-R) is a function scale which has been used to monitor progression 
of the ALS disease in the clinical setting [53]. Among subjects with typical ALS, older age and bulbar 
onset are associated with more rapid progression [54]. Conversely, patients with younger age and upper 
motor neuron predominant type of disease have a better prognosis [55]. The lower motor neuron 
dominant type of ALS has a poor prognosis due to complications such as lung or chest infection and 
increased risk of thromboembolic disease which are caused by the disability [56]. Generally, if the 
disease involves the respiratory system, the life expectancy is 2-3 years. If the patients enter into this 
stage of the disease, one study indicated that the non-invasive bi-level positive air pressure ventilation 
had a significant improvement of survival compared with those who did not use non-invasive 
ventilation [38]. 
 
1.4  Genetic and pathological overlaps between ALS and FTD  
Approximately 5–10% of the ALS patients have familial ALS and in these subjects there are 
various genetic mutations [57]. Since 1993, a number of causative genes have been identified in ALS 
patients. The first gene that was identified was superoxide dismutase-1 gene (SOD1). SOD1 
mutations are found in nearly 10% of familial ALS patients [58], but are found in less than 1% of 
sporadic ALS patients. In 2009, two other causative genes were found: transactive response DNA 
binding protein gene mutation (TARDBP) and fused in sarcoma mutation (FUS). Mutations in these 
two genes account for about 20% of familial ALS patients, but are found in less than 5% of sporadic 
ALS patients [59]. Furthermore, FUS mutations are also responsible for some juvenile familial ALS 
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cases [60]. These two gene mutations can disturb the regular DNA or RNA binding. In 2011, an intronic 
hexanucleotide repeat expansion in open reading frame 72 on chromosome 9 (C9orf72) was found to 
cause ALS [61, 62]. This gene is found in 40% of the familial cases of ALS. Interestingly, the C9orf72 
gene is also found in 10% of sporadic ALS patients in western countries [63]. Healthy people usually 
have at most 20 hexanucleotide repeats in this open reading frame. In a striking contrast, ALS patients 
have hundreds to thousands of repeats. Some other less common gene mutations have also been 
reported in the last decade. These include mutations in ubiquilin-2 gene (UBQLN2), optineurin 
(OPTN), angiogenin (ANG), heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) and calcium-
responsive transactivator (CREST) [64-67]. Some researchers have found that there is correlation 
between the site of onset and gene mutation. For patients with FUS and TARDBP mutations, upper 
limb onset was more common than in patients with SOD1 mutation [60]. Interestingly, the first onset 
site would involve both upper and lower motor neuron signs in the most ALS patients with TARDBP 
mutations [60]. The pathological inclusions caused by these two gene mutations are different, being 
the FUS protein and TDP-43, respectively. 
In FTD, C9orf72 hexanucleotide repeat expansions are found in about 30% of the total patients, 
with the other causative genes being microtubule-associated protein tau (MAPT) and progranulin 
(GRN). Mutations in these two genes account for 5% -10% of FTD patients [68]. There are also some 
other rare genes that show mutations in ALS, including valosin containing protein (VCP) and 
chromatin-modifying protein 2B(CHMP2B) gene [69]. TARDBP and FUS gene mutations are also 
reported in some familial ALS patients with FTD [70]. Another gene UNC13A has been found to have 
mutations in both ALS and FTD patients [71]. 
There is overlap of the pathology of FTD and ALS. Tau, ubiquitin, FUS, and TAR DNA-
binding protein-43 (TDP-43) proteins are all found in the inclusions of both ALS and FTD patients 
[72-75]. These proteins that are found in the aggregates are encoded by the different genes as mentioned 
above. 
Thus, there is evidence of a close association between ALS and FTD. The finding of C9orf72 
mutation in both diseases, and the finding of an aggregation of similar proteins in neurons indicate 
that these diseases have genetic and pathological overlap. However, the mechanism by which C9orf72 
repeat expansions cause disease is still unknown, although C9orf72 repeat expansions appear to be 
translated into toxic poly-dipeptides [76] and one study described that this mutation can lead to 
dysfunction of RNA splicing and sequestration of RNA-binding proteins [77]. 
 
1.5  Overlap of clinical features between ALS and FTD  
Previously, ALS was thought to be a disease of motor neurons sparing the cognitive system. 
However, it is now known that subjects with ALS can have cognitive impairment. Most of the ALS 
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patients have mild cognitive impairment and subtle executive dysfunction. Some studies have shown 
that the incidence of cognitive impairment in ALS patients is about 55 to 75% [78, 79]. One study 
reported that 51% of ALS patients had cognitive impairment over their disease course, and 49% of 
the ALS patients did not. Approximately 15% of total ALS patients will also fulfil criteria for 
diagnosis of FTD [80]. Compared with ALS patients without FTD, ALS patients with FTD have shorter 
life span [81]. One prospective study reported that ALS patients with bulbar-onset were likely to be 
vulnerable to a rapid decline of cognitive impairment. One study has shown dynamic progression 
from ALS to ALS with FTD [82].  
Therefore a variety of neurophysiological cognitive tools have been developed and used to 
screen for cognitive impairment in ALS. These include Addenbrooke’s cognitive examination–III 
(ACE-III) [83], the Frontal assessment battery (FAB) [84], the Edinburgh cognitive and behavioural 
ALS screen (ECAS) [85], and the ALS cognitive behavioural screen (ALS CBS) [86]. Some scales for 
evaluation of behavioural impairment are also used in the carers of ALS patients. These include the 
Amyotrophic lateral sclerosis-Frontotemporal dementia-questionnaire (ALS-FTD-Q) and the Motor 
Neuron Disease Behavioural instrument (MiND-B) [87, 88]. The consensus criteria for the diagnosis of 
frontotemporal cognitive and behavioural syndromes in ALS patients were established in 2009 [82]. 
The correlation between clinical heterogeneity and cognitive impairment or the rate of cognitive 
deterioration over the course of ALS is still unclear and need to be investigated. 
 
1.6  Heterogeneity of TDP-43 pathology 
As mentioned above, TDP-43 is the pathological protein which is important in both FTD and 
ALS. Deposition of TDP-43 is found in approximately 40% and 90% of the FTD and ALS patients, 
respectively [89, 90]. FUS and Tau inclusions only make up a small portion of the two diseases. The 
C9orf72 repeat mutation can cause TDP-43 pathology on rodent animal model [91]. There are four 
different pathological types in TDP-43. Type A manifests as intracytoplasmic inclusion or short 
neurites mainly in the upper cortical layer, Type B shows changes throughout the cortical layer with 
only intracytoplasmic aggregation. Long neurites are the only feature of Type C. Type D is 
characterised with intranuclear inclusion [92]. Some papers have indicated the relationship between 
TDP-43 and different stage of the ALS or FTD [93, 94].  
However, the relationship between pathological finding and ALSbi or ALSci is still elusive, 
which underlies the possible early stage mechanism transitioning from ALS towards ALS-FTD. 
Whether the pattern of spread or level of inclusion is correlated with the dynamic change of ALS-
FTD spectrum or the sequence of behavioural and cognitive impairment is still unknown. So ante 
mortem neuroimaging and post mortem pathology are the keys to unravel the mystery. If available, a 
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TDP-43 PET tracer might provide information about this dynamic change between the two diseases 
[95]. 
 
1.7  Heterogeneity of ALS animal model 
As mentioned above, SOD1 is the first causative gene to be identified in the familial ALS 
patients. More than 170 SOD1 gene mutations have been reported [52]. The SOD1 rodent model is the 
most common animal model of ALS. Different gene mutations have been used in the SOD1 mice 
model [96]. There are heterogeneous phenotypical manifestations in SOD1 models with different gene 
mutations. These vary in rate of progression, time of symptom onset and pathological findings [96].   
FUS, TDP-43, UBQLN2 and VCP mutation rodent models have also been developed [97, 98]. 
Among these models there is variation in the clinical manifestations and pathological findings, 
possibly due to different pathogenic mechanisms. What makes it further complicated is that there are 
differences in the phenotypical manifestations between ALS mice model and ALS patients with the 
identical gene mutation [99]. Some other studies have used drosophilia or zebrafish models to express 
the TDP-43 mutation [100, 101], which undoubtedly could give us a new insight into the ALS.  
These animal models, regardless of the gene mutations still need large experiments to validate. 
To date, it is still challenging to say whether these animal models can really represent the 
heterogeneous pathogenesis of ALS or just reflect one small portion of the whole process. It must be 
noted that the animal models are produced in inbred strains, with all affected animals being 
genetically identical whereas genetic mutations in patients arise in people with differing genetic 
background. Genes that modify the course of ALS have now been identified (CAMTA1, CX3CR1 
and UNC13A) [102-104] and genetic variation in these genes could modify the effects of causative genes 
such as those used for animal models. 
Induced pluripotent stem cells, which keep the characteristics of the individual patient [105], 
could be a good approach to test new therapy. Due to the heterogeneity of ALS animal model, using 
human subjects when possible is a good alternative to avoid relevant animal model bias. 
 
1.8  Biomarkers in ALS 
There is a need for a biomarker in ALS. At present there is no bodily fluid biomarker that can 
assist the clinician to make early diagnosis, monitor the progression and prognosis of ALS. A reliable 
biomarker is not only beneficial for prognosis but also would be useful in the evaluation of potential 
therapies.                
There are several types of bodily fluids that have been used for the study of biomarkers. These 
include blood, cerebrospinal fluid (CSF), urine and saliva. Among these fluids, blood and CSF have 
differing advantages. CSF is a reliable biofluid sample, and is expected to contain proteins arising 
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from the degenerating neurons because of its direct contact with the central nervous system. However, 
the more invasive procedure of collection limits the wide-scale use of CSF. Blood samples have a 
simple and less invasive process of collection, which is much more acceptable for the patients. 
Proteins released from degenerated cells into the interstitial fluid of central nervous system could 
enter the blood through lymphatic drainage [106, 107]. Blood samples can also reflect the change of the 
level of the targeted protein or peptide released from the degenerated muscle tissue [108, 109]. 
Blood contains a complex mixture of numerous proteins and reflects the dynamic state of 
patients. Therefore it is necessary to establish standardized protocols which detail the conditions for 
sampling, processing and storage, including the type of blood sample tubes and the clinical status of 
the ALS patients on the day of collection. Some researchers suggest using plasma [110], while other 
researchers recommend serum [111, 112]. The key difference between plasma and serum is that plasma 
contains fibrinogen and clotting factors which are closely related with coagulation. However, 
currently there is no consensus on which blood sample is better. However, the potential pathogenesis 
of ALS was found associated with complement and coagulation system [113], so plasma samples were 
used in this study. 
 
1.8.1  Biomarkers in plasma 
Axonal degeneration is one of the pathological characteristics of amyotrophic lateral sclerosis. 
Axonal degeneration results in the release of neurofilament medium polypeptide (NEFM) which was 
found to be significantly increased in the plasma samples of the ALS patients [114]. The same research 
group also found that levels of two other proteins (solute carrier family 25 and regulator of G-protein 
signaling 18) have close correlation with the progression of disease in ALS patients. However, the 
use of neurofilaments as a biomarker to differentiate ALS from other mimic disease needs to be 
investigated further. 
Fibronectin is a high molecular weight protein (440 kDa) which is present in most of the 
biofluids. It has the function of sustaining and supporting the neuron cells [115]. One study found that 
that the level of fibronectin was decreased in the plasma samples of the ALS patients [116]. Like 
fibronectin, transforming growth factor-β is also important in the survival, development and 
maintenance of the nervous system. Using enzyme-linked immunosorbent assay technology (ELISA), 
it was shown that levels of TGF-β1 in plasma were increased significantly with progression of the 
ALS [117]. TDP-43 protein has become a focus of ALS research. The hallmark ubiquitinated protein 
TDP-43 which is coded by TARDBP could be a good potential blood biomarker candidate. TDP-43 
has multiple functions in transcriptional repression, pre-mRNA splicing stabilization and translational 
regulation. One group found that TDP-43 was elevated in the plasma samples of the ALS patients 
[118]. 
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1.8.2  Biomarkers in serum 
There are also reports of biomarkers in the serum of subjects with ALS. It is thought that motor 
neurons die by apoptosis [119]. Some researchers have found that the level of tumor necrosis factor-α, 
which can trigger apoptosis, was upregulated in the serum of the ALS patients [120, 121]. Furthermore, 
the level of transglutaminase activity, which is also involved in apoptosis, has also been found to be 
significantly elevated in the serum samples of the ALS patients [122]. Reactive oxygen species (ROS) 
are another trigger of apoptosis. One study reported that the ALS patients have high level of serum 
ferritin which can further cause the ROS formation [123]. 
Inflammation also plays a pivotal role in the pathogenesis of ALS. In the past decades, serum 
levels of some proinflammatory cytokines or other inflammatory factors, such as monocyte 
chemoattractant protein-1(MCP-1) [124], angiogenin [125], interleukin-6 [126],chemokines 2,11,13 [127], 
matrix metalloproteinase-9 [128], lipopolysaccharide (LPS) [129] have been found to have a close 
relationship with ALS disease course and progression.           
Insulin-like growth factor (IGF) is a protein which promotes the development and survival of 
neurons. One research group found that IGF was significantly increased in ALS patients [112]. 
Conversely, another research group showed that the significant statistical difference only existed in 
CSF sample and that there was no significant difference of IGF-1 level in serum samples between 
ALS patients group and control group [130]. 
 
1.9  Mass spectrometry based proteomics application in biomarker finding 
High performance liquid chromatography (HPLC) coupled with mass spectrometry (MS) have 
been available for proteomics studies and have been used in the search for biomarkers. Several types 
of MS are used in the search for biomarkers: time of flight (TOF) MS, quadrupole MS, ion trap MS. 
Different types of MS have different advantages and disadvantages. TOF MS has higher resolution 
but lower sensitivity in comparison with quadrupole MS and ion trap MS which have better 
sensitivity. SWATHTM (Sequential Window Acquisition of all theoretical fragment-ion spectra) 
based on TOF MS is a data independent acquisition (DIA) method for MS [131]. It is a label free 
technology that offers an approach to quantify all the analytes in a sample. Quadrupole MS has the 
advantage of separating and selecting different precursor ions and product ion by changing the ratio 
of direct current to radio frequency in Q1 and Q3, respectively, which can be used in precise protein 
concentration validation. In ion trap MS, only a limited quantity of ions can be trapped, resulting in 
a narrower dynamic range than quadrupole MS. Different MS techniques can also be used together; 
this is known as tandem or hybrid MS. Tandem MS can strike a balance between resolution and 
sensitivity. In brief, MS ionizes the digested peptide and compares the peptide fingerprint data with 
protein structure database, using these fingerprint data to determine the structure of the protein. There 
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are many methods to ionize digested peptides. The main ionization methods for proteomics are 
electrospray ionization (ESI), atmospheric chemical ionization (APCI) and matrix assisted laser 
desorption ionization (MALDI). ESI is more suitable to unstable peptides than APCI which is limited 
to compounds with relatively low or medium molecular mass and samples with high thermal stability. 
Several studies have utilized different combinations of chromatography and MS to investigate the 
biomarkers of ALS in CSF and blood samples, using both proteomics and metabolomics. The results 
of these studies are summarized in Table 2 and Table 3, respectively. These biomarkers include 
proteins and small molecules. There were heterogeneous results and discrepancy about biomarkers 
across these published papers. The reason for low reproducibility could be due to the different MS 
technology and parameters settings. 
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Table 2. Mass spectrometry studies of biomarkers in the blood samples of ALS patients 
Year Number of 
ALS 
patients 
Number 
of 
healthy 
control 
Number of 
disease 
controls 
Type of mass 
spectrometry   
Upregulated biomarkers Downregulated 
biomarkers 
Reference 
2008 4 familial 
ALS 
patients 
4 N/A Matrix-assisted laser 
desorption/ionization – 
time of flight (MALDI-
TOF) mass 
spectrometry 
Group component (GC) 2 isoform of 
vitamin D binding protein 
N/A Palma et al [132]. 
2011 62/99( two 
cohorts) 
69/48 
( two 
cohorts) 
N/A Gas chromatography 
/mass spectrometry 
C-glycosyltryptophan, 
2-hydroxybutyrate, 
Creatine, 
Pro-hydroxy-pro, 
Mannose, 
Pyruvate, 
Carnitine, 
1-
Palmitoleoylglycerophosphocholine, 
Stearoyl sphingomyelin, 
Pseudouridine, 
Pantothenate, 
Riluzole, 
Caffeine 
3-
phenylpropionate, 
Tryptophan betaine, 
Indolepropionate, 
Creatinine, 
Cyclo, 
Catechol sulfate, 
4-vinylphenol 
sulfate, 
Paraxanthine, 
Theobromine, 
Theophylline 
Lawton et al [133]. 
2012 17 10 N/A High resolution 
inductively coupled 
plasma mass 
spectrometry ( HR-
ICP-MS) 
Mercury, 
Silver 
 
N/A Roos et al [134]. 
2013 30 30 N/A MALDI-TOF mass 
spectrometry 
Peptides signals from these four 
proteins (Integrin alpha-IIb, 
Zyxin,thymosin beta-4, platelet factor 
4) 
 
N/A Conraux et al 
[135]. 
2014 172 N/A 73 Gas chromatography 
/mass spectrometry 
Phosphate, 
Cortisone, 
3-methylxanthine, 
Delta-tocopherol, 
Lawton et al [136]. 
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Creatine, 
5,6-dihydrourcil, 
Iminodiacetate, 
Palmitoyl phingomyelin, 
10-undecenoate, 
Octadecanedioate, 
1,2-propanediol, 
Serine, Hexadecanedioate, 
2-hydroxybutyrate, 
Alpha-ketobutyrate, 
Dodecanedioate, 
Cholesterol, 
Prolylhydroxyproline, 
1-stearoyl-GPI, 
Arachidonate 
Theobromine, 
7-mehylxanthine, 
3-dehydrocarnitine, 
Urate, 
4-vinylphenol 
sulfate, 
Cysteine, 
Proline, 
1-methylurate, 
Pyroglutamine, 
Paraxamthine, 
Creatinine, 
Glutamine 
 
 
 
 
 
 
 
Table 3. Mass spectrometry studies of biomarkers in the CSF samples of ALS patients 
Year Number of 
ALS 
patients 
Number of 
healthy 
control 
Number of 
disease 
controls 
Type of Mass 
spectrometry   
Upregulated 
biomarkers 
Downregulated 
biomarkers 
Reference 
2004 12 10 N/A Fourier transform ion 
cyclotron resonance mass 
spectrometry ( FT-ICR-
MS) 
No specific protein was matched, however the 
characteristic peptides pattern can distinguish 
the patients correctly 
Ramström et al 
[137]. 
2005 23 16 15 Surface-enhanced laser 
desorption/ionization time 
of flight (SELDI) mass 
spectrometry 
Carboxy-terminal 
fragment of 
neuroendocrine protein 
7B2 
Transthyretin, 
Cystatin C 
Ranganathan et 
al [138]. 
2006 36 21 N/A SELDI mass spectrometry N/A 13.4ka Cystatin C, 
4.8ka peptic 
fragment of VGF, 
Pasinetti et al 
[139]. 
32 
 
6.7ka unidentified 
protein 
2008 14 14 N/A MALDI-TOF mass 
spectrometry 
Alpha-1-1 antitrypsin 
precursor, 
Zin-alpha-2-
glycoprotein 
Ceruloplasmin 
precursor, 
Transferrin, 
Beta-2-
microglobulin 
Brettschneider et 
al [140]. 
2010 100 41 100 SELDI mass spectrometry CysGly-transthyretin, 
C reactive protein 
Cystatin C 
 
Ryberg et al [141]. 
2010 18(9 patients 
for rapid 
progression,9 
patients for 
slow 
progression 
N/A N/A MALDI-TOF mass 
spectrometry 
Heat shock protein1, 
Alpha-1 antitrypsin, 
Fetuin-A precursor, 
Transferrin, 
Transthyretin(TTR), 
Nebulin-related 
anchoring proteins. 
N/A Brettschneider et 
al [142]. 
2012 35 N/A 23 MALDI-TOF mass 
spectrometry 
Secreted 
phosphoprotein 
VGF, 
Cystatin C, 
Chromogranin A 
Neuhoff et al 
[143]. 
2012 17 10 N/A High resolution 
inductively coupled 
plasma mass spectrometry 
( HR-ICP-MS) 
Manganese, 
Aluminium, Cadmium, 
Cobalt,Copper, Zinc, 
Lead, Vanadium and 
Uranium 
N/A Roos et al [134]. 
2012 110(90 
sporadic 
ALS, 20 
familial 
ALS) 
80 55 Linear ion trap( LIT) 
mass spectrometry 
RNA-binding motif 45 
protein. 
N/A Collins et al [144]. 
2013 10 10 N/A MALDI-TOF mass 
spectrometry 
Parkin, 
Splice isoform short of 
sulfotransferase 1C1,  
Splice isoform 2 of 
fizzy related protein,  
DEPC-1 protein,  
N/A Mendonça et al 
[145]. 
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Lectin, galactoside-
binding, soluble, 8 
(LGALS8),  
Stromelysin-3,  
Splice isoform 2 of 
neurotrimin precursor, 
DHHC, 
Small nuclear 
ribonuclearprotein 
associated N, 
Clathrin coat assembly 
protein AP50,  
40S ribosomal protein 
S10, 
Matrin 3,  
CYP2C19 protein, 
Lissencephaly 1, 
CYP4F3 protein, 
Solute carrier family 27 
(fatty acid transporter), 
member 4 (SLC27A4 
protein), 
Eosinophil 
lysophospholipase 
2013 66 N/A 128 Liquid chromatography 
coupled to high-resolution 
mass spectrometry(LC-
HRMS) 
N/A Peak areas of four 
Variable importance 
parameters (VIP) 
( VIP1785, VIP 
1134,VIP 414,VIP 
376) 
Blasco et al [146]. 
2013 10 10 N/A Isobaric tags for relative 
and absolute 
quantitation( iTRAQ )LC-
MS/MS 
Chitotriosidase-1 N/A Varghese et al 
[147]. 
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2014 29 N/A 19 Reversed phase high 
performance liquid 
chromatography and 
electrospray mass 
spectrometry 
Monosialylated 
diantennary glycans 
A2G2S (6)1 and 
FA2G2S (3)1 
N/A Gonçalves et al 
[148]. 
2015 105 80 60 LC-MS/MS label free 
method 
WD repeat-containing 
protein 63 
Amyloid-like 
protein 1, 
SPARC-like protein 
1, 
Cell adhesion 
molecule 3 
Collins et al [149]. 
2016 35 N/A 18 iTRAQ LC-MS/MS Glutamate receptor 4 Insulin-like growth 
factor 3 
Chen et al [150]. 
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Chapter 2.  Hypotheses and Aims  
2.1  Hypotheses of the three studies 
1: A meta-analysis will show the usefulness of neurofilaments as a biomarker to monitor the 
progression of ALS.  
2a: Patients with normal cognitive and behavioural function at onset of ALS will continue to 
be free of cognitive impairment over time. 
2b: Some ALS patients have cognitive and behavioural impairment and these have shorter 
length of survival than those without. 
3a:  Protein biomarkers will be found at different levels in the plasma of ALS patients compared 
with healthy controls. 
3b: Bio-informatic analysis of proteomic data will reveal pathways and networks that are 
dysregulated in ALS patients compared to healthy controls. 
2.2  Aims of the three studies 
Aim 1.The aim of the first study was to perform a systematic review and use meta-analysis to 
investigate whether the levels of NF in blood or CSF could be a reliable biomarker for amyotrophic 
lateral sclerosis, either in distinguishing patients from controls or as markers for monitoring disease 
progression or predicting prognosis. 
Aim 2 
a) The aim of the second study was to screen for cognitive and behavioural impairment in 
people with ALS and controls with neuromuscular disease by using ACE-III, FAB, the executive 
function component of ECAS, ALS-FTD-Q and MiND-B. In addition, the aim was to investigate 
whether the performance of ALS patients on these scales will change over the course of disease. 
b) To correlate scores of cognition and behaviour with clinical features. 
Aim 3 
a) The aim of the third study was to search for plasma biomarkers in ALS patients compared to 
healthy controls by using SWATH™ quantification analysis, to compare proteomic analysis of ALS 
patients with and without cognitive impairment (CI). 
b) The further aim was to perform pathway analysis using Ingenuity Pathway Analysis to look 
for pathways that are perturbed in ALS. 
 
 
 
 
 
 
 
36 
 
Chapter 3.  Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic 
Review and Meta-analysis 
3.1  Introduction of Chapter 3 
Neurofilaments (NF) are intermediate filaments that are major components of neuronal 
cytoskeleton. NF can be divided according to the observed molecular weight into NF light chain (68 
kDa), NF intermediate chain (160 kDa) and NF heavy chain (205 kDa) [151]. The three different NFs 
share a conserved alpha-helical rod domain, but differ in the head and tail domains [152]. NFM and 
NFH are always phosphorylated [153]. NFL is susceptible to protease degradation, while NFH, which 
is phosphorylated, can resist protein degradation [154]. Damage to axons of the central nervous system 
(CNS) or peripheral nervous system (PNS) could release the NF, which would then appear in the 
cerebrospinal fluid (CSF) and the blood, where NF can be detected with techniques such as ELISA, 
western blot and mass spectrometry [155, 156]. 
Analysis of spinal cord tissue has suggested abnormal NFH subunit accumulation in neuronal 
perikarya and spheroids in ALS patients compared with control [157]. There is a need for a biomarker 
in ALS, for use in diagnosis, prognosis and in clinical trials. Katz et al. defined biomarkers as a 
"objectively measured and evaluated parameters for indication of pathological processes, disease 
progression or response to pharmacological interventions" [158]. Various bodily fluids have been used 
for biomarkers, including blood, CSF, urine and saliva. Among these biofluids, blood and CSF have 
differing advantages, as discussed above.  
The aim of this systematic review and meta-analysis was to investigate whether NF levels in 
blood or CSF could be a reliable biomarker for amyotrophic lateral sclerosis, either in distinguishing 
patients from controls or as markers monitoring disease progression or predicting prognosis.  
 
3.2  Methods 
3.2.1  Search strategy 
A systematic search was conducted in Pubmed, Embase, Scopus and Medline, with the latest 
date of search being 20th May 2016. 
The search strategy in Pubmed was as follows: 
((((((((((("Blood"[Mesh]) OR (((("Cerebrospinal Fluid"[Mesh]) OR "Cerebrospinal Fluid") OR 
"Cerebrospinal Fluids")))) OR blood)) AND "Amyotrophic Lateral Sclerosis"[Mesh]) AND 
neurofilament*) AND "Humans"[Mesh]) AND English[lang])) AND (((((("Biomarkers"[Mesh]) OR 
biomarker*)))))) 
The search strategy in Embase was as follows: 
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 'amyotrophic lateral sclerosis'/exp AND ('biological marker'/exp OR biomarker OR 
biomarkers) AND ('neurofilament'/exp OR neurofilament OR neurofilaments) AND ('blood'/exp OR 
‘cerebrospinal fluid'/exp OR ‘cerebrospinal fluid’ OR 'cerebrospinal fluids') AND 'human'/de 
The search strategy in Scopus was as follows: 
(TITLE-ABS-KEY (“Amyotrophic Lateral Sclerosis”)) AND ((TITLE-ABS-KEY (blood) OR 
TITLE-ABS-KEY(“Cerebrospinal Fluid”) OR TITLE-ABS-KEY (“Cerebrospinal Fluids”))) AND 
((TITLE-ABS-KEY(biomarker) OR TITLE-ABS-KEY (biomarkers))) AND ((TITLE-ABS-KEY 
(neurofilament) OR TITLE-ABS-KEY (neurofilaments))) AND (LIMIT-TO(EXACTKEYWORD, 
"Human")) AND ( LIMIT-TO (LANGUAGE,"English")) 
 
3.2.2  Selection criteria 
The inclusion criteria were as follows: 
1. The study must be carried out in humans more than 18 years of age.   
2. All the subjects with ALS must be diagnosed with the EL Escorial criteria or revised El Escorial 
[7] or Awaji [8] criteria. 
3. A demographic description of the patients must be provided.   
4. The study must use NF as a biomarker in the blood or CSF to differentiate ALS patients from a 
control group or to distinguish subgroups of ALS patients.   
5. The study must provide clear description of the time point and method for collection of blood and 
CSF.  
6. The study must provide a full description of the method used to measure NF levels.   
7. The study must be the original paper rather than abstracts, posters or reviews. 
 
The exclusion criteria were as follows:  
1. The subjects were younger than 18 years.  
2. The ALS subjects had additional neurological disorders or pathologic changes such as brain 
tumour, epilepsy or brain injury.   
3. The number of subjects was less than 5.   
4. Studies without healthy controls or without disease control. 
5. The study was not published in English.  
6. Studies with missing data such as details about the demographic information and details of method 
used for NF detection.  
7. The papers are abstracts or posters or reviews 
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3.2.3  Assessment of methodological quality 
Twenty papers were selected for the final systematic review. The QUADAS-2 (Quality 
Assessment of Diagnostic Accuracy Studies) criteria were used to assess these [159]. This tool is made 
up of 4 key domains which assess the risk of bias in patient selection, index test, reference standard 
and flow and timing. The first three domains also assessed the concerns in terms of applicability. The 
assessment was done independently by Zhouwei Xu and Pamela McCombe. If there was 
disagreement, Robert Henderson was consulted to resolve the disagreement. The final results of 
quality assessment of the 20 papers and the proportion of high quality and low quality papers are 
summarized in Appendix I. 
3.2.4  Data synthesis and statistics 
By contacting the authors of the selected papers I attempted to obtain the original data, but this 
was not available. Comprehensive meta-analysis software V 2.0 (Biostat, USA) was used to perform 
the final data combination and meta-analysis. When the mean value, standard deviation (SD), 
correlation coefficient and size of cohort were not available, a series of formulas, as described by 
Hozo et al. and Wan et al. [160, 161] was utilized to estimate the sample mean and standard deviation 
from the published sample size, median, range or inter-quartile range. If the median was the only 
value provided, the study could not be included in the meta-analysis. 
The studies used a variety of disease controls. To deal with this heterogeneity, the disease 
controls were subdivided into three groups; 1) healthy control/controls without parenchymal 
involvement of the CNS, 2) ALS mimics and 3) controls with neurological disease with parenchymal 
CNS involvement. The rationale of subdividing the non-ALS individuals was that the papers in the 
meta-analysis used heterogeneous disease controls in their own analyses. These three categories could 
help scale down the complexity of the disease controls. The controls without parenchymal CNS 
involvement had a range of conditions including Guillain-Barré syndrome, tension headache, back 
pain, normal pressure hydrocephalus, facial palsy and polyneuropathy. The ALS mimics were the 
neurological diseases which have similar clinical manifestations to those of ALS. The mimic diseases 
that were reported include spinobulbar muscular atrophy, multifocal motor neuropathy with 
conduction block, inclusion body myositis, primary lateral sclerosis, multiple system atrophy, 
hereditary spastic paraplegia and benign fasciculation.   
As required by the Cochrane handbook for systematic reviews of Interventions [162], when doing 
the meta-analysis, the standardized mean difference was used to combine the overall effect on the 
basis of the mean± SD value from each study. Fisher’s Z test was used to combine the overall effect 
on the basis of the correlation coefficient and sample size. P value less than 0.05 was considered as 
significant. If the I2 statistics of the heterogeneity of the studies was less than 40 %, the fixed effect 
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meta-analysis model was chosen. If the I2 statistics was more than 50%, the random effect model was 
applied [162]. 
The results of the meta-analysis of NF concentration difference between the ALS group and the 
control groups are illustrated as forest plots that show the standardized mean difference (SMD) 
between the two groups. The results of the meta-analysis of correlations between NF and disease 
duration or progression are also illustrated as forest plots that show the correlation coefficient between 
the two variables.  
3.3  Results 
3.3.1  Study characteristics 
The total number of papers obtained from the search was 49. The flow diagram based on 
PRISMA is shown in Figure 1[163]. Appendix II shows the details of 20 papers assessed as being 
suitable for the systematic review. The details of the controls and the type of the biofluid in every 
paper are also summarized in the Appendix II. There were more studies of NFH than NFL. Because 
the NF heavy chain is phosphorylated, all the detection methods were targeted to phosphorylated 
NFH (pNFH). The terms pNFH and NFH are used interchangeably in the literature. The results of the 
meta-analysis are summarized in Table 4. 
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Figure 1. PRISMA flowchart 
 
Figure 1: Flow diagram of systematic search in the 3 databases. After removal of duplicates, reviews and 
quality control, 20 papers were suitable for analysis. 
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Table 4. Summary of the meta-analyses 
 ALS v HC/non CNS disease ALS v mimic disease ALS v CNS disease 
 No of studies Total no of 
subjects ( 
patients/ 
controls) 
P value of 
meta-
analysis 
No of studies Total no of 
subjects ( 
patients/ 
control) 
P value of 
meta-
analysis 
No of studies Total no of 
subjects 
(patients/ 
controls 
P value of 
meta-
analysis 
NFH in CSF 4 studies  
(5 cohorts) 
443/267 P<0.0001 2 studies 251/100 P=0.013 6 studies 
(11 cohorts) 
468/329 P=0.075 
NFH in blood 2 studies  117/78 P=0.068       
NFL in CSF 6 studies 
(7 cohorts) 
463/214 P<0.0001 2 studies 250/99 P<0.0001 5 studies 398/405 P=0.001 
NFL in blood 3 studies 
(5 cohorts) 
202/277 P<0.0001       
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3.3.2  NFH levels in CSF 
3.3.2.1  ALS versus healthy controls/controls without parenchymal CNS involvement 
 
In CSF, the NFH meta-analysis between ALS patients and healthy controls/controls without 
parenchymal CNS involvement was based on 5 studies [164-168], all using ELISA, including 443 ALS 
patients and 267 healthy controls (Figure 2). The level of NFH in ALS patients is significantly higher 
than that of the controls (SMD= 1.018, P <0.0001). Another paper used western blot analysis and 
identified one unique pNFH in the CSF of ALS patients, which is absent in the CSF of healthy 
controls [169]. The size of the peptide for NFH is 200 kDa. 
 
Figure 2. NFH CSF ALS-healthy 
 
Figure 2: Meta-analysis of NFH levels in CSF between ALS patients and healthy controls/controls without 
parenchymal CNS disease. The random effect model was used. There was a highly significant difference 
between the two groups (P <0.0001) 
 
 
3.3.2.2  ALS versus ALS mimic disease   
In CSF, the NFH meta-analysis between ALS patients and ALS mimic disease controls was 
based on 2 studies [168, 170] including 251 patients and 100 ALS mimic disease controls on basis of 
ELISA technology (Figure 3). The standardized mean difference is significant (SMD= 0.796, 
P=0.013).  
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Figure 3. NFH CSF ALS-mimics 
 
Figure 3: Meta-analysis of NFH levels in CSF between ALS patients and ALS mimics. The random effect was 
applied. There was a significant difference between the two groups (P=0.013) 
 
 
3.3.2.3  ALS versus other neurological diseases with CNS involvement 
The NFH meta-analysis between ALS patients and patients with other neurological disease with 
CNS involvement was based on 6 studies [148, 164-166, 168, 171] including 329 disease controls and 468 
ALS patients (Figure 4). There was no significant difference between the two groups (P=0.075).  
 
Figure 4. NFH CSF ALS-CNS disease 
 
 
Figure 4: Meta-analysis of NFH levels in CSF between ALS patients and other neurological disease with CNS 
involvement. The random effect model was used. There is no significant difference between the two groups 
(P=0.075) 
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Higher levels of pNFHSMI35 were reported in upper motor neuron dominant ALS patients than 
in those with typical ALS [164]. Higher levels were also reported in symptomatic carriers of causative 
mutations than asymptomatic carriers [167]. Another paper suggested that the ratio of CSF 
pNFH/complement C3 could be used to discriminate the ALS patients and disease control [172]. 
 
3.3.3  NFH levels in blood 
3.3.3.1  ALS versus healthy controls/controls without parenchymal CNS involvement 
The NFH meta-analysis between healthy controls/controls without parenchymal CNS 
involvement and ALS patients in blood was based on 2 studies [173, 174] including 78 healthy controls 
and 117 patients (Figure 5). The concentration of NFH in the ALS patients group was not significantly 
increased relative to the healthy controls/ without CNS involvement (P =0.068). Another paper [172] 
also found an increased level of NFH in ALS compared to healthy controls and other neurological 
disease, but there was insufficient data for inclusion in the meta-analysis.  
 
Figure 5. NFH Blood ALS-healthy 
 
Figure 5: Meta-analysis of NFH levels in blood between ALS patients and healthy controls /controls without 
parenchymal CNS disease. The random effect model was applied. There is no significant difference between 
the two groups (P=0.068) 
 
There was no significant difference in levels of NFH between patients treated with Riluzole and 
those without [173]. Bulbar onset patients were reported to have elevated concentration of NFH in 
plasma compared with spinal onset patients [175]. There is correlation of pNFH between CSF and 
blood levels of NFH [172]. Two papers reported that the concentration of NFH in the blood showed an 
initial rise but later the levels fell [173, 175] 
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3.3.4  NFL levels in CSF 
3.3.4.1  ALS versus healthy controls/controls without parenchymal CNS involvement 
The NFL meta-analysis between ALS patients and healthy controls/controls without 
parenchymal CNS involvement in CSF was based on 6 studies [167, 168, 176-179] including 463 ALS 
patients and 214 healthy controls (Figure 6). The standardized mean difference was significantly 
increased in comparison with the controls (SMD=1.627, P <0.0001). 
 
 
Figure 6. NFL CSF ALS-healthy 
 
Figure 6: Meta-analysis of NFL levels in CSF between ALS patients and healthy controls/controls without 
parenchymal CNS disease. The random effect model was applied. There is significant difference between the 
two groups (P <0.0001) 
 
 
3.3.4.2  ALS versus ALS mimic disease 
 
The NFL meta-analysis between ALS patients and mimic disease control was based on 2 studies 
[168, 170] including 250 ALS patients and 99 ALS mimic disease patients (Figure 7). The level of NFL 
in ALS mimic disease was significantly lower than the ALS patients group (SMD=0.742, P <0.0001). 
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Figure 7. NFL ALS-mimics 
 
 
Figure 7: Meta-analysis of NFL levels in CSF between ALS patients and ALS mimics. Because the I2= 0, the 
fixed effect model was applied. There is significant difference between the two groups (P<0.0001) 
 
 
3.3.4.3  ALS versus other neurological diseases with CNS involvement 
The meta-analysis of ALS patients and disease control with CNS involvement in CSF samples 
was based on 5 studies [168, 176-178, 180] including 398 ALS patients and 405 disease controls. (Figure 
8). A significant elevation of NFL was found in the ALS patients (SMD=1.352, P =0.001). 
 
Figure 8. NFL CSF ALS-CNS disease 
 
 
Figure 8: Meta-analysis of NFL levels in CSF between ALS patients and other neurological disease with CNS 
involvement. The random effect model was applied. There is significant difference between the two groups 
(P=0.001) 
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No difference of NFL level in the CSF was found between different phenotypes and no 
correlation was found between NFL level in the CSF and EMG features of lower motor neuron 
denervation [180]. The level of NFL in the CSF of symptomatic ALS gene mutation carriers was 
significantly greater than that of asymptomatic ALS mutation carriers [167] and patients carrying a 
SOD1 mutation have a lower concentration of NFL than those without [177]. 
 
3.3.5  NFL levels in blood 
3.3.5.1  ALS versus healthy controls/controls without parenchymal CNS involvement 
In blood, the NFL meta-analysis between ALS patients and healthy controls /controls without 
CNS involvement was based on 3 studies [167, 178, 179] including 277 healthy controls and 202 ALS 
patients (Figure 9). The standardized mean difference between the two groups was statistically 
significant (SMD=1.448, P<0.0001). All the papers used ELISA except for one which used 
electrochemiluminescence (ECL) based immune assay [178].   
 
Figure 9. NFL Blood ALS-healthy 
 
Figure 9: Meta-analysis of NFL levels in blood between ALS patients and healthy controls/controls without 
parenchymal CNS disease. The fixed effect model was applied. There is significant difference between the 
two groups (P< 0.0001) 
 
 
Symptomatic ALS gene mutation carriers had significantly increased blood levels of NFL 
compared to asymptomatic carriers of causative mutations [167]. There were no differences in the blood 
NFL level between ALS patients treated with Riluzole and those without [173]. Three papers found 
that there was a high correlation of NFL levels between CSF and serum and/or plasma [167, 178, 179].  
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3.3.6  Correlation with the measures of disease. 
In the papers selected for analysis, there have been attempts to determine whether levels of NF 
are related to clinical features of disease. This has been done by examining the relationship of NF 
with the disease duration, disease progression measured by revised ALS functional rating scale 
(ALSFRS-R) [53] and survival time. There was considerable heterogeneity among the statistical 
approaches used in the different papers, so only limited meta-analysis was possible. 
 
3.3.6.1  Correlation with disease duration 
The extracted results and statistical methods of the correlation with disease duration are 
summarised in Appendix III. The majority of papers showed a negative correlation of disease duration 
with NF levels. There was heterogeneity in the statistical methods. However, a meta-analysis was 
possible for correlation of CSF NFH and NFL levels with disease duration. These are shown in Figure 
10 and Figure 11, respectively.  
The correlation meta-analysis between CSF NFH and disease duration was based on 2 studies 
[167, 168] including 516 patients. The overall correlation coefficient was significant (r=-0.447, 
P<0.0001). The correlation meta-analysis between CSF NFL and disease duration was based on 4 
studies [167, 168, 177, 180] including 622 patients. The overall correlation coefficient was significant (r=-
0.486, P<0.0001). 
 
Figure 10. CSF NFH and disease duration 
 
Figure 10: Meta-analysis of correlation between CSF NFH and disease duration. The fixed effect model was 
applied. There is significant negative correlation between two variables (P< 0.0001) 
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Figure 11. CSF NFL and disease duration 
 
Figure 11: Meta-analysis of correlation between CSF NFL and disease duration. The random effect model was 
applied. There is significant negative correlation between two variables (P< 0.0001) 
 
 
3.3.6.2  Correlation with disease progression 
The extracted results and statistical methods of the correlation with disease progression are 
summarised in Appendix III. The papers used different statistical methods to find the correlation with 
ALSFRS-R or the rate of change of ALSFRS-R. Cross sectional correlation of NF levels with 
ALSFRS-R scores and comparison between patients with rapid progression and those with slow 
progression were also mentioned in the papers. A meta-analysis was possible for correlation of CSF 
NFH and NFL levels with ALSFRS-R score. These are shown in Figure 12 and Figure 13 
respectively.  
The correlation meta-analysis between CSF NFH and ALSFRS-R score was based on 3 studies 
[167, 168, 175] including 536 patients. The overall correlation coefficient was significant (r=-0.279, 
P=0.011). The correlation meta-analysis between CSF NFL and ALSFRS-R was based on 3 studies 
[167, 168, 180] including 543 patients. The overall correlation coefficient was not significant (r=-0.175, 
P=0.156). One study suggested using the ratio CSF pNFHSMI35/CSF soluble beta-amyloid precursor 
protein (sAPP) α - β to monitor disease progression [165]. Another paper discovered that the CSF NFL 
was correlated with spreading from localized to generalized weakness [181]. 
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Figure 12. CSF NFH and ALSFRS-R 
 
Figure 12: Meta-analysis of correlation between CSF NFH and ALSFRS-R. The random effect model was 
applied. There is significant negative correlation between two variables (P= 0.011) 
 
 
Figure 13. CSF NFL and ALSFRS-R 
 
 
Figure 13: Meta-analysis of correlation between CSF NFL and ALSFRS-R. The random effect model was 
applied. There is no significant negative correlation between two variables (P= 0.156) 
 
 
3.3.6.3  Correlation with survival time or prognosis 
The extracted results and statistical methods of the correlation with survival time or prognosis 
are summarised in Appendix III. Due to the considerable heterogeneity of statistical methods, meta-
analysis of correlation between NF and survival time was impossible. Several papers found that the 
level of NF or the rate of rise of NF was negatively correlated with survival time or increasing odds 
ratio of death in both CSF and blood [168, 173, 175, 177, 179, 180]. Only one paper pointed out that no 
correlation was found between cumulative mortality and base line pNFH [174]. 
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3.3.7  Sensitivity and Specificity of NF 
Some of the papers provided and used receiver operating characteristic (ROC) to analyse the 
sensitivity and sensitivity of the NF levels in distinguishing ALS from the various control groups. 
The extracted results of ROC are shown in the Appendix IV. Different optimal cut-off values were 
used among the papers, the sensitivity of ROC analysis ranges from 0.71 to 0.91. The specificity of 
ROC analysis ranges from 0.647 to 0.95. The area under the curve (AUC) ranged from 0.77 to 0.9987. 
There were few ROC analyses on blood NF. 
 
3.4  Discussion 
This study analysed the reports of NFH and NFL as biomarkers of ALS. The studies used 
different controls to compare with ALS patients. The studies were grouped into those that used 
healthy controls or controls without parenchymal CNS disease, those that used ALS mimic diseases 
and those that used CNS parenchymal diseases to compare with ALS. In CSF, both NFL and NFH 
levels were significantly greater in ALS than in healthy controls/patients without parenchymal CNS 
disease, while for blood, NFL levels showed a highly significant difference. For NFH, the number of 
subjects was lower than for CSF, and the difference was not statistically significant. Comparing ALS 
with other CNS disease, and comparing ALS with ALS mimic disease, only CSF was studied. CSF 
NFL and NFH levels were significantly greater in ALS than ALS mimic disease. CSF NFL levels, 
but not CSF NFH levels, were significantly greater in ALS than the other CNS diseases that were 
tested.  
Before doing the meta-analysis, I attempted to obtain original data from the author of every 
paper. However, it was not possible due to confidentiality or other various reasons. Therefore a series 
of formulas was used to infer and calculate the mean and SD from the published sample size, median, 
range or inter-quartile range. These formulas are widely accepted and have been used in other meta-
analysis [182, 183]. 
The finding that NFH levels are higher in ALS than in healthy controls/non CNS parenchymal 
disease is consistent with the view that damage to axons releases NF. There was a significant 
difference between CSF NFL and the CNS diseases used as controls, but it must be noted that 
elevation of NF levels is not specific for ALS and has been reported in a number of other CNS 
diseases [184, 185] [152, 186-189]. For example, levels of NF in subarachnoid haemorrhage were much 
higher than those in ALS patients [166] and similar results were also observed in the other studies [190, 
191].  
In the meta-analysis, GBS data was included in the control group without parenchymal CNS 
involvement. However, two researchers reported that the level of NFH or NFL in the CSF of GBS 
patients was higher than that in the other neurological disease such as AD and PD with CNS 
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involvement but less than in ALS [166, 178]. NF are found in peripheral as well as central nervous system 
axons, and can also be released by peripheral axonal degeneration.  
Given that raised NF levels are not specific for ALS, the most useful role of NF levels is likely 
to be in monitoring duration, progression or prognosis of disease. Therefore meta-analyses of the 
correlation between CSF NFH or CSF NFL with ALSFRS-R score and disease duration were 
performed. The final results showed that CSF NFH had a significant negative association with both 
disease duration and progression. Significant correlation was also found between CSF NFL and 
disease duration. Conversely no significant relationship was found between CSF NFL and disease 
progression. Worse prognosis or high odds ratio of death was also closely related with high baseline 
NF in most of the papers. However, the association of NFL levels with these clinical features still 
needs to be verified and replicated with a larger cohort by using same or standardized measurement 
scale in these three fields. There were some attempts to correlate NF levels with disease phenotype, 
but these were few. 
To advance the field of NF as a biomarker, there needs to be standardization of the techniques 
that are used. In the papers reviewed here, ELISA, electrochemiluminescence (ECL) based 
immunoassay and western blot were used, with ELISA being used most commonly. One paper 
pointed out the traditional ELISA kit method was more sensitive than the ECL based immunoassay 
[192]. The versions of ELISA used in these studies were more sensitive than earlier methods [156, 193, 
194]. The minimum detectable limit of NFL ELISA kit used by the relevant papers ranges from 30 
ng/ml to 125ng/ml. The phenomenon of the "hook effect" is an issue with measurements of NFH. 
This effect occurs when there is neurofilament aggregation in the sample [195]. Appropriate dilution 
of blood samples can prevent this effect and assist in accurate quantification by immunoassay. This 
phenomenon was not observed in NFL in blood or with either NFL or NFH in CSF. As to the 
specificity and sensitivity of NF in the ALS patients, they not only depend on the detection methods 
as mentioned above, but also on the optimal cut-off and what other diseases to be differentiated from 
ALS. Patients with neurological diseases with axonal injury were less easy than healthy people to 
differentiate from ALS. 
The stability of various isoform affects the level of NF in the blood. Phosphorylation of NF is 
one of the important issues in study of NF, which plays a key role in the dynamic of NF. Protease 
found in blood can degrade the NF. Dephosphorylation of NF could facilitate its self-degradation, 
while phosphorylation can prevent the protease related degradation [154]. Kinase and phosphatase have 
a close relationship with the phosphoration and dephosphorylation of NF [196]. Dysregulation of kinase 
and phosphatases or altered sensitivity of protease could alter the level of NF in the blood [197]. High 
levels of antibodies directed against NF have been seen in the ALS patients compared to healthy 
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controls, especially in advanced ALS [198]. This could lead to a reduction in the bioavailability of NF 
and a reduction in detection of NF. 
In summary, a series of meta-analyses have shown that the NFH and NFL in CSF sample can 
be used to discriminate the ALS patients from the healthy people, and ALS mimics. NFL chain in 
CSF and blood sample can also be used to differentiate the ALS patients from the other neurological 
diseases and healthy people respectively. There is promising evidence that NF levels could be used 
to monitor disease progression but this needs further work. 
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Chapter 4.  Screening for Cognitive and Behavioural Impairment in Amyotrophic Lateral 
Sclerosis: frequency of abnormality and effect on survival 
4.1  Introduction of Chapter 4 
Amyotrophic lateral sclerosis is defined by progressive loss of upper and lower motor neurones 
[7]. Some people with ALS also have FTD while others have lesser degrees of cognitive impairment 
[89]. Some of the overlap between ALS and FTD is associated with the presence of a C9orf72 gene 
mutation [61, 62]. Different approaches have been used to study the frequency of cognitive impairment 
in ALS. Full neuropsychological testing is time-consuming. Therefore a variety of simple tools have 
been used to screen for cognitive impairment in ALS. These include ACE-III, an updated version of 
the ACE-R [83, 199-201], FAB [84, 202, 203], ECAS, which includes tests of social cognition [85, 204-207] and 
ALS CBS [86]. Table 5 shows the elements tested in the different tools. Other scales have been 
developed to detect behavioural dysfunction in ALS [87, 88]. These include ALS-FTD-Q and the 
MiND-B, which are administered to carers of the patients.  
With such screening tools, the incidence of the cognitive impairment in ALS ranges from 30 to 
75% [78, 79, 208, 209] and the rate of behavioural impairment ranges from 14% to 40% [85, 209-211] (Table 
6). 
Table 5. Summary of domains tested by screening tools used in ALS 
Cognitive Domain 
 
ACE-III FAB ECAS ALS CBS 
Attention  
 
Yes* No No Yes 
Memory  
 
Yes* No Yes  No 
Verbal fluency  
 
Yes* Yes* Yes Yes 
Language or conceptualization  Yes* Yes* Yes No 
Visuospatial 
 
Yes* No No No 
Prehension behaviour 
 
No Yes* No No 
Executive function 
 
No Yes* Yes* Yes 
Social cognition (as part of 
executive function) 
 
No No Yes* No 
           *Test used in the present study 
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Table 6. Summary of studies of cognitive and behavioural impairment in ALS 
Measurement Country/year No of 
patients 
Percentage of 
cognitive 
impairment 
Percentage of 
behavioural 
impairment 
Reference 
ALS CBS USA/2016 274 54% 14% Murphy et al.[209] 
ECAS China/2016 84 36 % 27 % Ye et al.[204] 
ECAS Italy/2016 107 37% 54% Poletti et al.[207] 
ALS CBS USA/2015 86 62% 37% Bock et al.[212] 
FAB Greece/2015 34 50% N/A Nidos et al.[213] 
ALS CBS Spain/2015 50 46% 18% Turon-sans et al.[214] 
ACE-R China/2014 145 30% N/A Wei et al.[208] 
FAB  Canada/2014 44 21%  N/A Osborne et al.[215] 
MoCA Canada/2014 39 53% N/A Osborne et al.[215] 
FAB and FBI China/2014 126 32% 46% Wei et al.[208] 
ECAS Germany/2014 136 22% 30% Lule et al.[205] 
FAB USA/2009 16 50% N/A Oskarsson et al.[216] 
                                      FBI: Frontal behaviour inventory MoCA: Montreal cognitive assessment    
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Current evidence suggests that some people with ALS have cognitive and behavioural 
impairment, and others do not. The cause of behavioural impairment in ALS is unclear. As already 
mentioned, carriage of a repeat expansion in C9orf72 is a cause of cognitive impairment in ALS, but 
there could be other factors, including other genes such as TARDBP. There have been attempts to 
determine whether clinical features are correlated with the presence of cognitive and behavioural 
testing. Some studies have found cognitive impairment to be more common in people with bulbar 
onset than limb onset of ALS [217]. However, other studies suggest that site of onset has no influence 
on the presence of cognitive impairment [80, 218, 219]. Therefore further information is required.  
There have also been studies of whether the presence of cognitive or behavioural impairment 
affects prognosis, as might be the case if the presence of cognitive impairment indicates more severe 
or widespread disease. Some studies have suggested that the presence of cognitive impairment [220] 
or behavioural abnormality is associated with worse prognosis [221]. However, other studies suggest 
that cognitive impairment has no influence on survival [219]. Therefore further information is required. 
Another possibility is that cognitive impairment, and other extramotor features of ALS, might 
develop in all people with ALS over time, as disease spreads more widely [222]. If this were the case, 
cognitive impairment would correlate with disease severity, but there is little information about this. 
There is conflicting information about whether there is later development of cognitive impairment in 
patients who are cognitively normal at onset of ALS [218, 223-225]. Further information is required about 
this issue as well.  
The first aim of the study was to measure cognitive and behavioural impairment in the ALS 
patients by using 5 different clinic based questionnaires (ACE-III, FAB, the executive component of 
the ECAS, ALS-FTD-Q, MiND-B), and to compare with results from controls with other 
neuromuscular disease, with the hypothesis that cognitive and behavioural impairment in ALS is 
greater than in neuromuscular disease. The rationale for this study was that people with neurological 
disorders would be more suitable controls than healthy people, because people with neuromuscular 
disease attending the same department would have similar background and experience many of the 
same physical difficulties as people with ALS attending the clinic.  
The second aim was to determine whether the presence of cognitive and behavioural 
impairment is related to the clinical features of the patient, to test the hypotheses, based on previous 
reports, that bulbar onset of ALS is correlated with cognitive impairment, that age and education 
would influence cognition in ALS, as is the case in healthy people [226] and that cognitive impairment 
is related to disease severity as would be the case if cognitive impairment occurs with more severe 
and widespread disease. The rationale for this was to provide further information about this 
unresolved issue. The third aim was to evaluate the effects of cognitive and behavioural impairment 
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on survival, with the hypothesis that the presence of cognitive impairment indicates more severe and 
wide spread disease as the disease develops, and would be expected to worsen prognosis. 
The final aim was to determine if there is deterioration in cognition and behaviour over time. 
The reasoning behind this study was to investigate whether patients who are cognitively normal at 
onset develop dysfunction over time, or whether ALS can be divided into people with cognitive issues 
and people without cognitive issues. 
 
4.2  Methods 
4.2.1  Subjects 
People with probable or definite ALS [7] were recruited from the multidisciplinary MND clinic 
at Royal Brisbane and Women’s Hospital (RBWH). The caregivers of the patients were also asked to 
complete questionnaires about the behaviour of the person with ALS. There was no systematic genetic 
testing; however, 5 of the people with ALS were known to have causative mutations (3 with C9orf72 
repeat expansions, one with TARDBP mutation and one with SOD1 mutation). Of 81 people with 
ALS for whom there was information about the family history of ALS, 10 had familial ALS. 
Information about a family history of dementia was available from 54 people with ALS, of whom 10 
had a positive family history. 
The controls were people with neuromuscular diseases with no evidence of disease of the 
central nervous system. Informed written consent was obtained from all participants and caregivers. 
This research project was approved by the RBWH ethics committee (HREC/15/QRBW/68).  
 
4.2.2  Clinical details 
The age, gender, the date of onset of symptoms and the site of onset of symptoms were recorded. 
The ALSFRS-R [53] was recorded at each visit. When applicable, the date of death was recorded and 
the length of survival from onset of disease to death or censoring was calculated. 
 
4.2.3  Cognitive and behavioural tests 
All participants were tested with the ACE-III, which has a maximum possible score of 100. A 
score of less than 88 was defined as possible cognitive impairment [227]. The FAB, with a maximum 
possible score of 18, was also administered to all participants. A score of less than 12 was regarded 
as high possibility of cognitive impairment [202]. 
The executive function section of the ECAS (which includes reverse digit span, alternation, 
sentence completion and social cognition) was added to the testing panel later in the study. It was 
administered to 41 people with ALS and 30 controls. The cutoff value for cognitive impairment is 33 
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of 48 [85]. Some people with ALS were unable to complete the tests due to physical disability. This 
was the case for 19 people for the ACE-III and for 3 for the FAB. To deal with this, the percentage 
of correct responses of the items that were tested was calculated, and then the final score was 
estimated as this percentage of the total possible. This approach is an approximation, but has been 
used by others in this field [228].  
Carers were tested with ALS-FTD-Q and MiND-B to detect behavioural abnormalities in the 
ALS patients. The MiND-B evaluates disinhibition, apathy and stereotypical behaviour. The cutoff 
values for ALS-FTD-Q and MiND-B were 29 and 34, respectively [87, 88]. The relationship between 
the carer and the person with ALS was also recorded.   
To evaluate any changes over time, serial cognitive tests, at intervals of 6 months or more, were 
obtained from 37 patients.  
 
4.2.4  Statistical analysis 
Statistical analysis was performed with SPSS 20 software. To compare groups, t-test was used 
if the variables were normally distributed. Otherwise, the data were compared with the Mann-
Whitney U test for two independent groups. To compare the proportions of groups, the χ2 test was 
used. To determine whether cognitive and behavioural function were influenced by clinical features, 
multiple logistic regression was used to evaluate the effects of age, gender, disease duration at the 
time of testing, years of education, site of onset and relationship of the carer to the person with ALS, 
To determine whether there was an association between disease severity measured by ALSFRS-R 
and scores of cognitive and behavioural testing, the Spearman rank test was used. To assess the effects 
of cognition and behaviour on survival, Kaplan-Meier curve and log rank test were utilized to 
compare survival between patients with normal and those with abnormal results. A Cox proportional 
regression model was used to report the hazard ratio and 95% confidence interval for each cofactor 
affecting prognosis. A generalized estimating equation model was used to test the longitudinal data. 
The model based estimator was chosen in the covariance matrix. Unstructured working correlation 
matrix was selected. P<0.05 was considered to be significant.  
 
4.3  Results 
4.3.1  Clinical features 
Clinical features of patients and controls, and numbers of participants for each test, are given 
in Table 7. The diagnoses of the people with neuromuscular disease are given in Table 8. 
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Table 7. Clinical features of the patients and controls 
 ALS Other neuromuscular 
disease 
P value# 
Total number  108 60  
Males: females 68/40 35/25 0.5550 
Age (mean, SD) 63.8±10.6 62.3±12.1 0.4025 
Years of school education( median, range)  11 (5,30) 10 (7,19) 0.1160 
Number tested with ALSFRS-R  88 N/A  
Number tested with ACE-III 108  60  
Number needing adjustment of ACE-III* 19 N/A  
Number tested with FAB 108  60  
Number needing adjusting of FAB* 3 N/A  
Number with executive section of ECAS 41 30  
Number tested with ALS-FTD-Q 84 N/A  
Number tested with MiND-B 66 N/A  
        *In these patients, some test items were omitted and the score was adjusted 
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Table 8. Diagnoses of controls 
Disease category No  
Peripheral nerve disorder  
Idiopathic neuropathy 15 
Carpel tunnel syndrome 2 
Diabetic neuropathy 2 
Guillain–Barré syndrome 1 
Pelvic neurofibroma 1 
Charcot-Marie-Tooth disease 5 
Anterior interosseous syndrome 1 
Anti Myelin-associated glycoprotein (MAG) neuropathy 1 
Brachial plexus injury 1 
Cramp fasciculation syndrome 1 
Chronic inflammatory demyelinating polyneuropathy 3 
Schwannoma posterior tibial nerve 1 
Small fibre neuropathy 2 
Trigeminal neuropathy 1 
Multifocal motor neuropathy 2 
Muscle disease  
Mitochondrial myopathy 2 
Pompe disease 1 
Inclusion body myositis 3 
Facioscapulohumeral muscular dystrophy 5 
Myopathy 1 
Idiopathic hyperCKemia 1 
Anterior horn cell non-ALS  
Spinal muscular atrophy type 2 1 
Myasthenia gravis 7 
Total 60 
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4.3.2  What is the prevalence of cognitive and behavioural impairment? 
The frequency distributions of ACE-III and FAB scores in disease controls and ALS patients 
are shown in Figure 14. The cognitive test scores are summarized in Table 9. There were significant 
differences in total ACE-III, ACE-III attention and language scores and FAB total score between the 
groups. There were no significant differences in the other components of the ACE-III or in the 
executive section of the ECAS. In the different groups, the percentages of subjects with cognitive 
impairment are shown in Table 10. Between people with ALS and controls there was a significant 
difference in the percentage with abnormal results of ACE-III and FAB. However, no significant 
differences were found between the two groups in the scores of ECAS executive function and social 
cognition.  
Of the patients with known causative genes, one with C9orf72 repeat expansions had normal 
cognitive function, and the other patients (2 with C9orf72 repeat expansions, one with TARDBP 
mutation and one with SOD1 mutation) had cognitive impairment, defined as abnormal result on 
ACE-III testing.  
 
Figure 14. Frequency distribution of ACE-III and FAB in ALS and controls 
 
 
Figure 14: A: Frequency distribution of ACE-III in ALS patients. B: Frequency distribution of FAB in ALS 
patients. C: Frequency distribution of ACE-III in disease control. D: Frequency distribution of FAB in disease 
control. 
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Table 9. Results of cognitive tests 
Test ALS  Controls P value# 
ACE-III total score ( median range) 92 (60-100) 94 (79-100) P=0.023* 
        Attention score ( mean SD) 16.4±1.9 17.2±1.0 P=0.003** 
        Memory score ( mean SD) 23.1±2.9 23.6±2.0 P=0.552 
        Fluency score ( mean SD) 10.9±3.0 11.6±2.2 P=0.343 
        Language score ( mean SD) 24.5±2.1 25.2±1.0 P=0.024* 
        Visuospatial score ( mean SD) 15.3±1.1 15.5±0.9 P=0.305 
FAB total score ( median range) 16(6-18) 17(12-18) P=0.004** 
ECAS executive score ( median 
range) 
40(17-45) 40(26-47) P=0.487 
        Social cognition subsection 
score(median range) 
12(0-12) 12(0-12) P=0.192 
         *: P<0.05 **: P<0.01 # Mann-Whitney U test was used. 
 
 
Table 10. Percentage of people with cognitive impairment 
Test  Cut off value for 
abnormality 
ALS 
percent 
abnormal   
Controls 
percent 
abnormal 
P value# 
ACE-III  ≤88 30.0% 11.7% P=0.013* 
FAB  ≤12 14.0% 3.3% P=0.033* 
ECAS executive 
function 
≤33 22.0% 16.7% P=0.802 
     *: P<0.05, # χ2 test was used 
 
The behavioural test scores are shown in Table 11. The frequencies of behavioural impairment 
measured by ALS-FTD-Q and MiND-B are 32.1% and 39.4%, respectively. The rates of 
disinhibition, apathy and stereotypical behaviour are 9.1%, 21.2% and 7.6%, respectively. 
 
 
Table 11. Results of behavioural testing 
Test  Cut off value for 
abnormality 
ALS  
(median, range) 
Percentage with 
abnormality 
ALS-FTD-Q score ≥22 15(0-57) 32.1% 
MiND-B total score  <34 34(14-36) 39.4% 
          Disinhibition  <13 16(8-16) 9.1% 
          Apathy  <9 11(4-12) 21.2% 
          Stereotypical 
behaviour  
<5 8(2-8) 7.6% 
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4.3.3  Correlation between cognitive and behavioural impairment and other clinical features 
Multiple logistic regression analysis was used to investigate whether age, gender, years of 
education, disease duration at the time of testing and site of onset influenced the results of the ACE-
III, FAB and ECAS cognitive tests. The detailed results are given in Table 12. For ACE-III, age and 
years of education influence the results. One year increase in age can increase hazard odds of 
cognitive impairment on ACE-III testing by 5.3%, while one year increase in the years of school 
education can reduce hazard odds of cognitive impairment by 27%. There was no effect of site of 
onset, disease duration and gender on the results of ACE-III testing.   
For ECAS executive function, one year increase in education can decrease by 26% of the hazard 
odds ratio of cognitive impairment. The other clinical factors did not affect the test result. 
For FAB, the site of onset affected the results. Compared with lower limb onset, people with 
bulbar onset of ALS had 61% less hazard odds ratio of cognitive impairment. There was no significant 
correlation between other variables and cognitive impairment as measured by FAB. 
The effects of the clinical variables in ALS-FTD-Q and MiND-B are presented in Table 13. 
Age, gender disease duration and the relationship of the carer to the person with ALS had no 
significant effect on behavioural impairment. 
The results of ACE-III and FAB in patients with and without positive family history of ALS 
and dementia are summarized in Table 14, Table 15, Table 16 and Table 17, respectively. The 
presence of a positive family history of ALS or dementia had no significant effect on the cognitive 
impairment based on ACE-III and FAB results.  
The correlation between disease severity measured by ALSFRS-R and cognitive function 
measured by ACE-III, FAB and ECAS was assessed by using Spearman correlation tests (Figure 15). 
There was no significant correlation. This indicates that cognition does not worsen as the disease 
becomes more severe. 
The relationship between disease severity (ALSFRS-R) and behavioural testing (ALS-FTD-Q 
or MiND-B) was assessed by Spearman correlation tests (Figure 16). There was a significant negative 
relationship between ALS-FTD-Q and ALSFRS-R score. There is a significant positive association 
between MiND-B and ALSFRS-R score. This indicates that behavioural impairment becomes worse 
as disease becomes more advanced. 
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Table 12. The multiple logistic regression results of ACE-III, FAB and ECAS  
  B    Sig    Exp(B)  
 ACE-III FAB ECAS  ACE-III FAB ECAS  ACE-III FAB ECAS 
Age 0.052 0.050 0.013  0.035* 0.143 0.809  1.053 1.053 1.013 
Gender -0.132 1.067 -0.300  0.794 0.129 0.754  0.876 0.876 0.741 
Years of education -0.310 -0.272 -0.611  0.018* 0.119 0.045*  0.733 0.733 0.743 
Disease duration -0.001 0.000 -0.001  0.160 0.429 0.232  0.999 0.999 0.999 
Site of onset     0.115 0.024 1.000     
Bulbar -0.953 -2.714 -0.011  0.144 0.019* 0.999  0.386 0.386 0.989 
Upper limb 0.496 -1.454 -20.287  0.384 0.054 0.196  1.642 1.642 0.000 
*: P<0.05, the reference variables for gender and site of onset are female and lower limb onset 
 
 
 
Table 13. The multiple logistic regression results of ALS-FTD-Q and MiND-B  
 B  Sig  Exp(B) 
 ALS-FTD-Q MiND-B  ALS-FTD-Q MiND-B  ALS-FTD-Q MiND-B 
Age 0.013 -0.034  0.601 0.195  1.013 0966 
Gender 0.144 0.534  0.786 0.356  1.155 1.705 
Disease duration -0.001 0.000  0.138 0.441  0.999 1.000 
Carer’s relationship    0.709 0.935    
Partner or spouse 0.558 -0.543  0.641 0.714  0.913 0.581 
Children or parents -0.091 -4.84  0.949 0.774  0.209 0.616 
  The reference variables for gender and carer’s relationship with patient are female and siblings or good friends 
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Table 14. Summary of family history of ALS based on ACE-III 
 
 
 
 
 
 
Table 15. Summary of family history of dementia based on ACE-III 
 Total number Cognitive impairment No cognitive impairment P value for χ2 test 
Family history of dementia 10 3 7  
No family history of dementia  44 9 35 P=0.67 
 
 
 
Table 16. Summary of family history of ALS based on FAB 
 Total number Cognitive impairment No cognitive impairment P value for χ2 test 
Family history of ALS 10 1 9  
No family history of ALS 71 10 61 P=1.00 
 
 
 
Table 17. Summary of family history of dementia based on FAB 
 Total number  Cognitive impairment No cognitive impairment P value for χ2 test 
Family history of dementia 10 1 9  
No family history of dementia 44 7 37 P=1.00 
 
 
 Total  Cognitive impairment No cognitive impairment P value for χ2 test 
Family history of ALS 10 4 6  
No family history of ALS 71 19 52 P=0.46 
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                 Figure 15. Correlation between ACE-III, FAB and ECAS score and ALSFRS-R 
score. 
 
Figure 15: A: Correlation between ACE-III and ALSFRS-R score. B: Correlation between FAB and ALSFRS-
R C: Correlation between ECAS and ALSFRS-R. No significant correlation was found between ACE-III and 
ALSFRS-R score (P=0.732). No significant correlation was found between FAB and ALSFRS-R score 
(P=0.957). No significant correlation was found between ECAS and ALSFRS-R score (P=0.957). 
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Figure 16. Correlation of behavioural testing with disease severity 
 
Figure 16: A: ALS-FTD-Q correlation with ALSFRS-R. B: MiND-B correlation with ALSFRS-R. Significant 
negative correlation was found between ALS-FTD-Q score and ALSFRS-R score (P=0.0068).Significant 
positive correlation was found between MiND-B score and ALSFRS-R score (P=0.02). The solid red line and 
red curve line are the simple linear regression and its 95% confidence interval, respectively 
 
 
4.3.4  Correlation with the survival time in cognitive and behavioural tests 
The effect on survival of cognitive and behavioural impairment measured by ACE-III, FAB, 
ALS-FTD-Q and MiND-B was assessed. The results for ACE-III, FAB, ALS-FTD-Q and MiND-B 
are shown in Figure 17. There is a significant effect on survival of cognitive and behavioural 
impairment measured by ACE-III and ALS-FTD-Q. For cognitive impairment measured by FAB, 
there was an apparent effect, but this was not statistically significant. For behavioural impairment 
measured by MiND-B, there was no apparent effect on survival.   
Cox regression analysis of the effects of cognitive and behavioural testing and other clinical 
features on survival was performed. The Cox regression models of ACE-III, FAB, ALS-FTD-Q and 
MiND-B which included age, gender and site of onset are shown in Table 18, Table 19, Table 20, 
Table 21, respectively. 
Patients with cognitive impairment defined by performance on ACE-III had significantly 
shorter survival than the patients without cognitive impairment (P=0.0276), with no additional effect 
of age or gender. There was no significant effect on survival time based on FAB (P=0.1746). The site 
of onset affected the survival time of patients with bulbar onset leading to a significant increase in 
comparison with the patients with lower limb onset after adjusting the age, gender and cognitive 
impairment ( P=0.045). 
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Patients with behavioural impairment based on ALS-FTD-Q had significantly shorter survival 
than the patients without (P=0.0054). There are no significant differences between survival time of 
patients with and without behavioural impairment assessed with MiND-B (P= 0.5685). The Cox 
regression model of MiND-B illustrates that other variables including gender, age, disinhibition, 
apathy and stereotypical behaviour do not impact the survival time of the patients.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
Figure 17. Survival curve of ACE-III, FAB, ALS-FTD-Q and MiND-B 
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Figure 17:A: Kaplan Meier survival curve of ACE-III. B: Kaplan Meier survival curve of FAB. C: Kaplan 
Meier survival curve of ALS-FTD-Q. D: Kaplan Meier survival curve of MiND-B 
 
 
Table 18. Cox regression model based on ACE-III test 
 B Sig Exp(B) 
Age 0.014 0.415 1.014 
Gender 0.208 0.551 1.231 
Cognitive impairment -0.823 0.014* 0.439 
Site of onset    
         Bulbar 0.732 0.072 2.078 
         Upper limb -0.316 0.414 0.729 
                               *: P<0.05 the reference of site of onset variable is lower limb 
                                 The reference of gender is female 
 
 
Table 19. Cox regression model based on FAB test 
 B Sig Exp(B) 
Age 0.017 0.361 1.017 
Gender 0.085 0.812 1.089 
Cognitive impairment -0.623 0.212 0.536 
Site of onset    
         Bulbar 0.888 0.045* 2.430 
         Upper limb -0.129 0.760 0.879 
                    *: P<0.05 the reference of site of onset variable is lower limb 
                                  The reference of gender is female 
 
  
  
Table 20. Cox regression model based on ALS-FTD-Q score 
 B Sig Exp(B) 
Age 0.019 0.324 1.020 
Gender 0.028 0.948 1.028 
Behaviour impairment -1.004 0.010* 0.366 
                                  *: P<0.05 the reference of gender variable is female 
 
                                    
Table 21. Cox regression model based on MiND-B test 
 B Sig Exp(B) 
Age 0.045 0.120 1.046 
Gender 0.288 0.656 1.334 
Behaviour impairment -0.929 0.277 0.395 
Disinhibition 2.271 0.096 9.693 
Apathy 0.412 0.694 1.509 
Stereotypical behaviour    -1.436 0.247 0.238 
                                   *: P<0.05 the reference of gender variable is female 
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4.3.5  The longitudinal study of cognition 
A longitudinal study of 37 people with ALS was performed to determine whether cognitive 
impairment develops over time in people who are cognitively normal on first testing. The longitudinal 
curves for 37 patients with different sites of onset based on ACE-III and FAB are presented in Figure 
18 and Figure 19, respectively. The five domains of ACE-III serial tests results are shown in Figure 
20. Some patients show a decline with serial testing, but most do not. There were fewer tests for the 
third and fourth time points due to death or advanced progression of the disease. 
For statistical analysis, generalized estimating equations were used for the first two tests of 
ACE-III and FAB (Table 22 and Table 23). The GEE analysis for ACE-III found that there was no 
significant difference between the first two consecutive tests (P=0.080). However, patients with 
bulbar onset of ALS have 3.25 higher ACE-III scores than the patients with lower limb onset over 
the time course (P=0.033).  
The GEE analysis for FAB found no significant difference between the first two serial tests 
(P=1.00). For FAB, the site of onset did not affect the results of FAB performance over time 
(P=0.190).   
 
 
Figure 18. ACE-III longitudinal results in three different site of onset. 
 
Figure 18: The longitudinal curves were plotted in every patient according to different site of onset 
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Figure 19. FAB longitudinal results in three different site of onset 
 
Figure 19: The longitudinal curves were plotted in every patient according to different site of onset 
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Figure 20. Longitudinal study in 5 domains 
 
 
Figure 20: A: longitudinal study in Attention. B: longitudinal study in Fluency. C: longitudinal study in 
Language. D: longitudinal study in Memory. E: longitudinal study in Visualspatial. 
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Table 22. The results of generalized estimating equations of ACE-III longitudinal score 
Parameter B Std Error df Sig 
Intercept 93.356 1.552 1 0.000 
Bulbar onset 3.25 1.5230 1 0.033* 
Upper limb onset -0.772 1.8887 1 0.683 
Lower limb onset 0a    
First test 5.391E-017  0.3972 1 1.000 
Second test 0a    
Dependent Variable: ACE-III; Model: (Intercept), site of onset, visit; a. Set to zero because this parameter is 
redundant. The reference variable is lower limb and the second test result 
 
 
 
 
 
 
Table 23. The results of generalized estimating equations of FAB longitudinal score 
Parameter B Std Error df Sig 
Intercept 15.667 0.5058 1 0.000 
Bulbar onset 1.000 0.7196 1 0.190 
Upper limb onset 0.281 0.5939 1 0.636 
Lower limb onset 0a    
First test -0.111 0.3972 1 0.817 
Second test 0a    
Dependent Variable: ACE-III; Model: (Intercept), site of onset, visit; a. Set to zero because this parameter is 
redundant. The reference variable is lower limb and the second test result 
 
 
4.4  Discussion  
Using simple clinic based testing, this study assessed cognition and behaviour in people with 
ALS and controls with neuromuscular disease. In the ALS cohort, the prevalence of cognitive 
impairment was approximately 30% and 14% based on ACE-III and FAB, respectively. This is 
similar to the rates of cognitive impairment found in previous studies [204, 207] (Table 6). The 
prevalence of behavioural impairment in the cohort is also just over 30% and approximately 40% 
based on ALS-FTD-Q and MiND-B. This is slightly less than that found by others [207, 229] (Table 6). 
Previous studies compared people with ALS with normal healthy controls [85, 210] or used no 
controls. In the present study, the controls came from the same population as the people with ALS. 
None of the controls had evidence of disease of central nervous system, although two had 
mitochondrial myopathy, which could indicate a multi-system disorder. Both the average scores and 
the frequency of cognitive impairment were significantly different between the groups. In the ACE-
III subdomains, significant differences were found in attention and language. The study did not find 
fluency difference between the two groups, in contrast to previous studies that compared ALS patients 
75 
 
with healthy controls [230, 231]. It is noted that the tasks and scoring of fluency vary among the different 
tools, reducing the ability to compare results. 
Multiple logistic regression analysis was used to investigate factors that influence the 
development of cognitive or behavioural impairment in ALS. Age and years of education were found 
to affect cognition measured by ACE-III. This is unsurprising as age and years of education are known 
to affect cognitive performance in the healthy population [226] and to reduce the risk of dementia [232]. 
Age and lower levels of education have been observed in several previous ALS studies as risk factors 
for cognitive impairment [79, 204, 233], although others found no significant effect of these factors [219, 
234, 235]. Using age corrected or education level corrected scoring guide would be desirable in future 
studies of cognition in ALS.  
Previously, some studies have found that people with bulbar onset of ALS are more likely to 
have cognitive impairment than those with spinal onset [218, 236, 237], but others do not [80, 219, 238]. In the 
present study, the site of onset had no effect of the presence of cognitive impairment as determined 
by the ACE-III, but site of onset influenced cognitive impairment based on FAB logistic regression 
results. The bulbar onset patients had decreased ratio of cognitive impairment and longer survival in 
the Cox regression model. This needs to be studied further. 
In the cohort, the patients with cognitive or behavioural impairment based on ACE-III and ALS-
FTD-Q had worse prognosis than those without. This is consistent with some previous studies [221, 239] 
but contrary to other studies [219, 240]. In the present study, stereotypical behaviour, apathy, and 
disinhibition did not predict the survival of ALS patients, which is consistent with one previous study 
using the same scale [241]. However, another study found that apathy measured with the revised 
version of the Cambridge behavioural inventory (CBI-R) is good indicator of survival [242]. 
Classifying the patients into different levels of cognitive and behavioural impairment could be better 
than using a cutoff value in predicting the prognosis. A possible explanation for the worse prognosis 
of patients with cognitive impairment is that they have a disease that is more widespread and extensive 
than that of patients with only motor symptoms. Another possibility is that those with cognitive 
impairment have different causative genes than those without. The most prominent gene that causes 
ALS with cognitive impairment is C9orf72 [61, 62], but there are others such as TARDBP and FUS [243, 
244]. In the present study, one subject with C9orf72 repeat expansions had normal cognitive function, 
and the other patients (2 with C9orf72 repeat expansions, one with TARDBP mutation and one with 
SOD1 mutation) had cognitive impairment based on ACEIII testing results. Not all the patients had 
C9orf72 genetic testing, so it is impossible to explore the association between cognitive impairment 
and genotype.              
In the longitudinal study, only a limited number of people had more than two tests. Because of 
variability in attendance at the clinic, the interval between two consecutive time points ranges from 
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6 months to 33 months. Therefore a generalized estimating equation (GEE) was used to investigate 
whether there is difference between first two serial tests. The GEE statistical model is very robust to 
abnormal distributions, missing data and heterogeneity in timing of measurement. No significant 
difference was found between the first two visits in both ACE-III and FAB, which suggests that the 
cognitive test performance is relatively stable, and these patients who are cognitively normal at first 
testing will remain so over time. However, more people with ALS are needed at later time points to 
clarify this. In the present study, the disease controls were not followed up because they were all 
patients who gave consent for a single test. In the future, the follow-up study of disease controls 
would be a good reference for the parallel comparison with ALS patients.   
Previous longitudinal studies showed conflicting results. One study found that in bulbar onset 
patients, cognitive impairment was progressive over time [218], another found that 37% of patients 
developed cognitive deficit over a six month follow-up period [223], and another found that cognitive 
impairment was greater at the later stages of disease, when only 14% of patients had normal cognition 
[224], thus providing evidence that cognition is progressively affected in ALS. The previous serial 
studies of cognition are summarised in Table 24. If there were a progressive deterioration of cognition 
over time, this could be due to the spread of pathology from motor regions to other regions, through 
prion-like spread, as has been proposed [245]. However, the finding that some patients have cognitive 
impairment at presentation while others remain cognitively normal throughout disease would be more 
consistent with ALS being a heterogeneous disease [55, 222]. 
One weakness of this study is that genotyping was limited. Another weakness is that simple 
screening tools were used and these have not detected subtle deficits. However, the tools that were 
used are available for use in ALS clinics and provide evidence that some patients with ALS have 
cognitive impairment, which is a poor prognostic marker, that patients who are cognitively normal at 
onset show little evidence of deterioration over 6 months and possibly longer, and that age and 
education are risk factors for cognitive impairment in ALS. 
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Table 24. Summary of longitudinal studies of cognition in ALS 
Study Number  Results 
M.J. Strong et al. [218] 8 Cognitive impairment in the patients with bulbar onset 
but with limb-onset appeared to progress over the time 
course. 
K.M. Robinson et al. 
[223] 
19 7 of 19 patients had a decline of cognition over time. 
F.Trojs et al. [224] 74 Cognitive impairment was more serious in the 
advanced stage of ALS. 
S.Abrahams et al. [246] 20 No evidence of deterioration of cognition over time. 
E.Kasper et al. [225] 93 No significant decline in executive function over time. 
M.Kilani et al. [247] 18 No decline in cognitive function over 12 months 
M.Elamin et al. [248] 98 for the second 
visit 
48 for the third visit 
Cognitive function declined faster in patients who were 
cognitively impaired at the first visit. 
H.Schreiber et al. [217] 52 Cognitive deficits did not substantially decline on 
follow-up. 
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Chapter 5.  Mass spectrometry analysis of plasma from Amyotrophic lateral sclerosis and 
control subjects: evidence of widespread physiological change 
5.1  Introduction of Chapter 5 
ALS is a neurodegenerative disease characterized by progressive loss of upper and lower motor 
neurons [249]. ALS is thought to be due to a combination of genetic and environmental factors [250] and 
leads to death within 3–5 years. The pathology of ALS includes aggregation of proteins within 
neurons [251]. ALS is heterogeneous, with one important source of heterogeneity being the presence 
or absence of cognitive impairment [80].   
ALS can be sporadic (SALS) or familial (FALS), although the distinction can be difficult [252]. 
ALS is thought to arise from a combination of genetic susceptibility [253, 254] and environmental [255] 
exposure, possibly due to a multi-stage process [256]. Causative genes have been identified in FALS, 
and some of these genetic mutations are also found in SALS [257] and for people with these genes, 
inheritance is monogenic. It has been estimated that 61% of the variance in risk of developing 
sporadic ALS is due to genetic factors [258] and in some patients there could be oligogenic inheritance. 
The pathology of ALS includes protein aggregation in cells [251], but varies among patients and can 
be categorized into TDP-43 pathology, TDP-43 with C9orf72 pathology, FUS pathology and SOD1 
pathology [259]. The known causative genes usually encode for the proteins that accumulate within 
cells or are involved in the metabolism of protein aggregates. The most common causative gene is 
C9orf72, which is associated with ALS with cognitive impairment [61, 260]. 
In ALS, there is a need for biomarkers to monitor disease progression and for use in clinical 
trials [261]. Biomarkers that discriminate between ALS and controls could also provide information 
about disease pathogenesis. 
In the search for a biomarker, there have been studies of candidate molecules, chosen on the 
basis of knowledge of disease pathogenesis. For example, neurofilaments are released from damaged 
axons, and are a promising biomarker in ALS [262]. There are also studies using proteomics, which 
uses a hypothesis free approach that is well suited for discovery of new biomarkers [263]. Blood and 
CSF are the biofluids most often used to search for biomarkers [264]. There has been interest in using 
MS to search for biomarkers in neurodegenerative disease such as Alzheimer’s disease,[265] 
Parkinson’s disease[266] and frontotemporal dementia [267]. 
The existing proteomic studies of ALS mostly use CSF. However, blood samples are simple to 
collect, and could contain protein released from damaged degenerated tissue, or changes in 
physiology that occur in response to neuronal loss. Proteins released from damaged cells into the 
interstitial fluid of the brain could enter the blood through lymphatic drainage [107, 268]. CSF is 
produced by secretion from the choroid plexus but is expected to contain proteins released from 
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degenerating neurons because of its direct contact with the central nervous system. However, CSF is 
more difficult than blood to obtain. 
SWATHTM is a data independent acquisition (DIA) method for MS. It is a label free technology 
that offers an approach to quantify all the analytes in a sample [131]. Thus SWATH enables 
comprehensive protein quantitation in relatively complex samples such as plasma or serum [263]. 
The basis for the present study was the possibility that MS of blood samples would reveal novel 
biomarkers in ALS. The basis for subdivision into cognitive and non-cognitive groups was that these 
subgroups have different survival [239, 269] and patients with cognitive impairment have more 
widespread disease [270]. The basis for the study of carriers of C9orf72 mutations is that these represent 
a clear subgroup of ALS. Therefore the aims of this study were to use SWATH technology to search 
for potential biological markers in the blood of the ALS patients and to utilize western blot to validate 
these biomarkers, using a second independent set of subjects for confirmation. The further aim was 
to use Ingenuity pathway analysis (IPA) to search for pathological pathways and networks involved 
in ALS.  
 
5.2  Methods 
5.2.1  ALS Patients recruitment and plasma collection 
For the discovery cohort, 42 ALS patients with probable or definite ALS [7] were recruited from 
the motor neuron disease multidisciplinary clinic at Royal Brisbane and Women’s Hospital (RBWH). 
18 healthy controls, all of whom were the caregivers of the ALS patients, were also recruited. For the 
validation cohort, an additional 10 subjects with ALS and 10 healthy controls were recruited. This 
study was approved by the RBWH ethics committee and all the participants gave written informed 
consent. Samples (4ml) of whole blood were collected from both ALS patients and healthy controls 
in BD EDTA coated vacutainers, and the plasma was removed and stored as 50μl aliquots at -80℃. 
The key difference between plasma and serum is that plasma contains fibrinogen and clotting factors 
which are closely related with coagulation. However, the potential pathogenesis of ALS was found 
associated with complement and coagulation system [113], To avoid disturbance generated in the 
coagulation process, plasma was used in this study 
 
5.2.2  Cognitive testing 
 Of 42 ALS patients in the discovery cohort, 36 were tested with the Addenbrooke’s cognitive 
examination-III (ACE-III) [227], which comprises five subsections that assess attention, memory, 
language, fluency and visuospatial domains and has a maximum possible score of 100. A score less 
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than 88 is defined as possible cognitive impairment (CI). 19 of 36 patients were diagnosed with 
possible CI.          
 
5.2.3  Genetic testing 
There was no systematic testing of all patients, but 7 patients were tested by an accredited 
genetic laboratory and found to carry a C9orf72 repeat expansion that is the most common causative 
ALS gene [254]. These subjects were grouped together for comparison with non C9orf72 ALS patients.   
The whole work flow of this study is shown in the Figure 21. 
 
 
 
 
Figure 21. Workflow of the third study 
 
 
Figure 21: Plasma was collected from controls and patients with ALS. Some ALS patients had ACE-III 
cognitive testing and were further subdivided into NOCI and CI groups on the basis of presence or absence of 
cognitive impairment. Then 3 groups were analysed with SWATH method. The proteins with significant 
difference will be validated through western blot. And also Ingenuity pathway analysis was utilized to 
investigate the pathway based on these significant different proteins. 
 
 
5.2.4  Depletion of plasma 
Undepleted samples were used for SWATH analysis and gelsolin and clusterin western blot 
validation. To avoid background signals in western blot analysis for CD5 antigen like (CD5L), (650 
to 750μg total plasma protein) was extracted from the thawed sample and diluted with Tris-HCl (ph 
7.4) to 500μl. Using the manufacturer’s instructions, Seppro IgY 14 spin depletion columns (Sigma, 
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USA) were utilized to deplete the 14 highly abundant proteins (Albumin, IgG, α1-Antitrypsin, IgA, 
IgM, Transferrin, Haptoglobin, α2-Macroglobulin, Fibrinogen, Complement C3, α1-Acid 
Glycoprotein, HDL and LDL) from the plasma sample. The details of depletion are as follows. The 
samples were removed from the -80℃ freezer and put onto ice. When the samples were thoroughly 
thawed, Seppro IgY 14 spin depletion columns were used to deplete the 14 highly abundant proteins 
in the plasma samples. 10μl plasma (650 to 750μg total plasma protein) plasma was extracted from 
the thawed sample and Tris-HCl (Ph 7.4) was used to dilute the extracted plasma to 500µl. The 
depletion column was placed in a 2 ml collection tube. Then the column was centrifuged for 30 
seconds at 2,000 rpm to obtain dried beads. 500μl diluted sample was immediately transferred on the 
dried beads in the column. The beads were mixed with the sample by inversion and shaking of the 
column, which was then placed on an end-to-end rotator at room temperature for 15 minutes. The 
depletion column was then placed in a brand new 2 ml collection tube, and was centrifuged for 30 
seconds at 2,000 rpm. The flow-through was collected in a new collection tube, and at -80 ℃. The 
beads were then washed by using washing buffer (Tris-HCl with 1.5 M NaCl, pH 7.4) for 3 times. 
This step is to wash the non-specifically bound proteins. The 14 specifically bound proteins were then 
stripped off by using stripping buffer (1 M Glycine, pH 2.5) for 4 times within 15 minutes. The first 
elution was collected for the western blot validation of the albumin. The neutralizing buffer (1 M 
Tris-HCl, pH 8.0) was used to restore the depletion function of the kit. 
To confirm the successful depletion and performance of the kit, albumin (66.5 kDa) western 
blot (1:20000, Sigma, A0433) was performed in the first elution, depleted and undepleted samples. 
The result of the western blot is shown in the Figure 22. 
Figure 22. Validation of depletion of albumin 
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Figure 22: The albumin in the depleted samples were largely reduced compared with the original plasma 
sample after using Seppro Ig Y 14 kit. 
 
The concentrations of protein in both undepleted and depleted samples were determined by 
using a bicinchoninic acid (BCA) protein assay kit (Thermo, USA). The procedures are as follows. 
The frozen depleted and undepleted samples were removed from -80 ℃ freezer and were put onto the 
ice. When the frozen samples were thoroughly thawed, 25μL of each standard or unknown sample 
replicates were pipetted into a 96-well microplate. 200μL working reagent (reagent A: reagent B 
50:1) was added into to each well and was further mixed with samples thoroughly on a plate shaker 
for 30 seconds. The microplate was incubated in an incubator at 37°C for 30 minutes, and then cooled 
to room temperature. The absorbance was measured at or near 562nm on a Tecan Spark 10M 
multimode plate reader (Tecan, Switzerland). 
 
5.2.5  Preparation of the samples by using filter-aided sample preparation 
To improve the MS signal, a filter aided sample prep (FASP) protocol was used to remove small 
molecular weight components (such as lipids) from the plasma. Buffer I (6M guanidine chloride, 
50mM Tris ph8, 10mM DTT) and buffer II (50mM ammonium bicarbonate) were prepared. 
Undepleted plasma (100μg) of each sample was mixed with 100μl Buffer I in Lobind tubes 
(Eppendorf, USA) and incubated at 30 ℃ for 30 minutes. After addition of 2.5μl 1M acrylamide, the 
tube was incubated at 30 ℃ for 30 minutes, then DTT was added to give a final DTT concentration 
of 15mM. The reduced and alkylated protein solution was transferred to a 10 kDa cut-off Amicon 
column (Millipore, Germany), then placed in a collection tube. The Amicon column was centrifuged 
at room temperature at 18,000rcf for at least 30 minutes, after which 200μl 100mM ammonium 
bicarbonate was added. The columns were centrifuged at room temperature at 18,000rcf for another 
30 minutes, followed by addition of 130μl 100mM ammonium bicarbonate and 2μg trypsin (Promega, 
USA) to digest the proteins on the membrane of the column. The columns were incubated at 37℃ 
overnight, then centrifuged in a new collection tube at 18000rcf for at least 30 minutes. Then 50μl 
0.5M sodium chloride was added into the spin column, which was centrifuged into the same collection 
tube for 30 minutes to elute the remaining digested peptides. Ziptips (Millipore, Germany) were used 
to desalt the samples. The details of desalting process are as follows. 
The solutions for desalting are: Wetting solution: 100% acetonitrile, Sample preparation 
solution: 0.1% formic acid in mass spectrometry grade water, Equilibration solution: 0.1% formic 
acid in mass spectrometry grade water, Wash solution: 0.1% formic acid in mass spectrometry grade 
water, Elution solution: 70% acetonitrile elution/0.1% formic acid. 10μl wetting solution was 
aspirated into the Ziptip and was dispensed into waste. This step was repeated 3 times. Then 10ul 
equilibration solution was aspirated into Ziptip and was dispensed into waste. This step was also 
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repeated 3 times. The pipettor was set to 10μl. The pipettor was used to aspirate and dispense the 
sample 15 to 20 times slowly into its original tube without aspirating any air into the Ziptip. This step 
is to bind the digested peptide. 10μl wash solution was aspirated into the Ziptip and dispensed to 
waste. The step was also repeated 3 times. A 10 μl aliquot of elution solution was aspirated and 
dispensed into another new Lobind tube. The step was repeated 4 times. Finally 40μl digested 
peptides were desalted. The first 6 steps were repeated 4 times. Due to the capacity of the Ziptip 
binding is 5μg. After 4 times, vacuum concentrator (Concentrator plus, Eppendorf) was utilized to 
remove the liquid and get the lyophilized digested peptides. The lyophilized sample was reconstituted 
with 20μl 0.1% formic acid in H2O.  
 
5.2.6  Nano high performance liquid chromatography (HPLC)-MS/MS analysis (IDA) 
To keep a stable performance of the mass spectrometry column, the whole desalted samples 
were divided into 2 batches. The first batch contained 8 healthy controls and 16 ALS subjects. The 
second batch contained 10 healthy controls and 26 ALS subjects. 5μl of peptides were extracted from 
each desalted sample and were pooled together to generate a comprehensive ion library in each batch 
by using IDA. The IDA data were generated using a nano HPLC system (Prominence, SHIMADZU) 
coupled with Triple-ToF 5600 mass spectrometer (ABSCIEX, USA). The order of injection was 
randomized. 5μl pooled samples for IDA were loaded onto the nano HPLC autosampler maintained 
at 12 °C, which was further trapped and desalted on a C18 trap column (150 µm × 150 mm, 5 µm, 
Agilent) for 3 minutes with 100% mobile phase buffer A (1% acetonitrile/0.1% formic acid) at a flow 
of 30 µL/min. The trapped peptides were eluted onto an C18 analytical column (150 µm 
ID × 150 mm, 300Å, 5 µm particle size, Vydac Everest) for chromatographic separation by a 70 min 
gradient time from 10% to 60 % buffer B (80% acetonitrile/0.1% formic acid) followed by 98% buffer 
B for washing at a flow of 1 µL/min. Eluted peptides were injected into the Triple-ToF 5600 MS 
through a Nanospray III ion source (ABSCIEX, USA) performed in positive ion mode. For data 
dependent acquisition, ToF MS scan was performed over 350–1600 m/z for 0.5 sec. 20 data 
dependent MS/MS scans with 2+ to 5+ charge were performed within the range of 100 – 1600 m/z 
for 0.05 sec with rolling collision energy.  
 
5.2.7  Quality control 
The IDA MS process was calibrated through using 5 fmol trypsin digested β–galactosidase by 
using 6 different parent ions at m/z 534.2489, 542.2645, 550.2802, 671.3379, 714.8469 and 729.3652. 
The IDA MS/MS process was calibrated by using product ions of the precursor ion at m/z 729.3652. 
The calibration process was conducted and monitored by Analyst software (Absciex). 
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5.2.8  Protein identification 
The IDA data was searched against the Swiss-Prot Homo sapiens protein database by using 
Proteinpilot 5.0 (ABSCIEX). This Homo sapiens protein database was released in May 2016 and 
includes 20168 proteins. The final group file including a comprehensive precursor masses and 
fragment ions library of each batch was generated through Proteinpilot software. The parameters for 
the thorough ID search were as follows: sample type, identification; cysteine alkylation, acrylamide; 
digestion, trypsin; detected protein threshold, 0.05. The search engine was ParagonTM algorithm [271]. 
The target-decoy approach was used to calculate the global and local false discovery rate (FDR). The 
number of missed cleavages was set to 5 and variable modifications were set to biological 
modifications.  
 
5.2.9  SWATH data collection 
1μl aliquot for each sample was injected for SWATH analyses. The order of SWATH injection 
was also randomized. An isolation width of 26 Da window which includes 1 Da for the window 
overlap was used to cover across the mass range 400 -1250 m/z. The dwell time for the SWATH-MS 
is 95.1ms. A total of 34 overlapping windows were constructed. The collision energy for each window 
was based on the calculation for a charge 2+ ion centered upon the window with a collision energy 
spread of 15 eV by using Analyst software (ABSCIEX). 
 
5.2.10  SWATH data analysis  
The group result file was imported into PeakView software (ABSCIEX) to create an ion library 
which was used as a reference spectral library and also for later label free SWATH quantification. 
The software calculates the peak area of selected fragment ion which constituted targeted proteins or 
peptides based on the extracted ion Chromagrams (XIC). Twelve spectral peaks across the 70 minutes 
gradient time were selected for peak alignment. Shared peptides and peptides with confidence level 
below 99% were not imported into ion library. 50 ppm was chosen on the ion mass tolerance. The 
number of peptides for one protein was set to 6. The number of ions for one peptide was also set to 
6. The protein mass spectrometry signal text files for the two batches which sum up the peak area of 
targeted peptides were exported from the Peakview software for further comparison analysis. 
 
5.2.11  Using surrogate variable analysis (SVA) to remove the batch effect 
There are significant batch effects between the two batches, as shown in Figure 23, which was 
plotted through the principal component analysis (PCA). This could be due to factors such as different 
performance of the analytical column at two different time points for loading the samples, technician 
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difference and buffer reagent lots [272, 273]. Therefore it was not appropriate to combine the two batches 
of SWATH data together without correction of the batch effect. After log2 transformation, the batch 
effect still exists, so the Combat function of SVA R code package (version 3.22.0) was used to remove 
the batch effect [273]. This function uses an empirical Bayes framework for adjusting the data. Figure 
24 illustrates that after this adjustment there was no batch effect with PCA analysis.  
 
                                  Figure 23. PCA analysis after log 2 transformation 
 
Figure 23: The blue triangles represent the samples in the first batch. The red triangles represent the samples 
in the second batch. Two batches were clearly separated by the PCA analysis. There was an obvious batch 
effect. 
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Figure 24. PCA analysis after using Combat R code package 
 
Figure 24: The blue triangles and red ones were organically scattered around each other. Two batches could 
not be separated by the PCA analysis. The batch effect was successfully removed. 
 
The Combat R code used for the batch combination is shown in Table 25.   
 
Table 25. R code for removing the batch effect 
cdata <- read.table("The whole proteins two batches all together.txt", header = T, sep = "\t", 
row.names = 1) 
cdata2<- log2(cdata) 
cdata <- as.matrix(cdata2) 
install.packages('mixOmics') 
library(mixOmics) 
trans.cdata<-t(cdata) 
pca.tune <- tune.pca(trans.cdata) 
ftrans.pca <- pca(trans.cdata, ncomp = 3, center = FALSE, scale = FALSE) 
csif <- read.table("latest batch information.txt", header = T, sep = "\t", row.names = 1) 
csif$batch <- as.factor(csif$batch) 
plotIndiv(ftrans.pca, comp = c(1, 2), ind.names = FALSE,  
          group = csif$batch, pch=17, 
          legend = TRUE, title = 'batch effect(after normalization') 
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modcombat = model.matrix(~1, data = csif) 
batch = csif$batch 
combat_edata = ComBat(dat=cdata, batch=batch, mod=modcombat, par.prior=TRUE, 
prior.plots=TRUE) 
trans.combat<-t(combat_edata) 
ftrans.pca <- pca(trans.combat, ncomp = 3, center = FALSE, scale = FALSE) 
csif <- read.table("latest batch information.txt", header = T, sep = "\t", row.names = 1) 
plotIndiv(ftrans.pca, comp = c(1, 2), ind.names = FALSE,  
          group = csif$batch, pch=17, 
          legend = TRUE, title = 'batch effect, after combat') 
 
After using the Combat R code to remove the batch effect, the final adjusted SWATH text file 
was imported to Markerview (ABSCIEX) software for data normalization and group comparison. In 
Markerview, the most likely ratio (MLR) normalization method was used to normalize the data by 
removing the experimental variance. The MLR method is a robust normalization method compared 
with other methods [274]. The proteins with P value less than 0.05 were uploaded to IPA software for 
pathway analysis. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE50 partner repository with the dataset identifier 
PXD006878. 
 
5.2.12  Western blot validation in both discovery cohort and validation cohort 
From the test cohort, 10 samples were randomly selected from healthy controls, NOCI group 
and CI group for validation. A replication study used samples from an independent group of subjects 
that were not used in the initial MS study. For western blot analysis of clusterin, gelsolin and ficolin 
3, 0.5 μg protein was extracted from the undepleted plasma. 1.5μg proteins were extracted from the 
depleted plasma to run CD5L western blot validation. β-actin (1:20,000, Imgenex) was used for 
protein loading control. Proteins were electrophoresed by the 10% sodium dodecylsulfate (SDS) 
polyacrylamide gel electrophoresis (BioRad, USA) and further transferred to pure nitrocellulose 
membrane (0.45μm, BioRad) by electroblotting. The membrane was blocked with 5% skim milk in 
Tris-Buffered Saline -Tween 20 0.1% at room temperature for 2 hours. Blots were then incubated 
with anti clusterin antibody (1:250, Santa Cruz, sc-5289), gelsolin (1:100, Santa Cruz, sc-514502), 
anti CD5L (1:500, Sigma, HPA065686) and ficolin 3 (1:1000, Sigma, SAB1401430) at 4℃ overnight. 
Then the blots were incubated in the horse-radish peroxidase (HRP) conjugated secondary anti-rabbit 
or anti-mouse IgG (1:20000, Sigma; 1:2000, Sigma) for 1 hour. The blots were then detected through 
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SuperSignal West Femto Maximum Sensitivity Substrate (Thermo,USA). Quantitative densitometry 
analyses of the bands were performed using Image J software. 
 
5.2.13  Statistical analysis 
The statistical analyses were conducted by using SPSS 20 and R software (version 3.2.5). 
Principal component analysis was utilised to investigate the batch effect. The Chi square test was 
used to test the difference between two or more proportions. T-test was used to test the difference in 
the mean between two groups. If the data were not normally distributed, Mann-Whitney U test was 
used for two independent groups’ comparison. Benjamini & Hochberg (BH) false discovery rate was 
used to correct for multiple comparison [275]. ANOVA was applied to determine whether there is 
significant difference between three groups. Tukey multiple comparison was applied for the post hoc 
test. P value less than 0.05 was considered significant.  
 
5.3  Results 
5.3.1  Subjects 
The clinical details of the subjects is summarized in Table 26. There was no significant 
difference between controls and ALS subjects in age or the ratio of males to females. There was a 
mixture of patients with upper limb, lower limb and bulbar onset. 
 
 
Table 26. Clinical details of participants 
 
HC ALS P value 
Discovery cohort    
Number  18 42 N/A 
Age(mean±SD) 59.3±6.8 61.8±9.6 0.31 
Male/female 9/9 28/14 0.26 
Disease duration (median, 
range)(days) 
N/A 747(99,4041) N/A 
ALSFRS-R( median, range) N/A 35(24,45) N/A 
Site of onset( bulbar/upper 
limb/lower limb) 
N/A 10/16/16 N/A 
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Of the 7 ALS patients with C9orf72 repeat expansion, 2 patients had possible CI and another 
one had normal cognitive function. Patients were also analyzed after grouping into patients without 
CI, with CI, and with and without the C9orf72 repeat expansion. The demographic information of 
these three groups is summarized in Table 27. There was no significant difference in age, the 
proportion of gender, disease duration or the severity of the disease among these three groups. 
 
Table 27. Demographic information of ALS subgroups 
 
NOCI CI C9orf72 P value 
Number  17 19 7 N/A 
Age(mean ± SD) 61.5 ± 9.2 61.7 ± 8.8 64.6 ± 13.1 0.77 
Male/female 13/4 13/6 3/4 0.28 
Disease duration at the date of 
blood collection (median，
range)(days) 
934(99,4041) 739(386,2628) 406(207,1642) 0.21 
ALSFRS-R( median, range) 36(25,43) 36(24,45) 31(25,38) 0.21 
Site of onset( bulbar/upper 
limb/lower limb) 
4/6/7 2/9/8 5/1/1 N/A 
 
5.3.2  Protein identification 
 With IDA, using global FDR <0.01% and using pooled samples, 127 proteins were identified 
in the first batch and 134 proteins were identified in the second batch. Using the combined lists of 
proteins from both batches, the overlap between ALS and controls is shown in Venn diagram (Figure 
25). The lists of these proteins are given in the Appendix V. In the pooled ALS samples there were 
22 proteins that were not found in the controls. These included 14-3-3 protein and Nesprin-2. In the 
Validation cohort    
Number 10 10 N/A 
Age(mean±SD) 63.5±8.8 62.3±8.4 0.76 
Male/female 5/5 5/5 1.00 
Disease duration (median, 
range)(days) 
N/A 838(275,2900) N/A 
ALSFRS-R( median, range) N/A 35(20,41) N/A 
onset( bulbar/upper 
limb/lower limb) 
N/A 4/3/3 N/A 
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pooled control samples there were 19 proteins that were not found in ALS subjects. These included 
properdin and attractin, as well as different regions of the immunoglobulins.   
 
Figure 25. Venn diagram of protein identification between control and ALS 
 
           Figure 25: In total, there were 115 proteins (FDR<0.01%) present in both control and ALS groups 
 
5.3.3  SWATH analysis 
SWATH analysis was performed separately on each batch. A total of 115 proteins was present 
in both batches, so the levels of these proteins were compared among groups. The list of these proteins 
is given in Appendix VI, where it can be seen that all the proteins have greater than 1.3 unused score 
(95% confidence). These 115 proteins were exported to Peakview for quantitation and further 
exported to Markerview for group comparison. The differences between groups are described below. 
The histograms of the frequency of p values for the different comparisons are listed in Figure 26. 
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Figure 26. The histograms of the frequency of p values for the different comparisons 
 
 
Figure 26: A: ALS versus Control; B: NOCI versus Control; C: CI versus Control; D: NOCI versus CI; E: 
Other ALS versus C9orf72. 
 
5.3.4  Healthy controls (HC) versus ALS patients 
There were 30 proteins with significantly different MS signal between healthy and total ALS 
patients (Table 28). The results for all the proteins are shown in Figure 27. The summary of the group 
comparison in 8 proteins is shown in Figure 28. The heatmap of these 30 proteins is shown in Figure 
29. The PCA analysis of these 30 proteins is listed in Figure 30. 
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Table 28. Protein comparison between HC and ALS 
Uniprot number Protein name p-value BH 
corrected 
P value 
HC (mean 
signal) 
ALS( mean 
signal) 
Fold 
change 
log( fold 
change) 
P02768 Serum albumin  0.0002 0.0037 2.67E+07 2.15E+07 0.81 -0.09 
P01591 Immunoglobulin J chain  0.0002 0.0037 5.41E+05 3.60E+05 0.67 -0.18 
P01613 Ig kappa chain V-I region Ni  0.0017 0.0151 1.03E+06 5.92E+05 0.58 -0.24 
P02652 Apolipoprotein A-II  0.0020 0.0151 3.75E+06 3.18E+06 0.85 -0.07 
P07225 Vitamin K-dependent protein S  0.0033 0.0203 1.82E+05 2.25E+05 1.24 0.09 
P00747 Plasminogen  0.0051 0.0243 1.37E+06 1.22E+06 0.89 -0.05 
P06396 Gelsolin  0.0062 0.0243 5.37E+05 4.47E+05 0.83 -0.08 
P02743 Serum amyloid P-component  0.0063 0.0243 4.63E+05 6.02E+05 1.30 0.11 
P06727 Apolipoprotein A-IV  0.0091 0.0285 2.02E+06 1.52E+06 0.75 -0.12 
P01602 Ig heavy chain V-I region 5 (Fragment)  0.0092 0.0285 9.89E+05 6.29E+05 0.64 -0.20 
P02763 Alpha-1-acid glycoprotein 1 0.0105 0.0295 5.41E+06 6.34E+06 1.17 0.07 
P01031 Complement C5  0.0124 0.0313 3.77E+05 4.31E+05 1.14 0.06 
P01860 Ig gamma-3 chain C region 0.0136 0.0313 1.59E+06 1.29E+06 0.81 -0.09 
P02748 Complement component C9  0.0144 0.0313 5.53E+05 6.41E+05 1.16 0.06 
P03952 Plasma kallikrein  0.0151 0.0313 3.16E+05 2.76E+05 0.87 -0.06 
P27169 Serum paraoxonase/arylesterase 1  0.0162 0.0315 8.22E+05 6.99E+05 0.85 -0.07 
P01611 Ig kappa chain V-I region Wes  0.0183 0.0333 2.78E+05 2.25E+05 0.81 -0.09 
P05156 Complement factor I  0.0234 0.0404 3.10E+05 3.52E+05 1.14 0.06 
P08697 Alpha-2-antiplasmin  0.0263 0.0415 6.92E+05 6.13E+05 0.88 -0.05 
O75636 Ficolin-3  0.0268 0.0415 2.93E+04 4.13E+04 1.41 0.15 
P02747 Complement C1q subcomponent 
subunit C  
0.0309 0.0430 1.36E+05 2.42E+05 1.77 0.25 
P0C0L4 Complement C4-A  0.0321 0.0430 2.80E+05 4.15E+05 1.48 0.17 
P80748 Ig lambda chain V-III region LOI 0.0321 0.0430 4.17E+05 3.40E+05 0.82 -0.09 
P02787 Serotransferrin  0.0342 0.0430 1.75E+07 1.60E+07 0.91 -0.04 
P01042 Kininogen-1  0.0347 0.0430 2.45E+06 2.22E+06 0.90 -0.04 
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P22792 Carboxypeptidase N subunit 2  0.0427 0.0499 4.12E+04 5.03E+04 1.22 0.09 
P01876 Ig alpha-1 chain C region  0.0434 0.0499 4.14E+06 3.46E+06 0.84 -0.08 
P02766 Transthyretin  0.0452 0.0500 2.51E+06 2.28E+06 0.91 -0.04 
P0CG06 Ig lambda-3 chain C regions  0.0484 0.0505 1.05E+05 1.55E+05 1.47 0.17 
P08603 Complement factor H  0.0489 0.0505 1.48E+06 1.59E+06 1.07 0.03 
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Figure 27. Volcano plot healthy controls vs ALS patients 
 
Figure 27: X axis represents the log 2 fold change, Y axis represents the –log10 (P values). Any protein dots 
above the dot line (P=0.05) are the potential biomarker. The protein dots with large P value and large absolute 
log2 fold change are good biomarkers to differentiate the groups.
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 Figure 28. Group comparisons in 8 proteins 
 
 
Figure 28: There were 18 controls and 42 ALS (total). 36 ALS patients had cognitive testing and were divided 
into 17 with NOCI (none cognitive impairment) and 19 with cognitive impairment (CI).  The C9orf72 group 
contains 7 subjects identified as carrying this mutation. The mean and SD of the levels of eight proteins are 
shown. Panel-A: albumin; Panel-B: CD5L; Panel-C: clusterin; Panel-D: ficolin 3; Panel-E: gelsolin; Panel-F: 
serum amyloid P component; Panel-G: complement C5; Panel-H: transthyretin *: P<0.05 ** P<0.01 
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Figure 29. Heatmap of 30 proteins with significant difference between ALS and controls 
 
Figure 29: Hierarchical clustering analysis is applied on these 30 proteins. From the heatmap, the pattern of change in these 30 proteins is clear between the two 
groups. 
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Figure 30. PCA analysis between ALS and Control after MLR normalization 
 
Figure 30: The blue triangles represent the samples in ALS group. The red triangles represent the samples in 
control group. The PCA analysis based on the 30 proteins with significant difference between ALS and control 
shows that the two groups could not be separated by the PCA analysis. 
 
 
 
5.3.5  Healthy controls versus non cognitive impairment (NOCI) patients 
15 proteins were significantly different in the level between healthy controls and NOCI patients. 
The list is shown in Table 29.The whole protein proteins comparisons are shown in Figure 31
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Table 29. Protein comparison between NOCI and HC 
Uniprot 
number 
Protein name p-value BH 
corrected 
P value 
HC (mean signal) NOCI (mean 
signal) 
Fold change log( fold 
change) 
P02748 Complement component C9  0.0025 0.0218 5.53E+05 6.68E+05 1.21 0.08 
P02768 Serum albumin  0.0054 0.0218 2.67E+07 2.20E+07 0.82 -0.09 
P08603 Complement factor H  0.0059 0.0218 1.48E+06 1.66E+06 1.12 0.05 
P00738 Haptoglobin  0.0067 0.0218 8.24E+06 1.08E+07 1.31 0.12 
P02652 Apolipoprotein A-II  0.0076 0.0218 3.75E+06 3.12E+06 0.83 -0.08 
P06396 Gelsolin  0.0077 0.0218 5.37E+05 4.21E+05 0.78 -0.11 
P01009 Alpha-1-antitrypsin  0.0114 0.0238 1.16E+07 1.35E+07 1.16 0.06 
O95445 Apolipoprotein M  0.0147 0.0238 5.10E+04 3.59E+04 0.70 -0.15 
P25311 Zinc-alpha-2-glycoprotein  0.0148 0.0238 1.18E+06 1.42E+06 1.21 0.08 
P01591 Immunoglobulin J chain  0.0149 0.0238 5.41E+05 3.70E+05 0.68 -0.17 
P07225 Vitamin K-dependent protein S 0.0154 0.0238 1.82E+05 2.29E+05 1.26 0.10 
P00747 Plasminogen  0.0286 0.0405 1.37E+06 1.23E+06 0.89 -0.05 
P02747 Complement C1q subcomponent subunit 
C  
0.0363 0.0474 1.36E+05 2.87E+05 2.11 0.32 
P02649 Apolipoprotein E  0.0437 0.0481 9.62E+05 1.18E+06 1.22 0.09 
P80748 Ig lambda chain V-III region LOI  0.0440 0.0481 4.17E+05 3.33E+05 0.80 -0.10 
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Figure 31. Volcano plot healthy control vs NOCI patients 
 
 
Figure 31: X axis represents the log 2 fold change, Y axis represents the –log10 (P values). Any protein dots 
above the dot line (P=0.05) are the potential biomarker. The protein dots with large P value and large absolute 
log2 fold change are good biomarkers to differentiate the groups. 
 
 
5.3.6  Healthy controls versus cognitive impairment (CI) patients 
Between CI patients and healthy group, 32 proteins showed significant differences in 
concentration. The protein list is presented in Table 30. All of proteins comparisons are presented in 
Figure 32. 
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Table 30. Protein comparison between CI and HC 
Uniprot 
number 
Protein name p-value BH corrected 
P value 
HC (mean 
signal) 
CI( mean signal) Fold change log(fold 
change) 
P02763 Alpha-1-acid glycoprotein 1  0.0004 0.0135 5.41E+06 6.74E+06 1.25 0.10 
P02768 Serum albumin  0.0012 0.0144 2.67E+07 2.13E+07 0.80 -0.10 
P02743 Serum amyloid P-component  0.0013 0.0144 4.63E+05 6.58E+05 1.42 0.15 
P01031 Complement C5  0.0019 0.0157 3.77E+05 4.51E+05 1.20 0.08 
P22792 Carboxypeptidase N subunit 2  0.0029 0.0172 4.12E+04 5.77E+04 1.40 0.15 
P01613 Ig kappa chain V-I region Ni  0.0031 0.0172 1.03E+06 4.61E+05 0.45 -0.35 
P01591 Immunoglobulin J chain  0.0047 0.0206 5.41E+05 3.53E+05 0.65 -0.19 
P06727 Apolipoprotein A-IV  0.0050 0.0206 2.02E+06 1.32E+06 0.65 -0.19 
P01834 Ig kappa chain C region  0.0082 0.0285 1.74E+07 1.46E+07 0.84 -0.08 
P02787 Serotransferrin  0.0086 0.0285 1.75E+07 1.52E+07 0.87 -0.06 
P05090 Apolipoprotein D  0.0113 0.0339 1.01E+06 7.40E+05 0.74 -0.13 
P02766 Transthyretin  0.0130 0.0345 2.51E+06 2.14E+06 0.85 -0.07 
P68871 Hemoglobin subunit beta  0.0136 0.0345 2.81E+06 4.78E+06 1.70 0.23 
P02652 Apolipoprotein A-II  0.0150 0.0354 3.75E+06 3.20E+06 0.85 -0.07 
P00747 Plasminogen  0.0177 0.0359 1.37E+06 1.21E+06 0.88 -0.05 
P27169 Serum paraoxonase/arylesterase 
1  
0.0177 0.0359 8.22E+05 6.82E+05 0.83 -0.08 
P01860 Ig gamma-3 chain C region  0.0192 0.0359 1.59E+06 1.23E+06 0.77 -0.11 
P05546 Heparin cofactor 2  0.0196 0.0359 3.74E+05 4.48E+05 1.20 0.08 
P06396 Gelsolin  0.0219 0.0381 5.37E+05 4.54E+05 0.84 -0.07 
O75636 Ficolin-3  0.0236 0.0383 2.93E+04 4.46E+04 1.52 0.18 
P01602 Ig heavy chain V-I region 5 
(Fragment) O 
0.0244 0.0383 9.89E+05 5.40E+05 0.55 -0.26 
P05156 Complement factor I  0.0265 0.0383 3.10E+05 3.64E+05 1.18 0.07 
P07225 Vitamin K-dependent protein S 0.0270 0.0383 1.82E+05 2.21E+05 1.22 0.09 
P03952 Plasma kallikrein  0.0279 0.0383 3.16E+05 2.68E+05 0.85 -0.07 
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P01023 Alpha-2-macroglobulin  0.0301 0.0398 7.44E+06 6.39E+06 0.86 -0.07 
P10909 Clusterin  0.0316 0.0398 1.66E+06 1.45E+06 0.87 -0.06 
P02790 Hemopexin  0.0325 0.0398 4.84E+06 5.27E+06 1.09 0.04 
P0C0L4 Complement C4-A  0.0363 0.0423 2.80E+05 4.29E+05 1.53 0.19 
P04004 Vitronectin  0.0385 0.0423 5.41E+06 6.74E+06 1.12 0.05 
P01611 Ig kappa chain V-I region Wes  0.0385 0.0423 2.67E+07 2.13E+07 0.79 -0.11 
P02748 Complement component C9  0.0401 0.0427 4.63E+05 6.58E+05 1.15 0.06 
P02654 Apolipoprotein C-I  0.0477 0.0492 3.77E+05 4.51E+05 0.85 -0.07 
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Figure 32. Volcano plot healthy control vs CI patients 
 
Figure 32: X axis represents the log 2 fold change, Y axis represents the –log10 (P values). Any protein dots 
above the dot line (P=0.05) are the potential biomarker. The protein dots with large P value and large absolute 
log2 fold change are good biomarkers to differentiate the groups. 
 
 
5.3.7  NOCI versus CI patients 
20 proteins were significantly different between NOCI group and CI group, as shown in Table 
31. The whole protein comparisons are shown in Figure 33. 
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Table 31. Protein comparison between NOCI and CI 
Uniprot 
number 
Protein name p-value BH corrected P 
value 
NOCI (mean 
signal) 
CI( mean 
signal) 
Fold 
change 
log(fold 
change) 
P01834 Ig kappa chain C region 0.0004 0.0082 1.79E+07 1.46E+07 0.81 -0.09 
P22792 Carboxypeptidase N subunit 2  0.0011 0.0120 4.37E+04 5.77E+04 1.32 0.12 
P25311 Zinc-alpha-2-glycoprotein  0.0019 0.0128 1.42E+06 1.19E+06 0.84 -0.08 
O95445 Apolipoprotein M  0.0027 0.0128 3.59E+04 5.17E+04 1.44 0.16 
O43866 CD5 antigen-like  0.0030 0.0128 3.62E+05 2.27E+05 0.63 -0.20 
P02649 Apolipoprotein E  0.0046 0.0160 1.18E+06 8.69E+05 0.74 -0.13 
P05090 Apolipoprotein D  0.0066 0.0198 9.99E+05 7.40E+05 0.74 -0.13 
P68871 Hemoglobin subunit beta  0.0100 0.0262 2.63E+06 4.78E+06 1.82 0.26 
P02766 Transthyretin  0.0121 0.0268 2.44E+06 2.14E+06 0.88 -0.06 
P02790 Hemopexin 0.0127 0.0268 4.76E+06 5.27E+06 1.11 0.04 
P01602 Ig heavy chain V-I region 5 (Fragment)  0.0197 0.0376 6.98E+05 5.40E+05 0.77 -0.11 
P04220 Ig mu heavy chain disease protein  0.0257 0.0392 2.77E+05 1.87E+05 0.68 -0.17 
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4  0.0257 0.0392 1.17E+06 1.30E+06 1.11 0.05 
P01613 Ig kappa chain V-I region Ni  0.0261 0.0392 6.84E+05 4.61E+05 0.67 -0.17 
P43251 Biotinidase  0.0297 0.0397 2.23E+04 3.15E+04 1.41 0.15 
P02749 Beta-2-glycoprotein 1  0.0302 0.0397 3.02E+06 2.63E+06 0.87 -0.06 
P01861 Ig gamma-4 chain C region  0.0385 0.0476 1.74E+06 9.30E+05 0.53 -0.27 
P05155 Plasma protease C1 inhibitor  0.0428 0.0500 1.82E+06 2.03E+06 1.12 0.05 
P29622 Kallistatin  0.0454 0.0502 6.92E+04 7.73E+04 1.12 0.05 
P69905 Hemoglobin subunit alpha 0.0480 0.0504 1.62E+06 2.63E+06 1.62 0.21 
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Figure 33. Volcano plot NOCI patients vs CI patients. 
 
 
Figure 33: X axis represents the log 2 fold change, Y axis represents the –log10 (P values). Any protein dots 
above the dot line (P=0.05) are the potential biomarker. The protein dots with large P value and large absolute 
log2 fold change are good biomarkers to differentiate the groups. 
 
 
5.3.8  C9orf72 patients versus other ALS patients  
Only one protein, complement C1s subcomponent, was found to be significantly upregulated 
in 7 C9orf72 patients compared with the other ALS patients (P=0.023). All proteins analyses are 
shown in Figure 34.  
                                      
 Figure 34. Volcano plot C9orf72 patients vs other ALS patients 
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Figure 34: X axis represents the log 2 fold change, Y axis represents the –log10 (P values). Any protein dots 
above the dot line (P=0.05) are the potential biomarker. The protein dots with large P value and large absolute 
log2 fold change are good biomarkers to differentiate the groups. 
 
5.3.9  Western blot  
The CD5L, clusterin and gelsolin western blots in the discovery cohort are shown in Figure 35.  
CD5L protein was significantly downregulated in the CI patients (P=0.0017, P=0.028). However, 
there was no statistical difference between the control group and NOCI patients (P=0.52). Based on 
the clusterin blot densitometry, the level of clusterin was also significantly higher in the control group 
compared with CI group (P=0.0089). No significant difference was found between control group 
(P=0.36) and NOCI group or between NOCI group and CI group (P=0.18). Conversely the expression 
of gelsolin was significantly reduced in both NOCI and CI in comparison with the healthy group (P= 
0.019, P=0.041). The gelsolin, clusterin and ficolin 3 western blots in the validation cohort are shown 
in Figure 36. The levels of gelsolin and clusterin are significantly higher in the control group than in 
the ALS group (P=0.006, P=0.015). The concentration of ficolin 3 was upregulated in the ALS group 
(P=0.018). 
 
 
Figure 35. CD5L, clusterin and gelsolin western blot validation in the discovery group. 
 
 
Figure 35: A: CD5L, clusterin and gelsolin western blot validation in the three groups. B: The comparisons of 
three proteins among the three groups 
OD: optical density *: P<0.05 **: P<0.01 the expression of CD5L was significantly reduced in the CI group 
compared with the healthy control group (n=10) and the NOCI group (n=10). The subunit α of clusterin was 
significantly downregulated in the CI group (n=10) compared with the healthy control group (n=10). The level 
of gelsolin was significantly reduced in the both NOCI group (n=10) and CI group (n=10). 
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Figure 36. Gelsolin, clusterin and ficolin 3 western blot validation in the validation cohort 
 
 
Figure 36: Western blot analysis was performed on samples form 10 ALS subjects and 10 controls. 
 
A: This shows examples of western blot from 3 ALS subjects and 3 controls for 3 proteins. ; B: Gesolin 
concentration comparison between two group (ALS n=10, controls n=10); Clusterin concentration comparison 
between two groups (ALS n=10, controls n=10); Ficolin 3 concentration comparison between two groups 
(ALS n=10, controls n=10). 
OD: optical density *: P<0.05 **: P<0.01 the level of gelsolin and clusterin were significantly reduced in the 
ALS group. The level of ficolin 3 was significantly increased in the ALS group 
 
5.3.10  IPA pathway results  
The proteins that showed significant difference in expression between healthy control and ALS 
patients were uploaded to IPA software. The observation value was set to log (fold change). The 
Ingenuity Knowledge Base was chosen as reference set. The canonical pathway bar chart and stacked 
bar chart are shown in Figure 37 and Figure 38, respectively. The liver X receptor/ retinoid X receptor 
(LXR/RXR) pathway, the coagulation pathway and production of nitric oxide and reactive oxygen 
species in macrophages were found have a significant pattern of inhibition. The acute phase response 
signaling and complement system pathways were significantly activated. Two new networks were 
created from the uploaded proteins which also involved in the inflammatory response, metabolic 
disease, cell death and survival. The networks based on the dataset are presented in Figure 39. 
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Figure 37. Canonical pathway bar chart 
 
 
Figure 37: The color of the column indicates the Z score of the pathway. The red vertical line refers to the 
cutoff value for –log (p-value).The height of the bar refers to the value of –log (p-value). Pathways with 
positive Z score are colored with orange. Pathways with negative Z score are colored with blue. Orange bars 
predict an overall increase in the activity of the pathway and blue bars indicate a prediction of an overall 
decrease in activity. The orange ratio symbol indicates the ratio of proteins from the dataset that map to the 
pathway divided by the total number of proteins that map to the same pathway. 
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Figure 38. Canonical pathway stacked bar chart 
 
 
Figure 38: The stacked bar chart displays the percentage of proteins that were upregulated (red), downregulated 
(green), and proteins not overlapping with the dataset (white). 
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Figure 39. Networks produced by IPA based on the dataset 
 
 
Figure 39: Red: upregulation Green: downregulation White open: not identified as differentially expressed but predicted to interact with other proteins, A: Network, 
which is centered around IL1 and includes immune proteins. B: Network, which is centered around NFκB  
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5.4  Discussion 
In this study, MS was used to search for biomarkers and abnormalities of biological pathways 
in the blood of patients with ALS, compared to controls. Blood samples were used for ease of access, 
and also because blood is likely to contain proteins that have moved from damaged cells, into the 
interstitial fluid, and then to the blood via the lymphatic drainage of the brain [107, 268].  
With protein identification, using stringent criteria for FDR, there were proteins that are present 
in ALS but not in controls. These included 14-3-3 protein, which is important in neurodegeneration 
[276], has been found in neuronal inclusions in ALS [277] and may have a role in RNA processing [278] 
which is fundamental to the pathogenesis of ALS [279]. Another protein found only in ALS was 
Nesprin-2. Nesprins are a family of proteins involved in maintaining cellular architecture [280]. There 
is little information about Nesprin-2 in ALS, although it is upregulated in the hippocampus in prion 
disease [281]. Another nesprin, Nesprin-1 is a binding partner for Matr3 [282]. Mutation in the Matr3 
gene are causative of ALS [59]. The list of proteins unique to controls included properdin and attractin 
both of which have a role in complement activation. However, because the IDA data was generated 
using pooled samples it is not known whether such identifications are present in all subjects or just 
some individuals from the control or patient cohorts, and there is no measure of the significance of 
these differences. 
The primary goal in this study was to identify a set of plasma proteins with significant 
differences in abundance between control subjects and ALS patients, rather than trying to maximize 
protein identification. Instead, SWATH analysis and protein quantitation was used to compare protein 
levels in different groups. BH method was used to correct for multiple comparisons [275]. Because 
ALS is a heterogeneous disease, patients were subdivided on the basis of the presence of absence of 
cognitive impairment based on results of the ACE-III test. ALS participants with cognitive 
impairment measured with ACE-III had worse prognosis [239, 269], so this is a distinction that has 
clinical importance. Patients with cognitive impairment measured with these tools have more severe 
and widespread MRI changes[283]. Patients with repeat expansions of C9orf72 also form a distinct 
subgroup of ALS [254], that was also studied.  
Between the whole ALS group and controls, there were significant differences in the levels of 
30 proteins. These include proteins involved in immunity, lipid transport and coagulation, as well as 
albumin, serum amyloid P component, gelsolin, ficolin 3 and transthyretin. The most significantly 
regulated protein was albumin. Low levels of serum albumin are already known to be a poor 
predictive marker of ALS [284]. 
The level of transthyretin in the plasma was significantly downregulated in the ALS patients, 
consistent with one previous study [138], but opposite to the results of two studies [141, 142]. These 
previous studies used CSF, so the present study is the first to show changes in blood. Transthyretin is 
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a transport protein, associated with amyloidosis. There is a link to ALS as patients with familial 
amyloid neuropathy due to transthyretin mutations can have signs that mimic ALS [285, 286]. There was 
upregulation of serum amyloid P component in blood in ALS as found previously by others in CSF 
[165].             
With MS and western blot, there was downregulation of gelsolin in ALS compared to controls. 
This was confirmed in an independent cohort. Gelsolin has the function of assembling and 
disassembling the actin filament [287] and in regulating and inhibiting apoptosis [288, 289].   
There was upregulation of complement proteins in ALS patients compared to controls. The 
elevation of C5a and C5b were found in the blood of ALS patients [290]. In animal models of ALS 
there is evidence of complement activation and inhibition of disease by blockade of complement 
activation [113, 291].  
There was upregulation of ficolin 3 in ALS, confirmed in an independent cohort. Ficolin 3 
initiates complement activation by its mannose-binding lectin (MBL)-associated serine proteases [292, 
293]. This is the first report of ficolin 3 as a possible biomarker for ALS, although there are reports of 
low level of ficolin 3 in the plasma having a positive relationship with the severity of the brain injury 
in ischemic stroke and subarachnoid hemorrhage [294, 295].  
There were 15 proteins that showed significantly different expression between healthy controls 
and ALS without cognitive impairment and 32 proteins that showed significant different expression 
between controls and ALS with cognitive impairment. In addition, the levels in patients with 
cognitive impairment showed greater deviation from the healthy controls than those of patients 
without cognitive impairment, consistent with the suggestion that patients with cognitive impairment 
have more severe and widespread disease [269]. Between ALS with cognitive impairment and controls 
there was a significant difference in the expression of clusterin. Clusterin is a glycoprotein c, that is 
widely expressed in the nervous system and biofluids [296]. It has a role as a protein chaperone and in 
inhibition of apoptosis [297]. The level of plasma clusterin is positively related with the prevalence and 
severity of Alzheimer disease [298]. Clusterin has been implicated in ALS, which plays a key role in 
protecting the motor neuron and removing the superoxide dismutase 1(SOD1) protein in SOD1 
familial ALS mouse model [299]. Another study also showed that clusterin prevented the aggregation 
of TDP-43 proteins in the Drosophila model [192]. 
Between the CI group and the NOCI group, there were significant differences in a number of 
proteins including CD5L. CD5 L, also known as apoptosis inhibitor 6 [300], is expressed on microglia 
[301] and also plays an important role in the apoptosis [302]. CD5L also acts to downregulate the 
pathogenicity of Th17 cells [303]. CD5L has been studied as a biomarker and is elevated in serum in 
chronic leukemia [304]. 
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The common feature among gelsolin, clusterin and CD5L is a role in apoptosis. There is 
evidence that programmed cell death is the final process in the pathogenesis of ALS [119]. Therefore 
the use of these proteins as biomarkers could provide measurements that are closely related to disease 
pathology. This could be useful in clinical trials, where there is a need for a surrogate biomarker of 
disease [305]. 
There are some limitations to the study. The size of this cohort is small. Some patients did not 
have cognitive testing due to physical disability, and a screening tool rather than comprehensive 
neuropsychological testing was used. There are now a number of different screening tools, including 
the Edinburgh cognitive and behavioural ALS screen (ECAS) [85] and the ALS cognitive behavioural 
screen (ALS CBS) [86] that can be used to screen ALS patients, but when this study was commenced, 
these were not available. Not all patients had genetic testing for C9orf72 repeat expansion.  
The list of proteins that differed between ALS and controls was used to perform bio-informatic 
analysis. With pathway analysis, there was evidence of widespread alteration of physiological 
pathways including coagulation, acute phase reaction and complement signaling. Although ALS is 
usually regarded as a disease causing degeneration of motor neurons, the present study shows that 
there is a generalized physiological response. In particular, the Liver X receptor/ Retinoid X receptor 
(LXR/RXR) and the Farnesoid X receptor/ Retinoid X receptor (FXR/RXR) pathways were regulated 
in ALS patients. LXR/RXR and FXR/RXR are nuclear receptors. This canonical pathway is related 
to lipid metabolism and inflammation in the central nervous system [306, 307]. These have been 
previously implicated in ALS. In one study, deactivating LXR led to the degeneration of motor 
neurons in the male mice [308]. A genetic study found that LXR genetic variants modify the phenotype 
of ALS [309]. It is thought that LXR is involved in the toxicity of plant sterols to motor neurons [310]. 
In one study, on the ALS SOD1 mouse model, using agonist Bexarotene to activate the RXR can 
relieve the astrogliosis and have neuroprotective effect [311]. Interestingly, CD5L is also a regulator 
of lipid synthesis. Thus with proteomics of peripheral blood, activation of a pathway that has an 
established role in ALS was found. This provided evidence that this approach is useful in studying 
the disease. 
Lipid metabolism has become prominent in the studies of ALS. There have been studies of lipid 
levels in ALS patients [312, 313]. There are abnormalities of cholesterol metabolism in ALS [314]. More 
broadly there have been studies indicating that metabolism is altered in patients with ALS [315], with 
evidence of hypermetabolism, which plays a role in prognosis [316]. There have been some studies 
using MS to show metabolic abnormalities in ALS [133, 136, 148]. 
The bio-informatic analysis produced two networks, one centered on interleukin-1 (IL-1) and 
one centered on nuclear factor kappa B (NFκB). While these changes are detected in blood, this could 
suggest that these pathways are perturbed in ALS, either as part of the pathogenesis or as a response 
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to disease. The finding of evidence of these networks in the peripheral blood could reflect alterations 
in the brain, since interstitial fluid from the brain drains via lymphatics to the blood.   
 IL-1 is a cytokine that is central to inflammation and innate immunity [317], It is important in 
neuroinflammation [318]. Immune pathways are thought to be important in the pathogenesis of ALS 
[319]. IL-1 is activated by caspases in inflammations [320]. Preclinical studies show that blocking 
caspase or IL-1 can prolong survival in mouse models of ALS [321, 322]. An antagonist of IL-1 has been 
used in a phase I clinical trial in ALS [208].  
NFκB, which is the term used for a complex of proteins and inhibitors, is a "master regulator" 
of cell functions [323]. It has a key role in inflammation [324]. In the nervous system, NFκB is found in 
a neurons and glia, and is important in cell function [325]. NFκB is a protein complex that regulates 
the transcription of DNA and is activated during acute hypoxia and acts to up-regulate inflammatory 
factors such as interlukin-6 (IL-6), cyclo-oxygenase (COX 2), TFN-α, and prostaglandin E-2 (PGE-
2) [326]. 
 In ALS, NFκB has been implicated in the death of motor neurons by microglial toxicity [327]. 
Genetic abnormalities in optineurin (OPTN) have also been found in ALS [328]. Analysis of cell 
transfection showed that the nonsense and missense mutations of OPTN abolished the inhibition of 
activation of NFκB. This protein is important in the NFκB pathway, and it was proposed that NFκB 
is important in as the final common pathway in ALS pathogenesis. In G93A SOD1 mutant mice, 
treatment with a peroxisome proliferator-activated receptor (PPAR) inhibitor lead to clinical 
improvement and reduced inducible nitric oxide synthase (iNOS) and NFκB reactivity [329]. On the 
other hand, phenylbutyrate induced NFκB translocation to the nucleus in G93A mice and this led to 
reduced motor neuron death [330].      
 The study is novel in showing that MS in peripheral blood can find biomarkers in ALS, and 
the proteins identified could play a role in pathogenesis. Blood will contain proteins that have drained 
from the damages brain and will also reflect physiological changes in the subject. There are few direct 
comparisons of blood and CSF in the search for biomarkers of ALS, but there is one study showing 
a correlation of levels of neurofilament in blood and CSF [331]. Pathway analysis shows evidence of 
widespread physiological changes indicating a physiological response to the disease. Analysis of 
peripheral blood also produced two novel networks centered on molecules that are probably related 
to disease pathogenesis. This study thus show that proteomic analysis of peripheral blood is useful in 
ALS and this could be the case in other neurodegenerative disease. 
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Chapter 6.  Conclusion and discussion 
6.1  Discussion    
This thesis has the theme that ALS is heterogeneous and that heterogeneity affects prognosis 
and that biomarkers are needed to evaluate disease in the individual patients. 
 
6.1.1  Motor heterogeneity and prognosis 
One of the most challenging issues in ALS patients is heterogeneity and disease classification 
[332]. Many patients fulfil criteria for the diagnosis of classic ALS [7], However, there is no consensus 
on how to include the other variants of ALS such as PMA, PLS, flail arm and flail leg [42]. Most of 
the studies only include patients who fulfil the criteria for definite or possible ALS. However, some 
PMA or PLS patients will go on to fulfil the diagnostic criteria of ALS, even though these criteria are 
not fulfilled at the onset of disease.   
Furthermore, even patients who fulfil the diagnostic criteria for ALS can have prominent upper 
or lower motor neurone clinical signs (upper motor neuron dominant and lower motor neuron 
dominant ALS). These variants of ALS have different prognosis from classic ALS and other variants, 
as shown in Table 32. The motor heterogeneity is one source of variability in prognosis. The 
pathogenesis of the different variants is unclear. 
 
Table 32. Prognosis in ALS variants 
Variants Prognosis 
Upper motor neuron dominant ALS Longer survival in UMN-dominant ALS compared to classic ALS 
patients [333]. 
Lower motor neuron dominant ALS Rapid disease course in LMN predominant ALS [334]. 
Primary lateral sclerosis Slower progression or long survival time with high level of 
function [43, 335]. 
Progressive muscle atrophy Longer survival time than typical ALS [51]. 
Flail arm  Longer survival time than ALS and PMA [40, 41]. 
Flail leg Better survival than typical ALS and PMA[40, 41] 
 
6.1.2  Heterogeneity of cognitive involvement 
Another source of heterogeneity is the presence of absence of cognitive involvement. The 
original work of this thesis was concerned with this heterogeneity and its effects on survival. As 
already described, ALS and FTD belong to the same disease continuum [336]. The subdivision based 
whether or not there is with cognitive impairment is key part of the classification of ALS. The study 
showed that some patients with ALS have cognitive and impairment based on simple bedside testing 
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and that the presence of cognitive impairment leads to worse prognosis. This shows that simple 
screening testing can give valuable information. The study used the ACE-III, the FAB for cognitive 
testing. There is no consensus about which test to use, and the ECAS [204] and the CBS [209] are 
becoming popular.   
A limitation of the study is the use of screening tools to do the cognitive testing. No formal 
neuropsychological tests were used, and patients could not be further divided into different subtypes 
which are non-fluent progressive aphasia, semantic dementia and logopenic progressive aphasia. 
Some studies have focused on the new consensus on the diagnostic criteria of ALS with FTD, 
cognitive impairment and behavioural impairment [82, 337]. However whether there is difference 
between ALS with different subtypes of cognitive impairment still needs to be established. The 
overlap of clinical symptoms among these three different subtypes of cognitive impairment further 
complicates the classification. There seems no clear demarcation among these subtypes in the clinical 
setting. 
The study showed that the level of education can affect the results of cognitive testing. One 
previous study also suggested that the performance of verbal fluency and other executive tests was 
correlated with intelligence quotient (IQ) [82]. As mentioned in the chapter 4 discussion, using the IQ 
or education level corrected scoring guide would be desirable in the clinical setting. 
The present study did not find significant difference in verbal fluency between ALS patients 
and disease controls without CNS involvement. The results are contrary to the previous studies when 
comparing the performance between ALS subjects with healthy people [204, 230]. Verbal fluency is a 
good tool to detect executive function, which is a prognostic risk factor in ALS patients [220]. However, 
there are some discrepancies between the scoring guidelines of verbal fluency in the ACE-III, FAB, 
ECAS and CBS. In the ACE-III and ECAS, a verbal fluency index calculation is required to control 
for bulbar dysfunction to avoid bias due to impaired speech. In contrast, there is no such requirement 
in the FAB and CBS. It is suggested that it is better to use this method to control for the bias caused 
by motor speech dysfunction. Writing is also a good alternative when the dysarthria is significant. 
Furthermore, if the patients initiate the test with speech or with writing, it is better to use the same 
method on all subsequent tests. Otherwise there may be differences in performance with different 
testing methods. In addition, numbers are not counted as correct answers in the CBS fluency test, 
unlike the ACE-III and FAB. In the future it would be better to use the verbal fluency test with same 
requirements. 
In the present study, a family history of dementia or ALS did not correlate with cognitive 
impairment. However, division of ALS patients into those with and without a family history of ALS 
or dementia is not a precise process, since most of the ALS-FTD genes are reported as showing 
dominant inheritance with incomplete penetrance [338]. Some researchers have proposed the modified 
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Goldman score to quantify the odds effect of the family history of FTD [339, 340]. In the future, 
comprehensive genetic testing will be possible to identify patients with causative genetic mutations, 
and will allow correlation of these with cognitive function. 
6.1.3  Behavioural changes 
Behavioural change occurs as part of FTD, and ALS patients are also heterogeneous in the 
presence or absence of this feature, which usually occurs with cognitive change. 
It is challenging to follow behavioural impairment of the ALS patients in a longitudinal way. 
One reason is that different carers accompany the patient to different visits to MND multidisciplinary 
clinic, and it is not appropriate to use the results from different carers in a longitudinal study. 
However, in the present study, the relationship of the carer to patient had no effect on the results of 
behavioural impairment. So the carer who can provide accurate assessment of behavioural change 
need not be a partner. The candidates can be extended to the people such as siblings, close friends 
and neighbours who have close association with the patients.      
If behavioural disturbance develops with cognitive impairment, it could suggest the global 
involvement of FTD, which is a risk factor of ALS patients [220]. Whether the sequence of 
development of behavioural and cognitive impairment will affect the prognosis of the patient also 
needs to be addressed.    
In addition, ALS can cause pseudobulbar palsy [341]. The symptom is caused by abnormality of 
the upper motor neuron (corticobulbar tract). The symptoms of pseudobulbar palsy such as 
uncontrollable laughing and crying sometimes are very like those of behavioural variant FTD. These 
symptoms can be mistaken by the carers as social behavioural change. Appropriate education for the 
carer will increase the accurate assessment of such mimic symptoms.  
The presence of apathy did not affect the prognosis of the patients. However, depression and 
apathy can influence the patients’ motivation to take the test, which will inevitably affect their 
performance during the test. In many occasions, it was noted that if the patients performed poorly at 
the initial sections of the cognitive test, they were reluctant to continue the tests or failed to take the 
test seriously. Sometimes encouragement was necessary. Whether discontinuation of participation in 
testing is directly caused by apathy or other psychological factors still needs to be investigated. So 
apathy or depression related questionnaires would also be useful in the initial cognitive test to rule 
out such alternative causes of the poor performance. 
 
6.1.4  Neurofilaments 
Given the variability among ALS patients, there is a need for biomarkers of disease progression. 
Neurofilaments in ALS have been studied [173]. Neurofilaments have also been used as biomarkers in 
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other neurological disease as a measure of damage (Table 33). In this thesis a meta-analysis of the 
use of neurofilaments as a biomarker in ALS was performed. 
 
Table 33. Neurofilaments as biomarker in other neurological diseases 
Disease Study showing neurofilament abnormality 
Multiple sclerosis Gresle et al.[186] 
Alzheimer’s disease Gaiottino et al.[178] 
Creutzfeldt-Jakob disease Steinacker et al.[342] 
Peripheral neuropathy in type 2 diabetes Qiao et al.[343] 
Frontotemporal dementia Meeter et al.[344] 
Spinal cord injury Kuhle et al.[345] 
Hypoxic-Ischemic Encephalopathy Douglas et al.[346] 
Traumatic brain injury Shahim et al.[347] 
Stroke Singh et al.[348] 
 
One of the limitations of the systematic review and meta-analysis of neurofilaments in ALS is 
that there was no standardization of the timing of the blood or CSF sampling after the onset of the 
disease. It is known that there is an average one year diagnostic delay after onset of symptoms [349]. 
Sometimes the patients are uncertain about the timing of symptom onset, which further complicates 
the measurement of disease duration. So the change rate of ALSFRS-R between two visits will be a 
more reasonable index to assess the progression of the disease between two time points.  
There are still not enough studies of the change of NFL longitudinally in both CSF and blood. 
For NFH, two papers reported that the concentration of NFH in the blood showed an initial rise but 
later the levels fell [173, 175]. Whether this same pattern can be applied to the NFL still needs to be 
validated. As to the neurofilaments in the blood and CSF samples, whether the increase in levels is a 
primary event or the secondary event is yet to be elucidated. Some studies have showed the close 
relationship between the SOD1 gene mutation and neurofilament aggregation in the motor neuron 
[350, 351]. 
 
6.1.5  Mass spectrometry in the search for biomarkers 
MS is a useful tool for the discovery of biomarkers. In this study, blood samples were used. 
Although blood samples are easy to obtain, there are still some challenges for processing the plasma 
or serum samples. One issue is that the highly abundant proteins will mask the less abundant proteins 
and generate high background noise. SWATH has its own benefits compared with other MS labelling 
technology SILAC and iTRAQ. First of all it is a label-free MS technology, avoids the large variation 
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of labeling efficiency in iTRAQ [263]. The prerequisite of MS labelling is that the targeted proteins 
have been screened out. SWATH is a hypothesis-free approach that can be used to quantify the 
proteins in the sample without target protein. Another merit of SWATH is the multiplexing proteins 
quantitation. This means it can quantify all the proteins detected in the first IDA spectrum. There is 
no limit number of proteins that can be quantified. In contrast, iTRAQ can only quantify 4 or 8 
proteins at the same time [352].  
SWATH has its own demerits. A first round of scanning is required to generate a comprehensive 
ion library. This is based on the information dependent acquisition. In the third study, the 20 most 
intense spectra will be picked up into the ion library within one cycle. Some low intensity spectra that 
are hidden in the other abundant proteins spectrums will not be captured into the ion library. So it is 
not appropriate to use IDA scan to compare the number of proteins that can be identified in different 
blood samples. Depletion would seem to be a good method to remove the highly abundant proteins. 
However, subtle differences in the depletion rate of the kit will disturb the later sensitive SWATH 
protein quantification. Therefore, in the present study, undepleted samples were used in the proteomic 
research. The retention time was optimized to get the highest proteins of IDA scanning to maximize 
the number of proteins able to be quantified in the blood sample. 
The small sample processing capability is one of the drawbacks of mass spectrometry. The bias 
will be inevitably generated during large amounts of samples processing due to changing property of 
separation column over time. Separating the samples into different batches will also generate the 
batch effect similar to that seen with microarray gene expression testing [353]. Due to the heterogeneity 
of ALS patients, small numbers of samples have insufficient statistical power to validate the 
hypothesis. So it is better use a consistent and robust batch effect removal and normalization method 
to minimize this internal bias. 
 
6.1.6  Do the proteins found with MS give insights into pathogenesis of ALS? 
The third study found a panel of proteins that are different in abundance between ALS patients 
and healthy controls. It is unclear whether these changes in protein levels are a primary event or are 
secondary to the neurodegeneration of ALS. The molecular mechanisms that have been put forward 
for ALS pathogenesis include the impaired proteostasis, impaired RNA or DNA splicing, oxidative 
stress caused by mitochondria dysfunction, high level of glutamate excitotoxity, non neuronal cell 
dysfunction, autophagy, apoptosis and neuroinflammation [354, 355].  
Several proteins found in the study are to be closely related with each other. The levels of 
gelsolin was found to decrease in the ALS cohort regardless of cognitive impairment. One study has 
reported that the level of the gelsolin was mediated by the ubiquitin proteasome system (UPS) [356]. 
Interestingly the normal proteostasis of TDP-43 and SOD1 are also closely associated with UPS [357, 
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358]. Whether the change of gelsolin levels is paralleled with the change of TDP-43 or SOD1 
aggregation is still unclear. Aggregation of TDP-43 can alter the dynamics of the membraneless 
organelles and further facilitate the formation of amyloid like fibrils in ALS pathogenesis [359]. 
Clusterin has the function of inhibiting the formation of amyloid and protecting neurons [360]. The 
level of clusterin was significantly downregulated in the CI group. So although these two 
pathogeneses are associated with each other, which protein is the initial trigger is still unknown.  
This is also the case in the two new IL-1and NFκB centered pathways. There is some evidence 
that the non neuronal cells such as microglial which can release the cytotoxic product IL-1β and then 
further activate the NFκB pathway [327, 361]. Using wild type non neuronal cell can prolong the survival 
time of motor neurons with SOD1 mutation in the mice model [362]. 
Several proteins found in the third study are associated with the production of ROS in 
macrophages. ROS can trigger and play an important role in the process of apoptosis [363]. The level 
of ROS was observed to be upregulated in lymphoblast cell of familial ALS patients with SOD1 
mutation [364]. In the present study, this pathway was downregulated, but whether this is a secondary 
protective mechanism is unclear, and the sequence of the involved pathways is still unknown.  
Some proteins that were detected in the MS study are related with lipid metabolism or nutrition. 
One uncertainty is whether the change in the concentration of these proteins was caused by 
behavioural change, especially a change in eating behaviour such as favouring the consumption of 
sweet food, as is described with FTD [365]. Another relevant issue is that there are metabolic changes 
in ALS including insulin resistance and redistribution of adipose tissue [366, 367].  
Several studies have reported the dysfunction of the lipid metabolism of ALS patients [312, 368]. 
Downregulation in the lipid metabolism was observed in the ALS cohort. High fat intake as a 
prognostic factor in ALS patients has been reported in several researches [369, 370]. High level of lipid 
such as LDL/HDL and triglyceride in the blood was observed in the patients with long survival time 
[371]. Body mass index has also been reported to be associated with improved outcome [372]. The 
mechanism of the abnormalities in the lipid metabolism is still unknown. One study has shown that 
ROS can cause the dysfunction of mitochondrial and further disturb the lipid metabolism [373]. In 
ALS, there are some heterogeneity in the vulnerability of muscle. Fast-fatiguable muscles are more 
vulnerable in the beginning stage of the disease than fatigue resistant muscle [374]. Whether there is 
association between the selective vulnerability and lipid dysfunction is unclear. Lower lipid levels 
were reported to relate with the respiratory failure caused by diaphragm [375]. Lipid not only plays a 
role in energy metabolism but also in the fluidity of the membrane, signalling pathways [313]. 
Unsaturated fatty acids and omega 3 fatty acid have shown to promote the progression of the disease 
and SOD1 aggregation in SOD1 mouse through different neurophysiological pathways [376, 377].  
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6.1.7  Limitations of MS study 
Another limitation of the MS study is the lack of correlation between these protein biomarkers 
with disease progression. One previous study has pointed out the Fetuin-A and transthyretin in the 
CSF could be used as a candidate to monitor the disease progression based on the MS analysis [142]. 
Future studies should perform serial measurements of the proteins that have been identified and that 
could be important in disease pathogenesis. As to the serial pathway analysis, whether the initial 
involved pathways will change to another group of pathways over the disease course is not well 
established, so this also needs to be investigated.  
In the third study, the only subgrouping was into patients with and without cognitive 
impairment, the difference in the proteomic profile between the patients with and without behavioural 
impairment has not been investigated. This should be investigated in the future. It would also be 
useful to test the difference between the patients with rapid progression and slow progression, using 
change in the ALSFRS-R, although there is still no consensus on the demarcation between rapid 
progression rate and slow progression rate.   
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6.2  Conclusion     
This thesis is concerned with clinical and laboratory aspects of ALS. The clinical issue that was 
studied was the occurrence of cognitive impairment in ALS. The laboratory aspects were the search 
for protein biomarkers of disease. The systematic review found that NF heavy and light chain levels 
have potential as a marker of neural degeneration in ALS, but are not specific for the disease, and are 
more likely to be used as measures of disease progression. This was more apparent in CSF than in 
blood, but the numbers were small and larger studies might give different results. 
The study of cognition found that there is a greater frequency of cognitive impairment in people 
with ALS than in patients with other neuromuscular diseases. This study is novel in the use of disease 
controls. The results of cognitive tests are stable over 6 months and possibly longer. This suggests 
that people who are cognitively normal at onset remain so through the course of disease. 
Abnormalities on cognitive and behavioural tests were correlated with poor prognosis. 
The proteomic study found that there are significant differences between ALS and controls in 
the proteins found in blood, and that there are differences between ALS patients with cognitive 
impairment and those without. Clusterin, gelsolin and ficolin 3 are novel potential biomarkers to 
differentiate the ALS patients and healthy controls. Abnormalities in the LXR/RXR pathway suggest 
that lipid metabolism is involved in ALS. There are widespread changes in immune and coagulation 
pathways in ALS.  
In summary the study found evidence of cognitive and behavioural impairment in a subgroup 
of subjects with ALS, that levels of neurofilaments are strong candidate biomarkers in ALS and that 
there are other protein biomarkers that can be found by MS. 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
6.3  Future direction 
The current revised El Escorial criteria and Awaji neurophysiological criteria are the gold-
standard for diagnosis, although there still exists the delay between the symptom onset and definite 
diagnosis. The heterogeneity of the motor features of ALS needs further emphasis. Detailed 
stratification of the ALS patients will play a key role in defining the heterogeneity of the disease, and 
will help us unravel the complicated clinical manifestation. This stratification should include the 
atypical and typical ALS, and should recognize that there can be dynamic transition from atypical 
ALS to typical ALS. The cognitive and behavioural impairment should also put into the stratification 
to further investigate the effect on prognosis and survival time. Standardized cognitive and 
behavioural screening scales with consistent scoring guide should become an indispensable part of 
the MND clinic. 
Biomarkers appear to have a place in the stratification of patients, and longitudinal study of the 
biomarker on individual patient is important. However, it will be important to adjust for other 
concomitant dysfunctions or disorders, environmental factors and standardize the whole sample 
processing in order to find the reliable biomarker specific to the ALS. 
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Appendices 
Appendix I 
 
The results of Quadas-2 
Study RISK OF BIAS APPLICABILITY CONCERNS 
PATIENT 
SELECTION 
INDEX TEST REFERENC
E 
STANDARD 
FLOW 
AND 
TIMING 
PATIENT 
SELECTIO
N 
 
INDEX 
TEST 
REFEREN
CE 
STANDAR
D 
Boylan 2009        
Boylan 2013        
Brettschneider 2005        
Gaiottino 2013        
Ganesalingam 2011        
Ganesalingam 2013        
Goncalves 2014        
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Kuhle 2010   ?   ?  
Lehnert 2016        
Lu 2015        
McCombe 2015        
Mendonca 2011        
Reijn 2009        
Rosengren 1996        
Steinacker 2011        
Steinacker 2015        
Tortelli 2012        
Tortelli 2014    ?    
Weydt 2016    ?    
Zettergerg 2007        
Low Risk High Risk   ? Unclear Risk  
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Appendix II 
 Summary of 20 papers selected for meta-analysis 
Paper NF tested  CSF Blood Excluded 
from meta-
analysis, 
included in 
systematic 
review 
Used for meta-analysis 
     Controls used 
     Healthy 
control 
Non CNS parenchymal 
disease  
ALS 
mimic 
disease  
CNS parenchymal 
disease 
Boylan 2009 NFH No  Yes   Yes No No No 
Boylan 2013 NFH Yes No longitudinal 
study, no 
controls 
N/A N/A N/A N/A 
Brettschneider 
2005 
NFH Yes No  No Tension headache No Alzheimer’s 
disease 
Gaiottino 2013 NFL Yes Yes  Yes Tension headache, lower 
back pain, psychiatric 
disorders, nonspecific 
symptoms without 
neurological 
explanation, Guillain-
Barré syndrome 
No Alzheimer’s 
disease 
Ganesalingam 
2011 
NFH Yes  Yes insufficient 
data 
Yes Migraine, Conversion 
disorder, Normal 
pressure 
hydrocephalus 
Yes Multiple Sclerosis, 
Frontotemporal 
lobar degeneration 
without motor 
involvement, 
Alzheimer’s 
Disease, 
Parkinson’s 
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Disease, 
Spinocerebellar 
Ataxia, Neoplasia, 
Inflammatory 
Conditions, 
infectious 
diseases 
Ganesalingam 
2013 
NFH Yes No insufficient 
data 
No Benign headache, 
normal pressure 
hydrocephalus 
 
Yes Parkinson ’ s and 
related syndromes, 
multiple sclerosis, 
other 
neuroinflammatory 
disorders 
Goncalves 2014 NFH Yes No  No No No Chronic 
inflammatory 
demyelinating 
neuropathy, 
hereditary 
demyelinating 
polyneuropathy, 
diabetic 
neuropathy, 
probable brachial 
plexitis, 
undetermined 
neuropathies, 
myelitis, headache, 
normal pressure 
hydrocephalus, 
undetermined 
spinal cord lesion 
Kuhle 2010 NFH Yes No   No Tension type headache, 
lower back pain, 
psychiatric disorders, 
miscellaneous diseases 
without neurological 
No multiple sclerosis, 
Mild cognitive 
impairment/ 
Alzheimer’s 
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explanation, Guillain-
Barré syndrome 
Disease, 
subarachnoid 
haemorrhage 
Lehnert 2016 NFH Yes  No  No No  No demyelinating 
neuropathy, 
myelitis, stroke, 
migraine, other 
headache, 
aneurism, 
neuropathy, hepatic 
encephalopathy, 
sensory TIA, 
parkinsonism, mild 
cognitive 
impairment, 
ischaemic optic 
neuropathy, 
cerebrovascular 
disease, 
somatisation 
disorder, 
hyperreflexia 
Lu 2015 NFL Yes  Yes  Yes No No No 
McCombe 2015 NFH No Yes  Yes No No No 
Mendonca 2011 NFH Yes No using 
western blot 
to measure 
NF 
No Headache No No 
Reijn 2009 NFH and 
NFL 
Yes No  No No Yes  No 
Rosengren 1996 NFL Yes  No  Yes No No Alzheimer’s 
disease 
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Steinacker 2011 NFH Yes  No  No Tension headache No Parkinson disease 
Steinacker 2015 NFH and 
NFL 
Yes No  No Polyneuropathies 
Facial Palsy 
 
Yes Alzheimer’s 
disease, Parkinson 
disease 
Tortelli 2012 NFL Yes No  No  No No Chronic 
inflammatory 
demyelinating 
neuropathy, 
Alzheimer’s 
disease, mild 
cognitive 
impairment, spino-
cerebellar ataxia, 
cortico basal 
degeneration, multi 
system atrophy 
Tortelli 2014 NFL Yes No longitudinal 
study) 
N/A N/A N/A N/A 
Weydt 2016 NFH and 
NFL 
Yes Yes  Yes No No No 
Zetterberg 2007 NFL Yes No  Yes No No headache, normal 
pressure 
hydrocephalus, 
multifocal motor 
neuropathy, 
spinobulbar 
muscular atrophy, 
Parkinson disease, 
non-ALS 
dementias, multiple 
sclerosis and 
cerebrovascular 
disease l 
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Appendix III 
 Studies of correlation with duration 
 The result of correlation The method P value Number of patients R value ( if use 
pearson or 
spearman 
correlation 
method) 
Studies of NF Heavy chain 
CSF 
Ganesalingam 2013 Inverse correlation between CSF 
NFH and disease duration  
Pearson’s correlation P<0.0001 150 -0.35 
Steinacker 2015 Inverse correlation between CSF 
NFH and disease duration 
Spearman’s correlation P<0.0001 455 -0.43 
 No significant difference between 
the first test and the second follow 
up test in CSF NFH 
Kruskal-Wallis test P=0.520 11 N/A 
Weydt 2016 Disease duration was significantly 
correlated with CSF NFH 
Spearman’s correlation P<0.0001 61 -0.565 
Blood      
Boylan 2009 No correlation between baseline 
pNF-H and disease duration  
Kendall’s tau correlation 
analysis 
P=0.20 19 N/A 
Studies of NF light chain 
CSF 
Tortelli 2012 There was negative correlation 
between CSF NFL and diagnostic 
delay ( time from onset to 
diagnosis) 
Spearman’s correlation P<0.0001 37 -0.55 
Zetterberg 2007 Inverse correlation between CSF 
NFL and disease duration  
Spearman’s correlation P=0.001 79 -0.518 
Steinacker 2015 Inverse correlation between CSF 
NFL and disease duration  
Spearman’s correlation P<0.0001 455 -0.376 
 There was significant difference 
between first test and the second 
follow up test in CSF NFL 
Kruskal-Wallis test P=0.007 11 N/A 
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Wedyt 2016 There was significant correlation 
between CSF NFL and disease 
duration  
Spearman’s correlation P<0.0001 51 -0.606 
Blood 
Lu 2015 ( London cohort) Negative correlation between blood 
NFL and disease duration  
Correlation analysis P=0.0002 108 -0.36 
Lu 2015 ( Oxford cohort) Negative correlation between blood 
NFL and disease duration 
Correlation analysis P<0.0001 64 -0.5 
Wedyt 2016 There was significant correlation 
between blood NFL and disease 
duration  
Spearman’s correlation P=0.012 51 -0.401 
 
Studies of correlation with disease progression 
 The result of correlation The method P value Number of 
patients 
R value ( if use 
pearson or spearman 
correlation method) 
Studies of NF heavy chain 
CSF 
Boylan 2012 ( Mayo 12 month 
Cohort) 
There was negative correlation 
between CSF pNFH and ALSFRS-
R change per month in the first 4 
months follow up   
Spearman’s correlation   P=0.006 20 -0.59 
 There was negative correlation 
between CSF pNFH and ALSFRS-
R change per month in the first 12 
months follow up  
Spearman’s correlation P=0.015 20 -0.54 
Brettschneider 2006 There was significant difference in 
the CSF pNFH between fast 
Wilcoxon two samples 
test 
P<0.001 49 N/A 
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progression patients and slow 
progression patients. 
Steinacker 2011 There was significant difference in 
the CSF pNFH between fast 
progression group and slow 
progression group  
Mann-Whitney Rank sum 
test 
P<0.001 68 N/A 
Steinacker 2015 There was a weak tendency 
between CSF pNFH and ALSFRS-
R  
Spearman’s correlation P=0.016 455 -0.163 
 There is significant difference 
between fast progression group and 
slow progression group  
Kruskal-Wallis test P=0.026 455 N/A 
Weydt 2016 Disease progression was not 
correlated with CSF NFH 
Spearman’s correlation P=0.27 61 -0.285 
Blood      
McCombe 2015 There was no relationship between 
the serum pNFH and ALSFRS-R  
Linear regression analysis  P>0.05 98 N/A 
 There was an inverse relationship 
between the serum pNFH and 
ALSFRS/days×103 
Linear regression analysis  P=0.005 98 N/A 
 There was an inverse relationship 
between the rate of rise in serum 
pNFH and ALSFRS/days×103 
Linear regression analysis  P=0.0635 98 N/A 
Boylan 2009 There was no correlation between 
baseline plasma pNFH and 
ALSFRS-R 
Kendall’s tau correlation 
analysis  
P=0.44 19 N/A 
 There was weak correlation 
between baseline plasma pNFH and 
ALSFRS-R decline over 4 months 
Kendall’s tau correlation 
analysis 
P=0.087 19 N/A 
Boylan 2012 ( Mayo 12 month 
cohort) 
There was negative correlation 
between serum pNFH and 
Spearman’s correlation P=0.042 20 -0.46 
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ALSFRS-R change per month in 
the first 4 months follow up 
 There was no significant negative 
correlation between serum pNFH 
and ALSFRS-R change per month 
in the first 12 months follow up 
Spearman’s correlation P=0.19 20 -0.31 
 There was significant negative 
correlation between plasma pNFH 
and ALSFRS-R change per month 
in the first 4 months follow up 
Spearman’s correlation P=0.03 38 -0.35 
 There was no negative correlation 
between plasma pNFH and 
ALSFRS-R change per month in 
the first 12 months follow up 
Spearman’s correlation P=0.29 20 -0.25 
Studies of light chain 
CSF 
Tortelli 2012 There was negative correlation 
between CSF NFL and ALSFRS-R 
Spearman’s correlation P=0.014 37 -0.41 
 There was positive correlation 
between CSF NFL and progression 
rate  
Spearman’s correlation P=0.65 37 0.65 
Steinacker 2015 There was a weak tendency 
between CSF NFL and ALSFRS-R  
Spearman’s correlation P=0.013 455 -0.016 
 There was significant difference in 
the CSF NFL between fast 
progression group and slow 
progression group 
Kruskal-Wallis test P=0.47 455 N/A 
Lu 2015 ( oxford cohort) The fast progression patients’ CSF 
NFL concentration was 
significantly higher than slow 
progression patients 
Non parametric analysis P=0.005 64 N/A 
Wedyt 2016 There was no significant correlation 
between CSF NFL and ALSFRS-R 
Spearman’s correlation P=0.46 51 -0.199 
Blood      
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Lu 2015 ( London cohort) The fast progression patients’ blood 
NFL concentration was 
significantly higher than slow 
progression patients 
Non parametric analysis  P=0.0002 103 N/A 
Lu 2015 ( Oxford cohort) The fast progression patients’ blood 
NFL concentration was 
significantly higher than slow 
progression patients 
Non parametric analysis P=0.0007 64 N/A 
Wedyt 20116 There was no significant correlation 
between blood NFL and ALSFRS-
R  
Spearman’s correlation P=0.14 51 -0.359 
 
Studies of correlation with survival time  
 The result of correlation The method P value Number of 
patients 
R value ( if use 
pearson or spearman 
correlation method) 
Studies of NF heavy chain 
CSF 
Boylan 2012 ( Mayo 12 month 
cohort) 
Doubling in CSF pNFH caused 
1.80 fold increase of hazard ratio of 
death ( time from sample) 
Cox proportional hazards 
regression model 
P=0.12 20 N/A 
 Doubling in CSF pNFH caused 
1.80 fold increase of hazard ratio of 
death ( time from onset) 
Cox proportional hazards 
regression model 
P=0.14 20 N/A 
Steinacker 2015 There is significant difference in 
the survival time among the 
patients with low, intermediate and 
high concentration CSF NFH  
Kaplan meier survival 
curve 
P=0.0024 45 N/A 
Blood      
McCombe 2015 There was an inverse correlation 
between pNFH level and survival 
time 
Linear regression analysis P=0.0481 98 N/A 
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 There was an inverse correlation 
between the rate of rise of pNFH 
and survival time  
Linear regression analysis P=0.0247 98 N/A 
Boylan 2009 There was no association between 
cumulative mortality and base line 
pNFH 
Kaplan meier survival 
curve  
P=0.21 19 N/A 
Boylan 2012 ( Mayo 12 month 
cohort plus Mayo 4 month 
cohort plus Emory cohort) 
Doubling in plasma pNFH caused 
1.32 fold increase of hazard ratio of 
death ( time from sample) 
Cox proportional hazards 
regression model 
P=0.012 62 N/A 
 Doubling in plasma NFH caused 
1.18 fold increase of hazard ratio of 
death ( time from onset) 
Cox proportional hazards 
regression model 
P=0.11 62 N/A 
Studies of Light chain 
CSF 
      
Tortelli 2013 The ALS patients’ survival time 
with high CSF NFL was significant 
reduced  
Kaplan meier survival 
curve 
P<0.0001 37 N/A 
Zetterberg 2007 CSF NFL was inversely correlated 
with survival time  
Spearman’s correlation P=0.001 79 -0.518 
 The ALS patients with high CSF 
NFL had short survival time 
compared with the ALS patients 
with low CSF NFL 
Kaplan meier survival 
curve 
P=0.002 79 N/A 
Steinacker 2015 There is significant difference in 
the survival time among the 
patients with low, intermediate and 
high concentration CSF NFL 
Kaplan meier survival 
curve 
P=0.0261 45 N/A 
Lu 2015 ( London cohort plus 
Oxford cohort) 
NFL in CSF was associated with 
poor survival  
Cox proportional hazards 
regression model 
P=0.002 12 N/A 
Blood 
Lu 2015 ( London cohort plus 
Oxford cohort) 
NFL in blood was associated wtih 
poor survival  
Cox proportional hazards 
regression model 
P<0.001 33 N/A 
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Appendix IV 
 
ALS versus healthy controls/without parenchymal CNS involvement in CSF NFH 
Study name Cut off value 
(ng/ml) 
Sensitivity Specificity  Area under 
curve ( AUC) 
Brettschneider 2006 0.95   0.71 0.88 0.87 
Weydt 2016 N/A N/A N/A N/A 
Steinacker 2011 N/A N/A N/A N/A 
Kuhle 2010 N/A N/A N/A N/A 
Steinacker 2016 0.56 0.83 0.80 0.871 
 
 
ALS versus ALS mimic disease in CSF NFH 
Study name  Cut off value 
(ng/ml) 
Sensitivity Specificity Area under 
curve (AUC) 
Steinacker 2016 0.56 0.83 0.80 0.841 
Reijn 2009 0.502 0.72 0.80 0.82 
 
 
ALS versus other neurological diseases with CNS involvement in CSF NFH 
Study name  Cut off value 
(ng/ml) 
Sensitivity Specificity Area under 
curve ( AUC) 
Brettschneider 2006 0.41 0.89 0.92 0.94 
Lehnert 2014 N/A N/A N/A N/A 
Steinacker 2011 N/A N/A N/A N/A 
Kuhle 2010 N/A N/A N/A N/A 
Steinacker 2016 0.56 0.83 0.80 0.871 
Goncalves 2015 0.385 0.828 0.647 0.8590 
 
ALS versus healthy controls/without parenchymal CNS involvement in blood NFH 
Study name  Cut off value 
(ng/ml) 
Sensitivity Specificity Area under 
curve ( AUC) 
McCombe 2015 N/A N/A N/A N/A 
Boylan 2009 N/A N/A N/A N/A 
 
ALS versus healthy controls/without parenchymal CNS involvement in CSF NFL 
Study name  Cut off value 
(ng/ml) 
Sensitivity Specificity Area under 
curve ( AUC) 
Gaiottino 2013 N/A N/A N/A N/A 
Rosengren 1996 N/A N/A N/A N/A 
Steinacker 2016 2.2 N/A N/A 0.871 
Lu 2015 1.781 0.97 0.95 0.9987 
Weydt 2016 N/A N/A N/A N/A 
Zetterberg 2007 N/A N/A N/A N/A 
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ALS versus ALS mimic disease in CSF NFL 
Study name  Cut off value 
(ng/ml) 
Sensitivity Specificity Area under 
curve ( AUC) 
Reijn 2009 22.6 0.75 0.79 0.77 
Steinacker 2016 2.2 0.77 0.88 0.841 
 
 
 
ALS versus other neurological diseases with CNS involvement in CSF NFL 
Study name  Cut off value 
(ng/ml) 
Sensitivity Specificity Area under 
curve ( AUC) 
Gaiottino 2013 N/A N/A N/A N/A 
Rosengren 1996 N/A N/A N/A N/A 
Steinacker 2011 N/A N/A N/A N/A 
Tortelli 2012 1.981 0.784 0.725 0.79 
Zetteberg 2007 N/A N/A N/A N/A 
 
 
 
ALS versus healthy controls/without parenchymal CNS involvement in blood NFL 
Study name  Cut off value 
(ng/ml) 
Sensitivity Specificity Area under 
curve ( AUC) 
Gaiottino 2013 0.026 0.913 0.91 N/A 
Lu 2015( oxford 
cohort) 
0.036 0.89 0.75 0.8626 
Lu 2015 (londone 
cohort) 
0.0362 0.90 0.71 0.8687 
Weydt 2016 N/A N/A N/A N/A 
 
 
 
 
 
 
159 
 
Appendix V 
 
The Protein list of the venn diagram 
19 proteins exclusive in control 115 common proteins in ALS and control 22 proteins exclusive in ALS 
 
Uniprot 
number 
Protein name Uniprot 
number 
Protein name Uniprot 
number 
Protein name 
P01766 Ig heavy chain V-III region 
BRO  P02768 Serum albumin  P04433 
Ig kappa chain V-III region VG 
(Fragment)  
P01622 Ig kappa chain V-III region Ti  P04114 Apolipoprotein B-100  P01597 Ig kappa chain V-I region DEE  
P01768 Ig heavy chain V-III region 
CAM  P01024 Complement C3  P18136 Ig kappa chain V-III region HIC  
P04430 Ig kappa chain V-I region BAN  P01023 Alpha-2-macroglobulin  Q8WZ42 Titin  
P27918 Properdin  P02787 Serotransferrin  P01764 Ig heavy chain V-III region 23  
O75882 Attractin  P0C0L5 Complement C4-B  P01762 Ig heavy chain V-III region TRO  
P02655 Apolipoprotein C-II  P01857 Ig gamma-1 chain C region  P18428 Lipopolysaccharide-binding protein  
P35542 Serum amyloid A-4 protein  P08603 Complement factor H  P20742 Pregnancy zone protein  
P22352 Glutathione peroxidase 3  P00450 Ceruloplasmin  P08519 Apolipoprotein(a)  
P20851 C4b-binding protein beta chain  P01009 Alpha-1-antitrypsin  P60709 Actin, cytoplasmic 1  
P0CG04 Ig lambda-1 chain C regions  P02675 Fibrinogen beta chain  P01780 Ig heavy chain V-III region JON  
Q03591 Complement factor H-related 
protein 1  P02671 Fibrinogen alpha chain  Q06033 
Inter-alpha-trypsin inhibitor heavy 
chain H3  
P01770 Ig heavy chain V-III region NIE  P02679 Fibrinogen gamma chain  P00488 Coagulation factor XIII A chain  
P01604 Ig kappa chain V-I region Kue  
Q14624 
Inter-alpha-trypsin inhibitor heavy 
chain H4  P05543 Thyroxine-binding globulin  
P01767 Ig heavy chain V-III region 
BUT  P02790 Hemopexin  B9A064 
Immunoglobulin lambda-like 
polypeptide 5  
P22792 Carboxypeptidase N subunit 2  P00747 Plasminogen  P46013 Antigen KI-67  
Q5T7N2 LINE-1 type transposase 
domain-containing protein 1  P02647 Apolipoprotein A-I  P0CF74 Ig lambda-6 chain C region  
P61769 Beta-2-microglobulin  P00738 Haptoglobin  P01765 Ig heavy chain V-III region TIL  
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P21802 Fibroblast growth factor 
receptor 2  P00734 Prothrombin  P01763 Ig heavy chain V-III region WEA  
  
P02774 Vitamin D-binding protein  P15814 
Immunoglobulin lambda-like 
polypeptide 1  
  P01008 Antithrombin-III  P62258 14-3-3 protein epsilon  
  P01859 Ig gamma-2 chain C region  Q8WXH0 Nesprin-2  
  
P19827 
Inter-alpha-trypsin inhibitor heavy 
chain H1  
  P01871 Ig mu chain C region  
  P00751 Complement factor B  
  P02652 Apolipoprotein A-II  
  P01876 Ig alpha-1 chain C region  
  
P19823 
Inter-alpha-trypsin inhibitor heavy 
chain H2  
  P02751 Fibronectin  
  P04217 Alpha-1B-glycoprotein  
  P04003 C4b-binding protein alpha chain  
  P01834 Ig kappa chain C region  
  P01042 Kininogen-1  
  P01011 Alpha-1-antichymotrypsin  
  P06727 Apolipoprotein A-IV  
  P02763 Alpha-1-acid glycoprotein 1  
  P06396 Gelsolin  
  P02766 Transthyretin  
  P02749 Beta-2-glycoprotein 1  
  P04004 Vitronectin  
  P05155 Plasma protease C1 inhibitor  
  P04196 Histidine-rich glycoprotein  
  P01031 Complement C5  
  P25311 Zinc-alpha-2-glycoprotein  
  P0CG06 Ig lambda-3 chain C regions  
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  P02760 Protein AMBP  
  P08697 Alpha-2-antiplasmin  
  P02748 Complement component C9  
  P02765 Alpha-2-HS-glycoprotein  
  P27169 Serum paraoxonase/arylesterase 1  
  P43652 Afamin  
  
Q96PD5 
N-acetylmuramoyl-L-alanine 
amidase  
  P68871 Hemoglobin subunit beta  
  P01019 Angiotensinogen  
  P10909 Clusterin  
  P36955 Pigment epithelium-derived factor  
  O43866 CD5 antigen-like  
  P01861 Ig gamma-4 chain C region  
  P19652 Alpha-1-acid glycoprotein 2  
  P03952 Plasma kallikrein  
  P02649 Apolipoprotein E  
  
P35858 
Insulin-like growth factor-binding 
protein complex acid labile subunit  
  P02750 Leucine-rich alpha-2-glycoprotein  
  
P07358 
Complement component C8 beta 
chain  
  P51884 Lumican  
  P00736 Complement C1r subcomponent  
  P00739 Haptoglobin-related protein  
  P05156 Complement factor I  
  P09871 Complement C1s subcomponent  
  P69905 Hemoglobin subunit alpha  
  P02656 Apolipoprotein C-III  
  P05546 Heparin cofactor 2  
  P01860 Ig gamma-3 chain C region  
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  P05090 Apolipoprotein D  
  P02753 Retinol-binding protein 4  
  
P07357 
Complement component C8 alpha 
chain  
  P06314 Ig kappa chain V-IV region B17  
  
P02746 
Complement C1q subcomponent 
subunit B  
  P13671 Complement component C6  
  P00748 Coagulation factor XII  
  P01609 Ig kappa chain V-I region Scw  
  P0C0L4 Complement C4-A  
  P01877 Ig alpha-2 chain C region  
  
P07360 
Complement component C8 gamma 
chain  
  P07225 Vitamin K-dependent protein S  
  P01591 Immunoglobulin J chain  
  
P06309 
Ig kappa chain V-II region GM607 
(Fragment)  
  
P02747 
Complement C1q subcomponent 
subunit C  
  P02743 Serum amyloid P-component  
  P01781 Ig heavy chain V-III region GAL  
  O14791 Apolipoprotein L1  
  P05452 Tetranectin  
  P04207 Ig kappa chain V-III region CLL  
  P10643 Complement component C7  
  P06681 Complement C2  
  P01779 Ig heavy chain V-III region TUR  
  O95445 Apolipoprotein M  
  P04220 Ig mu heavy chain disease protein  
  P01611 Ig kappa chain V-I region Wes  
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P01602 
Ig heavy chain V-I region 5 
(Fragment)  
  P04208 Ig lambda chain V-I region WAH  
  P01772 Ig heavy chain V-III region KOL  
  P80748 Ig lambda chain V-III region LOI  
  P23083 Ig heavy chain V-I region V35  
  P08185 Corticosteroid-binding globulin  
  P02654 Apolipoprotein C-I  
  P01613 Ig kappa chain V-I region Ni  
  P06316 Ig lambda chain V-I region BL2  
  
P02745 
Complement C1q subcomponent 
subunit A  
  
Q2TV78 
Putative macrophage stimulating 1-
like protein  
  
P04434 
Ig kappa chain V-III region VH 
(Fragment)  
  P29622 Kallistatin  
  O75636 Ficolin-3  
  P06331 Ig heavy chain V-II region ARH-77  
  P04278 Sex hormone-binding globulin  
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Appendix VI 
 
 
 115 proteins detected in the plasma sample 
N Unused Total %Cov Accession Protein Name 
1 379.71 379.71 90.14999866 sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 
2 214.02 214.02 38.06999922 sp|P04114|APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 
3 213.64 213.7 71.38000131 sp|P01024|CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 
4 151.22 151.22 67.10000038 sp|P01023|A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 
5 138.84 138.84 74.63999987 sp|P02787|TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 
6 118.22 118.22 50.85999966 sp|P0C0L5|CO4B_HUMAN Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 
7 87.29 87.29 79.69999909 sp|P01857|IGHG1_HUMAN Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 
8 82.6 82.6 51.91000104 sp|P08603|CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 
9 79.13 79.13 59.53000188 sp|P00450|CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 
10 72.45 72.45 71.07999921 sp|P02675|FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 
11 58.76 58.76 46.419999 sp|P02671|FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 
12 58.12 58.12 73.65000248 sp|P00738|HPT_HUMAN Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 
13 56.1 56.1 70.34999728 sp|P02790|HEMO_HUMAN Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 
14 56.05 56.06 68.65000129 sp|P02679|FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 
15 54 54 55.50000072 sp|P01009|A1AT_HUMAN Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 
16 52.39 52.39 42.37000048 sp|Q14624|ITIH4_HUMAN 
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 
PE=1 SV=4 
17 51.75 51.76 53.21000218 sp|P00747|PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 
18 50.13 50.13 50.31999946 sp|P00734|THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 
19 47.12 47.12 22.50999957 sp|P02751|FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 
20 46.26 46.26 41.26999974 sp|P19827|ITIH1_HUMAN 
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 
PE=1 SV=3 
21 46.01 46.01 62.91999817 sp|P02647|APOA1_HUMAN Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 
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22 44 44 64.77000117 sp|P02774|VTDB_HUMAN Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 
23 38 38 64.31000233 sp|P01876|IGHA1_HUMAN Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 
24 36.11 36.11 37.95000017 sp|P19823|ITIH2_HUMAN 
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 
PE=1 SV=2 
25 36.01 36.01 88.67999911 sp|P01834|IGKC_HUMAN Ig kappa chain C region OS=Homo sapiens GN=IGKC PE=1 SV=1 
26 36 36 57.95999765 sp|P01871|IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 
27 34.87 34.98 46.34000063 sp|P01011|AACT_HUMAN Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 
28 34.16 34.16 42.14999974 sp|P00751|CFAB_HUMAN Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 
29 32.94 32.95 47.63000011 sp|P01008|ANT3_HUMAN Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 
30 32.38 67.6 79.44999933 sp|P01859|IGHG2_HUMAN Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 
31 32.01 32.01 44.22000051 sp|P04003|C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 
32 30.26 30.26 51.52000189 sp|P04217|A1BG_HUMAN Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 
33 28.5 28.5 91.00000262 sp|P02652|APOA2_HUMAN Apolipoprotein A-II OS=Homo sapiens GN=APOA2 PE=1 SV=1 
34 28.06 28.11 15.92999995 sp|P01031|CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 
35 25.01 25.01 29.6600014 sp|P01042|KNG1_HUMAN Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 
36 24 24 33.55999887 sp|P43652|AFAM_HUMAN Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 
37 24 24 38.38 sp|P06727|APOA4_HUMAN Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 
38 24 24 52.74999738 sp|P02749|APOH_HUMAN Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 
39 22 22 30.32999933 sp|P04004|VTNC_HUMAN Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 
40 22 22 69.38999891 sp|P02766|TTHY_HUMAN Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 
41 20.98 21 27.20000148 sp|P05155|IC1_HUMAN Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 
42 20 20 33.19999874 sp|P08697|A2AP_HUMAN Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 
43 20 20 47.2600013 sp|P02763|A1AG1_HUMAN Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 
44 20 20 26.28999949 sp|P04196|HRG_HUMAN Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 
45 19.15 19.27 54.07999754 sp|P27169|PON1_HUMAN Serum paraoxonase/arylesterase 1 OS=Homo sapiens GN=PON1 PE=1 SV=3 
46 18.35 18.36 31.83999956 sp|P06396|GELS_HUMAN Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 
47 18.23 18.23 38.26000094 sp|P25311|ZA2G_HUMAN Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 
48 18.01 68.46 84.10000205 sp|P01861|IGHG4_HUMAN Ig gamma-4 chain C region OS=Homo sapiens GN=IGHG4 PE=1 SV=1 
49 18.01 18.01 81.12999797 sp|P0CG06|LAC3_HUMAN Ig lambda-3 chain C regions OS=Homo sapiens GN=IGLC3 PE=1 SV=1 
50 18 18 42.50999987 sp|P02765|FETUA_HUMAN Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 
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51 17.59 17.7 73.47000241 sp|P68871|HBB_HUMAN Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 
52 16.05 16.05 37.5 sp|P02760|AMBP_HUMAN Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 
53 16 16 24.74000007 sp|P01019|ANGT_HUMAN Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 
54 15.81 15.88 28.13000083 sp|Q96PD5|PGRP2_HUMAN 
N-acetylmuramoyl-L-alanine amidase OS=Homo sapiens GN=PGLYRP2 PE=1 
SV=1 
55 14.1 14.1 19.67999935 sp|P02748|CO9_HUMAN Complement component C9 OS=Homo sapiens GN=C9 PE=1 SV=2 
56 14 14 30.63000143 sp|P07358|CO8B_HUMAN Complement component C8 beta chain OS=Homo sapiens GN=C8B PE=1 SV=3 
57 14 14 35.33000052 sp|P02649|APOE_HUMAN Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 
58 13.84 13.87 37.45999932 sp|O43866|CD5L_HUMAN CD5 antigen-like OS=Homo sapiens GN=CD5L PE=1 SV=1 
59 13.26 13.28 25.74000061 sp|P51884|LUM_HUMAN Lumican OS=Homo sapiens GN=LUM PE=1 SV=2 
60 12.9 12.92 31.18000031 sp|P10909|CLUS_HUMAN Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 
61 12.02 12.02 18.44000071 sp|P00736|C1R_HUMAN Complement C1r subcomponent OS=Homo sapiens GN=C1R PE=1 SV=2 
62 12 18 44.78000104 sp|P19652|A1AG2_HUMAN Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 
63 12 12 12.70000041 sp|P03952|KLKB1_HUMAN Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1 SV=1 
64 12 12 49.75000024 sp|P02753|RET4_HUMAN Retinol-binding protein 4 OS=Homo sapiens GN=RBP4 PE=1 SV=3 
65 12 12 70.70999742 sp|P02656|APOC3_HUMAN Apolipoprotein C-III OS=Homo sapiens GN=APOC3 PE=1 SV=1 
66 11.06 11.14 9.742999822 sp|P13671|CO6_HUMAN Complement component C6 OS=Homo sapiens GN=C6 PE=1 SV=3 
67 10.94 11.02 23.9199996 sp|P36955|PEDF_HUMAN 
Pigment epithelium-derived factor OS=Homo sapiens GN=SERPINF1 PE=1 
SV=4 
68 10.04 10.04 22.64000028 sp|P05156|CFAI_HUMAN Complement factor I OS=Homo sapiens GN=CFI PE=1 SV=2 
69 10.03 10.03 32.85000026 sp|P02750|A2GL_HUMAN Leucine-rich alpha-2-glycoprotein OS=Homo sapiens GN=LRG1 PE=1 SV=2 
70 10.02 10.02 13.71999979 sp|P35858|ALS_HUMAN 
Insulin-like growth factor-binding protein complex acid labile subunit OS=Homo 
sapiens GN=IGFALS PE=1 SV=1 
71 10 36.07 53.74000072 sp|P00739|HPTR_HUMAN Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 
72 10 10 44.19000149 sp|P18136|KV313_HUMAN Ig kappa chain V-III region HIC OS=Homo sapiens PE=1 SV=2 
73 10 10 49.30000007 sp|P69905|HBA_HUMAN Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 
74 10 10 26.46000087 sp|P05090|APOD_HUMAN Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 
75 9.66 9.77 13.51999938 sp|P10643|CO7_HUMAN Complement component C7 OS=Homo sapiens GN=C7 PE=1 SV=2 
76 9.27 9.37 13.36999983 sp|P09871|C1S_HUMAN Complement C1s subcomponent OS=Homo sapiens GN=C1S PE=1 SV=1 
77 8.07 66.92 72.14999795 sp|P01860|IGHG3_HUMAN Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=1 SV=2 
78 8 8 31.34000003 sp|P06314|KV404_HUMAN Ig kappa chain V-IV region B17 OS=Homo sapiens PE=2 SV=1 
167 
 
79 8 8 25.63999891 sp|P01764|HV303_HUMAN Ig heavy chain V-III region 23 OS=Homo sapiens GN=IGHV3-23 PE=1 SV=2 
80 7.13 7.25 23.25000018 sp|P05546|HEP2_HUMAN Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3 
81 6 115.8 50.11000037 sp|P0C0L4|CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 
82 6 28 55.58999777 sp|P01877|IGHA2_HUMAN Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2 PE=1 SV=3 
83 6 7.07 8.377999812 sp|P06681|CO2_HUMAN Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2 
84 6 6 42.19999909 sp|P04208|LV106_HUMAN Ig lambda chain V-I region WAH OS=Homo sapiens PE=1 SV=1 
85 6 6 17.13999957 sp|P02747|C1QC_HUMAN 
Complement C1q subcomponent subunit C OS=Homo sapiens GN=C1QC PE=1 
SV=3 
86 6 6 14.80000019 sp|P00748|FA12_HUMAN Coagulation factor XII OS=Homo sapiens GN=F12 PE=1 SV=3 
87 6 6 13.81999999 sp|O14791|APOL1_HUMAN Apolipoprotein L1 OS=Homo sapiens GN=APOL1 PE=1 SV=5 
88 6 6 8.664999902 sp|P29622|KAIN_HUMAN Kallistatin OS=Homo sapiens GN=SERPINA4 PE=1 SV=3 
89 6 6 12.8700003 sp|P05452|TETN_HUMAN Tetranectin OS=Homo sapiens GN=CLEC3B PE=1 SV=3 
90 6 6 14.80000019 sp|P02743|SAMP_HUMAN Serum amyloid P-component OS=Homo sapiens GN=APCS PE=1 SV=2 
91 6 6 24.52999949 sp|P01591|IGJ_HUMAN Immunoglobulin J chain OS=Homo sapiens GN=JCHAIN PE=1 SV=4 
92 4.84 4.9 29.64000106 sp|P02746|C1QB_HUMAN 
Complement C1q subcomponent subunit B OS=Homo sapiens GN=C1QB PE=1 
SV=3 
93 4 28 52.9399991 sp|P04220|MUCB_HUMAN Ig mu heavy chain disease protein OS=Homo sapiens PE=1 SV=1 
94 4 6 30.36000133 sp|P01613|KV121_HUMAN Ig kappa chain V-I region Ni OS=Homo sapiens PE=1 SV=1 
95 4 4 19.0200001 sp|P08519|APOA_HUMAN Apolipoprotein(a) OS=Homo sapiens GN=LPA PE=1 SV=1 
96 4 4 34.1899991 sp|P06309|KV205_HUMAN Ig kappa chain V-II region GM607 (Fragment) OS=Homo sapiens PE=4 SV=1 
97 4 4 38.76000047 sp|P04207|KV308_HUMAN Ig kappa chain V-III region CLL OS=Homo sapiens PE=4 SV=2 
98 4 4 30.77000082 sp|P01602|KV110_HUMAN 
Ig heavy chain V-I region 5 (Fragment) OS=Homo sapiens GN=IGKV1-5 PE=4 
SV=2 
99 4 4 32.44999945 sp|O95445|APOM_HUMAN Apolipoprotein M OS=Homo sapiens GN=APOM PE=1 SV=2 
100 4 4 30.63000143 sp|P80748|LV302_HUMAN Ig lambda chain V-III region LOI OS=Homo sapiens PE=1 SV=1 
101 4 4 20.50999999 sp|P23083|HV103_HUMAN Ig heavy chain V-I region V35 OS=Homo sapiens PE=1 SV=1 
102 4 4 13.24999928 sp|P02654|APOC1_HUMAN Apolipoprotein C-I OS=Homo sapiens GN=APOC1 PE=1 SV=1 
103 4 4 3.962000087 sp|P00488|F13A_HUMAN Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 
104 3.11 3.38 14.04999942 sp|O75636|FCN3_HUMAN Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 SV=2 
105 2.77 3.02 31.47999942 sp|P01611|KV119_HUMAN Ig kappa chain V-I region Wes OS=Homo sapiens PE=1 SV=1 
106 2.32 2.32 9.453000128 sp|P04278|SHBG_HUMAN Sex hormone-binding globulin OS=Homo sapiens GN=SHBG PE=1 SV=2 
168 
 
107 2 2 9.35800001 sp|P22792|CPN2_HUMAN Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1 SV=3 
108 2 2 35.71000099 sp|P01616|KV203_HUMAN Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 SV=1 
109 2 2 29.40999866 sp|P61769|B2MG_HUMAN Beta-2-microglobulin OS=Homo sapiens GN=B2M PE=1 SV=1 
110 2 2 5.76899983 sp|P07225|PROS_HUMAN Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 PE=1 SV=1 
111 2 2 25.74000061 sp|P02655|APOC2_HUMAN Apolipoprotein C-II OS=Homo sapiens GN=APOC2 PE=1 SV=1 
112 2 2 17.75999963 sp|P01717|LV403_HUMAN Ig lambda chain V-IV region Hil OS=Homo sapiens PE=1 SV=1 
113 2 2 3.130999953 sp|P43251|BTD_HUMAN Biotinidase OS=Homo sapiens GN=BTD PE=1 SV=2 
114 2 2 16.67000055 sp|P01714|LV301_HUMAN Ig lambda chain V-III region SH OS=Homo sapiens PE=1 SV=1 
115 1.18 1.66 35.64999998 sp|P01767|HV306_HUMAN Ig heavy chain V-III region BUT OS=Homo sapiens PE=1 SV=1 
 
 
 
